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Abstract Title:  Characterization of Rift Valley fever virus nucleocapsid protein-RNA 
binding interactions and development of a high-throughput screening assay for 
identification of N-RNA binding inhibitors 
 
Chairperson:  Dr. J. Stephen Lodmell 
 
Rift Valley fever virus (RVFV) is an emerging infectious pathogen that causes severe 
disease in humans and livestock and has the potential for global spread.  Currently, there 
is no treatment for RVFV infection and there is no proven safe and effective vaccine.  
Inhibition of RNA binding to RVFV nucleocapsid (N) protein represents an innovative 
antiviral therapeutic strategy because several essential steps in the RVFV replication 
cycle involve N binding to viral RNA.  The overall goals of our research are to better 
understand how RVFV N protein interacts with RNA, to develop a high-throughput drug 
screening assay for identification of compounds that inhibit a N-RNA binding interaction 
and to test the efficacy of potential antiviral drug compounds during RVFV infection.  
Completion of the proposed research will result in an increased understanding of the 
basic biology of this important human pathogen and aid in the design of more powerful 
and effective anti-RVFV drugs. 
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CHAPTER 1:  GENERAL INTRODUCTION 198 
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Rift Valley fever virus (RVFV) was first discovered and characterized in the Great 199 
Rift Valley of Kenya in 1931 following the sudden death of approximately 4,700 lambs 200 
and ewes over a four week period (24).  Since then, RVFV has caused numerous 201 
alarming and devastating epidemics throughout Africa, Saudi Arabia and Yemen and is 202 
currently considered an emerging infectious pathogen due to increases in the incidence 203 
and geographic range of the virus.  Extensive efforts have been devoted to understanding 204 
the pathology, epidemiology and molecular biology of RVFV to learn how to better 205 
control the spread of disease during outbreaks and to develop vaccines and drug therapies 206 
for the treatment and prevention of viral infection.  This chapter begins by presenting a 207 
summary of RVFV transmission, infection and therapy.  Next it provides an overview of 208 
the information obtained over the past three decades regarding the molecular biology of 209 
RVFV and concludes with a discussion of the structure, function and therapeutic 210 
potential of viral nucleocapsid proteins.  211 
I.  Rift Valley fever virus 212 
Rift Valley fever virus (RVFV) is a single-stranded RNA virus that belongs to the 213 
Bunyaviridae family and Phlebovirus genus.  The Bunyaviridae family is composed of 214 
five genera of viruses:  Bunyavirus, Hantavirus, Nairovirus, Phlebovirus, and 215 
Tospovirus.   216 
A. Epidemiology 217 
RVFV can infect a wide range of vertebrate mammals but disease is limited to 218 
domestic livestock and humans.  RVFV is most commonly transmitted through the bite of 219 
an infected mosquito.  However, the virus can also be acquired by exposure to the blood 220 
or body fluids of infected animals or by consuming raw, unpasteurized milk from 221 
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infected cows (6).  The virus is maintained at low levels in the environment by occasional 222 
infection and amplification of the virus in native wildlife or livestock and by transovarial 223 
transmission in Aedes mosquitos.  Infected mosquito eggs are extremely hardy and the 224 
virus can lie dormant for years in the soil.  A shift to epidemic RVFV activity is typically 225 
preceded by periods of extended rainfall causing flooding and an increase in mosquito 226 
breeding and population density (25).  Infected Aedes mosquitos feed on livestock, which 227 
serve as amplification hosts by quickly becoming viremic (within 12-24 hours).  Other 228 
mosquito species that emerge after flooding act as secondary vectors (30 species from six 229 
genera have been documented thus far) and increase transmission of the virus to humans 230 
and other animals (70).  Man-made factors can also contribute to the initiation of an 231 
epidemic cycle.  For example, dam building creates reservoirs, stagnant backwater and 232 
generates new breeding ground for mosquitos (69).  Also, worldwide trade and 233 
international travel can aid in further dissemination of the virus.  Since RVFV can infect 234 
a wide range of mosquito and animal species it could easily survive on other continents 235 
besides Africa and the virus will become more widely distributed in the future. 236 
B. Pathogenesis 237 
The main sites of viral replication in a vertebrate host are the liver, spleen and brain.  238 
Disease symptoms in livestock include excessive salivation, nasal discharge, diarrhea, 239 
and high rates of miscarriage.  Newborn lambs and kids are most susceptible and 240 
mortality rates are between 70-100%.  The fatality rate in adult cattle and sheep is lower 241 
and may reach 30% (20, 21).  Disease in humans can take on several forms.  Most people 242 
experience a mild flu-like illness, however complications for infected individuals can be 243 
grave and can result in the development of hemorrhagic fever, hepatitis, encephalitis and 244 
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blindness (1, 2).  Historically, the case fatality rate for human RVFV infection has been 245 
low (2-5%) (68), however, reports from more recent outbreaks are much higher.  246 
Mortality rates of 14% were reported for the first Arabian outbreak in September 2000 247 
and rates as high as 23-45% were reported from outbreaks between November 2006 and 248 
May 2007 in Kenya, Somalia and United Republic of Tanzania (6, 120).  More research 249 
is required to determine if this is a result of under-reporting of mild cases, the virus 250 
encountering a naïve host as it spreads beyond the borders of its endemic region, or if the 251 
emergence of more virulent strains is causing an increase in fatal human cases.     252 
C. Vaccines and anti-viral therapies 253 
There is currently no specific treatment for RVFV infection other than supportive 254 
care.  Ribavirin is a guanosine analog that is thought to function by inhibiting RNA virus 255 
replication and was used to treat patients in Saudi Arabia suffering from the hemorrhagic 256 
form of RVF (13).  However, its use remains limited because it is a known teratogen in 257 
some animal species and can cause other adverse side effects such as hemolytic anemia.  258 
Furthermore, one study reported that treatment of RVFV infected laboratory animals with 259 
ribavirin resulted in a change in disease characteristics rather than a clearing of viral 260 
infection.  A shift from sudden onset of hepatitis to delayed onset of neurological disease 261 
was observed and is likely the result of ribavirin being too large of a molecule to cross 262 
the blood-brain barrier (93).  Favipiravir (T-705) is a pyrazinecarboxamide compound 263 
and its metabolite inhibits viral RNA-dependent RNA polymerases without affecting host 264 
cellular DNA or RNA synthesis (36).  It acts as a purine in viral RNA replication and 265 
displays more selectivity and specificity for its target than ribavirin.  Favipiravir is 266 
efficacious against RVFV infection in cell culture and prevents death from hamsters 267 
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infected with the closely related Punta Toro virus (41).  It is also a promising broad- 268 
spectrum antiviral compound because it is active against a variety of other RNA viruses.  269 
Phase II clinical evaluations of favipiravir for influenza therapy have recently been 270 
completed in the United States (35).   271 
Vaccines are in varying stages of development.  A formalin-inactivated vaccine (TSI- 272 
GSD-200) developed in the 1970’s has been administered to people at high risk of 273 
contracting RVFV but its use is limited because it is in short supply and difficult and 274 
expensive to produce (95).  Inactivated vaccines are generally not considered practical for 275 
immunization of livestock because they require multiple initial inoculations followed by 276 
annual boosters.  The use of a live-attenuated vaccine is the preferred method for 277 
immunization because protection against the virus requires only a single inoculation and 278 
during an outbreak it is important to be able to attain rapid immunization.  Many of the 279 
live-attenuated strains of RVFV tested thus far (Smithburn and MP-12) cause miscarriage 280 
and/or birth defects in the fetuses of pregnant animals (12, 50), however, one promising 281 
live-attenuated vaccine candidate is R566.  R566 is a reassortant of the L and M segments 282 
MP-12 and the S segment is from a strain of virus (Clone 13) where the NSs gene (a 283 
virulence factor) has been deleted.  A vaccination trial conducted using pregnant ewes 284 
reported that no animals showed signs of illness or aborted and all animals developed 285 
antibody responses.  A challenge experiment against live virus was not conducted (13). 286 
D. Public health implications 287 
RVFV represents a significant public health threat for several reasons.  RVF 288 
epidemics quickly overwhelm the local medical care system and cause both human and 289 
veterinary medical resources to be strained.  Extensive loss of livestock can have a major 290 
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economic impact on a region as well as individual farmers and concerns regarding food 291 
safety can have long lasting effects on trade.  Furthermore, RVF outbreaks tend to occur 292 
in developing countries that do not have the financial means or infrastructure to deal with 293 
emergency situations. 294 
II.  Molecular biology of Rift Valley fever virus 295 
The Rift Valley fever virion is spherically shaped and measures between 80-120 nm 296 
in diameter (48).  The outermost layer of the virus is composed of a lipid bilayer 297 
(envelope) that contains heterodimers of RVFV-specific glycoproteins Gn and Gc (31).  298 
Packaged within each viral particle are the three segments of the viral RNA genome 299 
complexed with nucleocapsid protein (ribonucleocapsids) and the viral RNA-dependent 300 
RNA polymerase (Fig. 1-1). 301 
 302 
Figure 1 - 1:  Schematic cross section of the Rift Valley fever virion. 303 
Three RNA segments (S, M, and L) are complexed with nucleocapsid protein (red circles) to form 304 
ribonucleocapsid structures.  The ribonucleocapsids and RNA-dependent RNA polymerase (green 305 
pentagon) are packaged within a lipid envelope that contains the viral glycoproteins Gn and Gc (blue and 306 
aqua ovals). 307 
 308 
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RNA dependent
RNA polymerase
Gn
Gc
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A. Genome coding strategy 309 
The RVFV single-stranded RNA genome contains three segments designated large 310 
(L), medium (M) and small (S) based on their relative nucleotide length.  All genome 311 
segments share identical termini (3’-UGUGUUUC-5’ or 3’-GAAACACA-5’) that are 312 
complementary.  Base pairing of terminal nucleotides results in the formation of 313 
panhandle structures and the genomic RNAs adopt a closed circular conformation (49).  314 
The L segment encodes the RNA-dependent RNA polymerase responsible for 315 
transcription and replication the viral genome (82, 83).  The M segment encodes 316 
glycoproteins (Gn and Gc) involved in attachment and entry into the host cell and non- 317 
structural proteins NSm and 78-kDa (23).  The NSm protein acts as a suppressor of virus- 318 
induced apoptosis (121) and the function of the 78-kDa protein (if any) is currently 319 
unknown.  The S segment utilizes an ambisense strategy to encode the nuclocapsid (N) 320 
and NSs proteins (51) whereas genes encoded by the M and L segments are oriented in 321 
the negative sense.  The ambisense coding strategy of the S segment produces NSs from a 322 
subgenomic mRNA of the same polarity as the viral RNA.  Time course studies 323 
conducted in the Phlebovirus Uukuniemi show that the mRNA for NSs is copied from 324 
complementary RNA (cRNA) after genome replication (117).  Non-structural protein 325 
NSs is an important virulence factor and utilizes several strategies to prevent activation of 326 
the host anti-viral response system.  NSs decreases the transcriptional activity of the host 327 
cell by sequestering TFIIH (63), a basal transcription factor, and acts as an interferon 328 
antagonist by inhibiting production of interferon-! (9, 14).  It also promotes the 329 
degradation of protein kinase R (43, 52), a protein that can activate the innate immune 330 
system by detecting the presence of double stranded viral RNA in the host cell.  The viral 331 
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N protein is an RNA-binding protein that plays an essential role during viral replication 332 
and its multiple functions will be discussed later in this chapter.   333 
B. Replication cycle 334 
The RVFV replication cycle begins by the virus attaching to the plasma membrane of 335 
the host cell.  Attachment is mediated by interactions between the viral glycoproteins (Gn 336 
and Gc) and host proteins present on the surface of the cell (59).  The virus is 337 
endocytosed and acidification of the endosome causes a conformational change in Gn 338 
and/or Gc that facilitates fusion of viral and cellular membranes and allows the viral 339 
genome and polymerase to be released into the host cell cytoplasm (31, 104).  After 340 
entry, primary transcription of the negative sense viral RNA to mRNA via the RNA 341 
dependent RNA polymerase occurs (Fig. 1-2; step 1).  Only ribonucleocapsids and not 342 
free RNA can serve as templates for primary transcription (64).  Capped oligos are 343 
scavenged from host mRNA by the viral polymerase, which has both endonuclease and 344 
polymerase activity (45, 90).  Some nucleotide preference for endonuclease cleavage has 345 
been observed amongst the Bunyaviruses and likely exists because the capped 5’ oligos 346 
are used as primers to synthesize the viral mRNA (96).  L and S segment mRNAs are 347 
translated by free ribosomes and translation of M segment mRNAs occurs on membrane- 348 
bound ribosomes (Fig. 1-2; step 2).  After primary transcription of viral mRNA the virus 349 
replicates the RNA genome.  The transition to genome replication requires a switch from 350 
mRNA synthesis to synthesis of full-length complementary RNA templates and then 351 
production of full length viral RNA (Fig. 1-2; step 3).  How this switch occurs is not well 352 
understood but some viral or host factor(s) suppress the transcription termination signal 353 
that generates truncated mRNAs.  Next, secondary transcription of NSs mRNA from full- 354 
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length complementary RNA occurs (117) as well as continued translation of viral protein 355 
and RNA replication (Fig. 1-2; step 4).  Gn, Gc and NSm proteins are transported through 356 
the ER, glycosylated and accumulate in the Golgi apparatus(57).  The viral genome is 357 
packaged into virus particles formed by budding from the Golgi apparatus and 358 
subsequent fusion with the plasma membrane results in the release of mature virions (3).  359 
Virus budding directly from the plasma membrane has been described as well (3).   360 
 361 
Figure 1 - 2:  Principal steps during viral replication. 362 
1.) After the viral genome has entered the cytoplasm of the host cell, primary transcription of negative- 363 
sense viral RNA (vRNA) to mRNA occurs.  2.) L and S segment capped mRNAs are translated by free 364 
ribosomes and the M segment is translated by membrane-bound ribosomes.  3.) A switch from primary 365 
mRNA synthesis to genome replication occurs.  Full-length complementary RNA (cRNA) templates are 366 
synthesized followed by production of full-length vRNA.  4.) Due to the ambisense nature of the S segment 367 
RNA, secondary transcription of NSs mRNA using full-length complementary RNA (cRNA) as a template 368 
occurs.  369 
Step 1
Step 2
Step 3
Step 4
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C. Nucleocapsid protein:  structure, function and specificity of RNA binding 370 
Nucleocapsid (N) proteins are essential, multifunctional, RNA-binding and RNA 371 
chaperone proteins that play an important role during several stages of the viral 372 
replication cycle.  N proteins are involved in regulation of viral transcription, translation 373 
and accumulation of N is thought to trigger the switch from mRNA synthesis to full- 374 
length cRNA synthesis during genome replication in some RNA viruses (77, 118).  N 375 
interacts with viral RNA by binding to and forming polymers along the entire length of 376 
the genome (Fig. 1-3).  This encapsidation process protects the viral RNA and prevents 377 
the formation of double-stranded RNA during replication, which would activate the host 378 
anti-viral response.  N encapsidates viral genomic and antigenomic RNA but not other 379 
cellular RNA’s (44).  Only encapsidated viral genomes are packaged into virions and 380 
assembly of the RNP complexes into the budding viral particle is mediated by 381 
interactions between N and the cytoplasmic tail of viral glycoproteins Gn and Gc (88, 382 
101, 114).  Most RNA viruses, retroviruses and hepadnaviruses encode a gene for N 383 
protein.  A rigid comparison of primary sequence and secondary structure suggests that 384 
these proteins are unrelated and structurally diverse.  However, a broad and general 385 
comparison reveals that N proteins are functionally homologous and common structural 386 
themes do exist, including a core domain that contains an RNA-binding cleft and N 387 
and/or C- terminal extensions that allow the protein to oligomerize. 388 
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 389 
Figure 1 - 3:  Schematic of N structural domains and RNA encapsidation. 390 
A) Cartoon of N structure based on the crystal structural model (32, 100).  The 33-residue N-terminal arm 391 
blocks the RNA-binding cleft in the N monomer.  B) A specific RNA-binding event triggers cooperative 392 
binding between N monomers, which then switch to a non-specific mode of RNA binding that allows N to 393 
coat the viral genome. 394 
The most recent crystal structure depicts RVFV N as a circular shaped multimer 395 
(hexa, penta or tetramer) in a complex with either DNA or RNA.  Analysis of this 396 
structure shows that interactions between the flexible N-terminal domains of neighboring 397 
proteins allow multimers to form (Fig. 1-4A).  An RNA-binding slot that contains several 398 
highly conserved basic amino acid residues lines the inner circle of the ring-like structure 399 
(Fig. 1-4B).  The RNA sugar phosphate backbone contacts polar residues located on the 400 
rim of the binding groove and nitrogenous bases are involved in hydrophobic and base 401 
stacking interactions with N.  Since this crystal structure shows a non-specific mode of N 402 
binding, no H-bond interactions between N and RNA bases are observed (100).  403 
However, since N is able to discriminate between different species of RNA in the host 404 
cell, N must possess a specific mode of binding in addition to the indiscriminant mode 405 
described above. 406 
Research using several different bunyaviruses as model systems shows that N 407 
recognizes and binds to specific sequence and/or secondary structures on its target RNA.  408 
One previously mentioned characteristic feature of all bunyavirus RNA segments is a 409 
conserved, self-complementary sequence present at the 5’ and 3’ ends of the genome and 410 
anti-genome that undergoes base pairing to form panhandle-like structures.  Preferential 411 
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binding of N to this panhandle structure has been demonstrated in Sin Nombre hantavirus 412 
(72, 76, 78) and it is thought that N binding to and unwinding this RNA helix allows the 413 
viral polymerase to bind and initiate replication (74, 75).  N is also able to mediate 414 
translation initiation by acting as a substitute for the eIF4F cap-binding complex (77).  415 
Experiments conducted in Sin Nombre hantavirus showed that although N increased 416 
translation of nonviral RNA, N-mediated translation of viral RNA was even greater.  This 417 
suggests that there must be some cis-acting signal present in the 5’ UTR of viral mRNA 418 
that allows for preferential initiation of viral mRNA.  Further investigation revealed that 419 
N binds with high affinity to a sequence present in the 5’ untranslated region of viral 420 
mRNA (GUAGUAG) and this sequence is necessary and sufficient for N-mediated 421 
translation initiation (79).  Another important function of N during replication is 422 
encapsidation of the viral genome and antigenome.  Experiments conducted in La Crosse 423 
virus infected cells provided the first clue that the nucleation site for encapsidation might 424 
be located at the 5’ end of the genome.  This was proposed because an unusual uncapped 425 
plus-sense S RNA transcript truncated at its 3’ end by ~ 100 nucleotides was found 426 
encapsidated in La Crosse virus infected cells (98).  This observation implies that the 427 
sequence near the 3’ end of the antigenome is not important for ribonucleocapsid 428 
assembly and the highly conserved 5’ end of the genome is likely where the 429 
encapsidation signal is located.  Support for this hypothesis was later obtained by binding 430 
assays conducted in Jamestown Canyon, Hantaan and Bunyamwera viruses that reported 431 
the first ~40 nucleotide residues at the 5’ end of the viral RNA mediate the specificity of 432 
N-RNA binding and contain the encapsidation signal (85, 87, 109).  Together, these data 433 
led to a proposed model of RNA encapsidation that involves an initial, specific 434 
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interaction occurring at the 5’ end of the nascent viral RNA, followed by N-N 435 
interactions that drive the nonspecific binding of the remaining RNA template (Fig. 3). 436 
437 
  438 
Figure 1 - 4 439 
A) The structure of a RVFV N hexamer bound to RNA.  Each individual N subunit is depicted using a 440 
different color and the N-terminal arm of each subunit wraps around the outside of the adjacent subunit.  441 
Single-stranded RNA (black) bind along the inner groove of the hexameric ring structure.  B) The core 442 
domain of RVFV N (aqua) bound to RNA (sticks).  The area where the helical arm of an adjacent N 443 
monomer interacts with the core domain of N is depicted in green (100). 444 
III. Nucleocapsid protein as an anti-viral therapeutic target 445 
Inhibition of RNA binding to Rift Valley fever virus (RVFV) nucleocapsid (N) 446 
protein represents a potentially attractive anti-viral therapeutic strategy because several 447 
essential steps in the RVFV replication cycle involve N binding to viral RNA.  448 
Nucleocapsid-targeting drugs have been shown to be effective and are in various stages 449 
of development for other RNA viruses such as HIV, respiratory syncytial virus and 450 
influenza.  Although these drugs all target N, many have been shown to utilize unique 451 
and interesting strategies to exert their inhibitory effect.  This is a result of the 452 
multifunctional nature of N during viral infection where each function represents a 453 
A B
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potential antiviral strategy.  Examples of a variety of inhibitors that disrupt nucleocapsid 454 
protein RNA binding interactions have been described in HIV.  Some inhibitors promote 455 
zinc ejection of the zinc finger RNA binding domain (28, 103) while others disrupt the 456 
ability of nucleocapsid to coordinate zinc resulting in protein aggregation and diminished 457 
protease processing (55, 71).  Inhibitors that target the nucleocapsid chaperone activity 458 
for HIV RNA have been described as well (110).  A small molecule that inhibits 459 
influenza virus replication by causing aberrant oligomerization of viral nucleocapsid has 460 
recently been described.  The ligand, nucleozin, induces the formation of stable 461 
nucleocapsid oligomers that interfere with ribonucleocapsid transport making it 462 
unavailable for assembly into polymerase complexes and virions (38).  A promising 463 
potential drug compound targeted against a respiratory syncytial virus nucleocapsid 464 
protein, RSV604, is currently in a phase II clinical trial and Arrow Therapeutics (a 465 
London-based pharmaceutical company) plans to develop and commercialize the small 466 
molecule inhibitor (18).  467 
IV. Concluding remarks 468 
Despite extensive research that has vastly increased our understanding of the 469 
molecular virology of Rift Valley fever virus, several key questions remain.  Although 470 
the structure of RVFV N bound non-specifically to nucleic acid has been solved how 471 
nucleocapsid proteins interact with their cognate RNA is not well understood and the 472 
mechanism of the dynamic encapsidation process has not been characterized.  473 
Furthermore, since N performs a variety of functions during the virus life cycle, it is 474 
likely that N interacts specifically with internal RNA sequences and secondary structural 475 
elements of the viral RNA and possibly even cellular RNAs.  The affinity of N for RNA 476 
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sequences other than the 5’ and 3’ termini of the viral genome and antigenome has not 477 
been explored for bunyaviruses.  Finally, it has been demonstrated in several other RNA 478 
viruses that N is promising drug target; however, no FDA-approved anti-viral drugs are 479 
currently available to treat RVFV infected individuals.  The research presented in this 480 
dissertation aims to address these underlying questions and issues that persist in the field 481 
of Rift Valley fever virus biology.  We use biochemical methods to explore the RNA- 482 
binding properties of RVFV N and develop a high-throughput assay for identification of 483 
compounds that inhibit an N-RNA binding interaction.  The efficacy of potential anti- 484 
viral drug compounds identified using the high-throughput assay during RVFV infection 485 
is also tested. 486 
 487 
 488 
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CHAPTER 2:  IDENTIFICATION AND 489 
CHARACTERIZATION OF RIFT VALLEY FEVER VIRUS 490 
NUCLEOCAPSID PROTEIN-RNA BINDING MOTIF 491 
This chapter is a modified version of the manuscript published in Antiviral Research in 492 
January 2012; http://dx.doi.org/10.1016/j.antiviral.2012.01.002 493 
 494 
 495 
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I. Introduction 496 
Rift Valley fever virus (RVFV) is a mosquito-borne bunyavirus (genus 497 
Phlebovirus) endemic to sub-Saharan Africa.  It is responsible for widespread outbreaks 498 
of severe disease such as hepatitis, encephalitis and hemorrhagic fever in humans and 499 
abortion storms in livestock.  In recent years the virus has spread as far north as Egypt 500 
and is now considered endemic in the Arabian Peninsula (6).  The ability to cross 501 
extensive geographic barriers as well as the presence of competent mosquito vectors in 502 
Europe, Asia and the Americas signify the potential for global distribution.  Currently 503 
there is no specific treatment for RVFV infection.  Ribavirin, a nucleoside analog, is one 504 
of few drugs approved for treatment of viral hemorrhagic fevers.  Although it has been 505 
administered to patients during past outbreaks, its use is limited due to adverse side 506 
effects (60, 67, 81).  T-705 is a pyrazinecarboxamide compound that inhibits viral 507 
replication post-infection in vitro and efficacy has been demonstrated for several RNA 508 
viruses in animal models (40, 41).  Despite these advances, T-705 is not licensed and 509 
therefore not a feasible treatment option for RVFV infection.  RVF is an emerging 510 
infectious disease and a major zoonotic threat, and the characteristics described above 511 
emphasize the need for therapeutics to treat infected individuals.          512 
RVFV has a tripartite single-stranded negative-sense RNA genome that encodes 513 
seven proteins.  One of these gene products, the nucleocapsid protein, N, is an RNA 514 
binding protein required for the production of viable virus because of its involvement in 515 
several stages of viral replication.  N protects the viral genome from degradation and 516 
prevents the formation of double stranded RNA intermediates during replication and 517 
transcription by encapsidating viral genomic and antigenomic RNA (105).  N also has 518 
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RNA chaperone activity predicted to function during initiation of viral replication by 519 
unwinding an RNA helix that sequesters the self-complementary ends of the genome and 520 
allowing the polymerase to bind (74, 75).  This activity could also remove higher order 521 
RNA structures that decrease the speed and efficiency of translation of viral mRNA.   522 
RVFV is a member of the large bunyavirus family (Bunyaviridae), which is 523 
composed of five genera:  Orthobunavirus, Hantavirus, Phlebovirus (including RVFV), 524 
Nairovirus and Tospovirus.  A notable feature of all bunyavirus RNA segments is a 525 
conserved, self-complementary sequence present at the 5’ and 3’ ends of the genome and 526 
antigenome.  This sequence undergoes base pairing to form panhandle-like structures and 527 
preferential binding of the termini of viral RNA segments by N has been demonstrated in 528 
Sin Nombre hantavirus (SNV) (72, 76, 78).  Further analysis of the RNA binding 529 
properties of SNV N reveal that it binds with high affinity to UAG repeats located in the 530 
5’ untranslated region of viral mRNA.  It has been proposed that this sequence is a cis- 531 
acting signal that enhances the initiation step of translation and subsequently increases 532 
the production of viral proteins (79).  The first 40 nucleotides present at the 5’ end of the 533 
viral genome and antigenome have also been shown to contain an RNA binding domain 534 
for N protein isolated from several members of the Bunyaviridae, such as Jamestown 535 
Canyon, Hantaan and Bunyamwera viruses (85, 87, 109).  This region is thought to 536 
contain a stem-loop structure specifically recognized by N and binding to this site may 537 
initiate encapsidation of viral RNA (87, 98).  Thus, all of the known essential functions 538 
performed by N during an infection involve RNA binding. Furthermore, the 539 
multifunctional and viral specific nature of the N protein underscores its potential as an 540 
antiviral therapeutic target.  Because nearly all RNA viruses, retroviruses, and 541 
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hepadnaviruses encode RNA-binding nucleocapsid proteins, disrupting the N-RNA 542 
interaction represents a potentially powerful new antiviral therapeutic strategy with broad 543 
applicability.  In this study, we explore the RNA binding properties of RVFV N using 544 
biochemical, biophysical, and combinatorial methods and describe construction of a 545 
fluorescent biosensor that reports on N-RNA interactions.  546 
II. Materials and Methods 547 
A. Overexpression and purification of Rift Valley fever virus N protein 548 
Plasmid encoding (His6)-tagged RVFV N protein was transformed into E. coli strain 549 
BL21(DE3)pLysS.  Transformed cells were grown at 37°C in LB media containing 100 550 
µg/ml ampicillin and 50 µg/ml chloramphenicol until OD600=0.6-0.8.  Protein expression 551 
was induced by addition of IPTG to a final concentration of 0.5mM and cultures were 552 
grown overnight at room temperature (24°C).  Cells were harvested by centrifugation and 553 
stored at -80°C. 554 
Cells were lysed by resuspension of thawed pellets in BugBuster (Novagen) in the 555 
presence of protease inhibitors.  Benzonase (Novagen) was added to the lysis buffer at a 556 
concentration of 12 units/mL to degrade DNA and RNA.  Insoluble cell debris was 557 
removed from the lysate by centrifugation at 12,000 RPM for 45 minutes at 4°C.  The 558 
(His6)-tagged N was batch purified from the cell lysate by using Ni-charged IMAC resin 559 
(Bio-Rad).  The resin was washed 5 times with 35mM imidazole/0.5M NaCl/1.5M urea 560 
in 50mM Tris-HCl buffer, pH 8.0 and the protein eluted with 300mM imidazole/0.5M 561 
NaCl in 50mM Tris-HCl buffer, pH 8.0.  The eluate was concentrated and the buffer 562 
exchanged to 0.5M NaCl in 50mM Tris-HCl pH 8.0 using Amicon centrifugal filters 563 
(10K MWCO).  After flash freezing with liquid nitrogen the N protein was stored at - 564 
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80°C.  The purity of the protein was checked by SDS-PAGE and its concentration was 565 
determined by the absorbance at 280 nm using extinction coefficient obtained from the 566 
ExPASy website (33,920 M-1cm-1). 567 
B. Preparation of pool 0 DNA 568 
In order to construct a pool of DNA template with a 30 nucleotide long randomized 569 
region flanked by constant regions, MMLV reverse transcriptase (Invitrogen) was used to 570 
perform an extension reaction on two chemically synthesized oligos that had 571 
complementary 3’ ends.  The sense primer contained an EcoRI site and a T7 promoter 572 
near the 5’ end followed by a 13 nucleotide long constant region (Fig. 2-1A, 573 
EcoT7SX5’).  The antisense primer contained a XbaI site near the 5’ end and a 30 574 
nucleotide randomized cassette flanked by constant regions (Fig. 2-1A, XBbSx30).  After 575 
extension the DNA was digested with EcoRI and XbaI to obtain templates of uniform 576 
size and purified by phenol/chloroform extraction and ethanol precipitation.   577 
C. Preparation of pool 0 RNA 578 
Pool 0 RNA was generated using pool 0 DNA as a template and a MEGAshortscript 579 
Kit (Ambion) (Fig. 2-1B).  The transcription reaction was DNase treated and purified by 580 
phenol/chloroform extraction and ethanol precipitation.  The pool RNA was further 581 
purified by denaturing gel electrophoresis.  The band corresponding to the RNA was 582 
visualized by UV shadowing, excised, eluted into 0.5M ammonium acetate, 1.0mM 583 
EDTA pH 8.0 and 0.2% SDS, and ethanol precipitated. 584 
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D. Selection of RNA aptamers to Rift Valley fever virus N protein 585 
Pool RNAs were incubated at 30°C with Ni-charged IMAC resin (Bio-Rad) in 586 
binding buffer (10mM HEPES pH 7.5, 150mM NaCl and 5mM MgCl2) using a rotisserie 587 
in a hybridization oven.  After incubation the reaction was placed on ice, the resin 588 
pelleted by gravity, and the unbound RNA in the supernatant collected and used for 589 
subsequent selections.  This “pre-selection” step was necessary to prevent amplification 590 
of RNAs that bind with high affinity to Ni-charged resin.  Next preselected RNAs were 591 
incubated with purified (His6)-tagged N protein that was pre-bound to Ni-charged resin in 592 
binding buffer with constant rotation at 30°C.  The binding and nonbinding RNAs were 593 
partitioned by allowing the resin to settle to the bottom of the microfuge tube on ice.  The 594 
unbound RNAs in the supernatant were removed and discarded.  The Ni resin pellet 595 
containing the target RNA-N complexes was washed multiple times with binding buffer 596 
to remove weakly bound RNAs and then phenol/chloroform extracted and ethanol 597 
precipitated to purify RNAs that bound to N with high affinity.   598 
The selected RNAs were then subjected to RT-PCR to obtain DNA templates for 599 
subsequent rounds of selection.  The reverse transcription step was performed in a final 600 
volume of 20 µL using AMV reverse transcriptase (Promega) according to the 601 
manufacturer’s protocol.  Approximately 200 ng XbaBbs primer (5’-GCT CTA GAA 602 
GAC GC-3’) and 400 ng RNA template (a 1:2 primer/template ratio was always used) 603 
were incubated at 70°C for 3 minutes and snap cooled on ice.  Next, AMV RT buffer, 604 
dNTP mix (0.6mM of each NTP) and 0.3 µL AMV RT enzyme were added and the 605 
reaction incubated at 42°C for 1 hour.  The PCR step was performed in a final volume of 606 
50 µL containing 5 µL of the cDNA template, 0.2µM of EcoT7SX5’ and XbaBbs 607 
 31 
primers, dNTP mix (0.2mM of each dNTP), MgCl2 (1.5mM final), 1X PCR buffer, and 608 
1.25 units of GoTaq Hot Start DNA polymerase.  Twenty five cycles of amplification 609 
were used and the annealing temperature varied and was empirically determined for each 610 
round of selection by performing a small scale gradient PCR.  The RT- PCR products 611 
were digested with EcoRI and XbaI and used as templates for T7 transcription to generate 612 
RNA for subsequent rounds of selection.   613 
Fifteen rounds of selection for RNA aptamers to RVFV N were conducted using the 614 
protocol described above (Fig. 2-1C).  We gradually increased the stringency of the 615 
selection each round by decreasing the amount of time allotted for RNA-protein 616 
complexes to form.  Pool 0 RNAs and N were incubated together for 5 hours whereas 617 
pool 14 and 15 RNAs were incubated with N for less than 1 minute.  The final (16th) 618 
round of selection was done by incubating N that had the His-tag removed by tobacco 619 
etch virus (TEV) protease digestion with a mixture of radioactive (200,000 cpm) and 620 
unlabeled (300 ng) pool 15 RNA for less than one minute at room temperature (24°C).   621 
The binding reactions were loaded with 2µL of glycerol loading dye onto a pre-chilled 622 
6% acrylamide/TBE gel and samples migrated at 10V/cm on the gel in the cold room for 623 
75 minutes.  The gel was visualized using phosphorimagery (Fuji) and the bands 624 
corresponding to the N-RNA complex were excised from the gel.  To obtain round 16 625 
RNA, slices of the excised bands were subjected to RT-PCR followed by T7 transcription 626 
using essentially the same protocol described for previous selections.   The only alteration 627 
involved performing the reverse transcription step in a final volume of 50 µL to 628 
synthesize cDNA from a 10 µL equivalent slice of gel.  For comparative analysis the 629 
digested RT-PCR products of rounds 1, 8, 15 and 16 were ligated into the XbaI and 630 
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EcoRI sites of the pUC18 plasmid and the DNA from individual clones isolated and 631 
sequenced.                  632 
E. Synthesis and purification of selected pool and clonal RNAs 633 
RNA was synthesized using either clones digested with XbaI or pool DNA obtained 634 
from digested RT-PCR products as templates for T7 RNA polymerase.  635 
MEGAshortscript kits (Ambion) were used to synthesize non-radioactive RNA and 636 
MAXIscript kits (Ambion) were used to synthesize RNA in the presence of radioactive "- 637 
32P-UTP (800Ci/mmol; PerkinElmer).  The transcription reactions were then DNase 638 
treated and purified by phenol/chloroform extraction and denaturing gel electrophoresis 639 
as described for the synthesis of pool 0 RNA.     640 
F. Nitrocellulose filter binding assays 641 
N was serial diluted to varying concentrations in a binding buffer (10mM HEPES pH 642 
7.3, 150mM NaCl, 20mM KCl, and 5mM MgCl2 final concentration).  Nine µL of 643 
various dilutions of N were added to each tube along with 1 µL of RNA that had been 644 
subjected to denaturation at 90°C for two minutes followed by snap cooling on ice.  In 645 
each experiment 25,000 cpm/#L of reference RNA (wild type) was added.  The cpm/#L 646 
of the other RNAs was adjusted based on their uridine content to ensure an equal number 647 
of molecules were used.  After incubation at 30°C for one hour, reactions were diluted to 648 
100 µL with ice-cold binding buffer and filtered through pre-soaked nitrocellulose filters 649 
(Millipore HAWP).  The filters were washed twice with 500 µL ice-cold binding buffer, 650 
dried, and the radioactivity retained on filters was measured by scintillation counting.  651 
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G. Electrophoretic mobility shift assays 652 
Samples for EMSAs were prepared as described for the filter binding assays.  After 653 
incubation the reactions were placed on ice and 2 µL of glycerol loading dye was added 654 
to each tube.  Samples were loaded onto pre-chilled 6% acrylamide/1X TBE gels that 655 
were run in the cold room at 10V/cm for 75 minutes.  Gels were then dried, exposed to a 656 
phosphorimager screen, and visualized on a Fuji FLA3000G Image Analyzer. 657 
H. Synthesis of mutant and truncated aptamer RNAs 658 
DNA template that contained the desired mutations to the aptamer sequence was 659 
generated by performing a PCR extension reaction on two chemically synthesized oligos 660 
that had complementary 3’ ends.  The PCR step was performed in a final volume of 50 661 
µL containing 0.3µM of sense and antisense oligo, dNTP mix (0.2mM of each dNTP), 662 
MgCl2 (1.5mM final), 1XPCR buffer, and 1.25 units of GoTaq Hot Start DNA 663 
polymerase.  Thirty cycles of amplification with an annealing temperature of 55°C were 664 
used.  The PCR products were digested with EcoRI and XbaI and used as templates T7 665 
transcription to generate mutant aptamer RNA.  A MAXIscript kit (Ambion) was used to 666 
synthesize RNA in the presence of radioactive "-32P-UTP (800Ci/mmol; PerkinElmer) 667 
using the same protocol described for synthesis and purification of clonal RNAs.  668 
I. RNA solution structure probing 669 
RNAs were dephosphorylated using Antarctic phosphatase (New England BioLabs).  670 
The 5’ ends were labeled with $-32P-ATP (6000Ci/mmol; PerkinElmer) using T4 671 
polynucleotide kinase (Invitrogen) and the RNA purified by denaturing gel 672 
electrophoresis.  Labeled RNAs were heated in water for two minutes at 90°C followed 673 
by snap cooling on ice.  Binding buffer (10mM HEPES pH 8, 150mM NaCl, 20mM KCl 674 
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and 5mM MgCl2) was added and samples incubated at 37°C for 10 minutes.  The folded 675 
RNA (60,000 cpm/rxn) was incubated in binding buffer with 2 µg tRNA and either 676 
RNase T1 (0.25 units/rxn) or RNase U2 (10 units/rxn at 37°C for 10 minutes.  A T1 677 
ladder was prepared by incubating the RNA at 50°C in a denaturing buffer (6mM sodium 678 
citrate pH 5, 7M urea and 1 mM EDTA) prior to digestion with RNase T1.  An alkaline 679 
ladder was prepared by incubating the RNA at 90°C for 4 minutes in 100mM sodium 680 
carbonate buffer pH 9.0.  All samples were ethanol precipitated, resuspended in 681 
formamide loading dye and analyzed by denaturing gel electrophoresis.  682 
J. Fluorescence polarization measurements 683 
A 35 nucleotide long RNA was chemically synthesized, 3’ end labeled with FAM 684 
and HPLC purified by TriLink BioTechnologies.  The fluorescent label was attached to 685 
the RNA using a six-carbon linker.  N was serial diluted to varying concentrations in a 686 
binding buffer (10mM HEPES pH 8, 150mM NaCl, 20mM KCl and 5mM MgCl2).  To 687 
determine the equilibrium dissociation constant of N/FAM-RNA complex, various 688 
dilutions of N were added to 10 nM FAM-labeled aptamer RNA that had been subjected 689 
to denaturation at 90°C for two minutes followed by snap cooling on ice.  Reactions were 690 
incubated at 30°C for 1 hour.  Samples for competitive binding experiments were 691 
prepared by incubating varying concentrations unlabeled competitor RNA (450 pM-5.0 692 
µM) with 4.5 µM N for 40 minutes at 30°C.  Next, 10 nM FAM-labeled RNA was added 693 
and the reaction incubated for 40 minutes at 30°C.  Fluorescence polarization values were 694 
measured using a VICTOR X multilabel plate reader.  Binding profiles were plotted and 695 
apparent Kd and Ki values were calculated using GraphPad Prism software. 696 
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K. Cell culture studies 697 
Human 293 cells were maintained in Dulbecco’s modified eagle medium (DMEM) 698 
supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin.  Vero 699 
cells were maintained in minimum essential medium (MEM) alpha medium 700 
supplemented with 10% FBS, penicillin and streptomycin.  The Rift Valley fever virus 701 
(RVFV) vaccine strain, MP-12, was provided by Brian Gowen (Utah State University, 702 
Logan, UT).  A Rift Valley fever reporter virus containing the gene for Renilla luciferase 703 
was provided by Richard Elliott (University of St. Andrews, St. Andrews, United 704 
Kingdom).  The Renilla luciferase open reading frame was inserted in place of the NSs 705 
gene encoded by the S segment of Rift Valley fever virus (RVFV) and is known to not be 706 
required for viral infection.  During infection, human 293 cells and virus were maintained 707 
in DMEM supplemented with 2% FBS, penicillin and streptomycin.  Incubations were 708 
carried out at 37°C and 5% CO2 unless otherwise stated. 709 
L. Cell culture and transfection 710 
Confluent monolayers of human 293 cells grown in 24-well plate were transiently 711 
cotransfected with 15 pmole RNA/well and 0.5 µg plasmid DNA/well using the 712 
Lipofectamine 2000 kit (Life Technologies).  The next morning transfected cells were 713 
harvested, counted and reseeded in 96-well plate format. 714 
M. Luciferase assays 715 
Confluent monolayers of transfected human 293 cells grown in 96-well plate format 716 
were infected with RVF-luc virus using a MOI of three.  Cells were harvested at eight 717 
hours post infection by removing the growth media, adding 20 µL of lysis buffer and 718 
rocking the cells for 15 minutes at room temperature.  The cell lysate substrate was 719 
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diluted (5-20x) in reagent buffer and 20 µL was transferred to a white 96-well plate.  A 720 
Biotek Synergy 2 plate reader was used to autoinject each sample well with 100 µL of 721 
Renilla luciferase assay reagent (Promega) and measure the luminescence. 722 
N. Plaque Assays 723 
Confluent monolayers of transfected human 293 cells grown in 96-well plate format 724 
were infected with RVF MP-12 virus using a MOI of 0.1, centrifuged at 2500 RPM for 725 
100 minutes and incubated for 1 hour.  After incubation the media was removed and 726 
replaced with DMEM supplemented with 2% FBS, penicillin and streptomycin.  727 
Supernatants of virus infected cells were harvested at 3 days post infection.  The 728 
supernatants were serially diluted in MEM and subsequently used to infect confluent 729 
Vero cells grown in 6-well plate format.  After a 2 hour incubation the cells were overlaid 730 
with MEM containing 1% agarose and incubated for 7 days.  Cells were fixed with 731 
9.25% formaldehyde and plaques revealed using crystal violet stain. 732 
III. Results 733 
A. In vitro evolution of RNA aptamers to Rift Valley fever virus N protein 734 
An 84 bp segment of DNA that contained a 30 bp random region flanked by constant 735 
sequences was used as a template for T7 RNA polymerase transcription.  The template 736 
contained a 5’ EcoRI site, a T7 promoter, a 13 nucleotide-long constant region followed 737 
by a 30 nucleotide-long randomized region and then another constant region with a 3’ 738 
XbaI site (Fig. 2-1A).  The presence of all 4 nucleotides in the randomized region was 739 
verified by batch sequencing of pool 0 DNA (data not shown) and by sequencing of 740 
individual clones from pool 1 DNA.  The recombinant nucleocapsid protein (N) from the 741 
M12 strain, a clinical isolate of RVFV (39), was overexpressed in E. coli and purified 742 
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using Ni-charged IMAC resin.  Next, a selection/amplification technique (SELEX) was 743 
used to isolate several families of RNA aptamers that bind with high affinity and 744 
specificity to the N protein from a starting pool of approximately 1014 small RNAs (Fig. 745 
2-1B).  The basic methodology for the in vitro selection is outlined in Figure 2-1C and 746 
the technique described in detail in Materials and Methods. 747 
The iterative selection step consisted of partitioning the unbound and bound RNA 748 
species by immobilizing the N protein onto Ni-charged IMAC resin.  This allowed the 749 
bound RNAs to be pelleted with the resin beads and the unbound RNAs in the 750 
supernatant to be discarded.  The selected RNAs were then purified from both N and Ni- 751 
resin by phenol/chloroform extraction and amplified using RT-PCR and primers specific 752 
to the constant sequences.  Sixteen rounds of selection were conducted and negative 753 
selections were periodically performed to eliminate Ni-resin binding species and ensure 754 
isolation and amplification of N-specific aptamers.  During the first rounds of selection N 755 
was allowed extended incubation with pool RNAs in order to capture and amplify a small 756 
number of functional molecules.  In later rounds, the stringency of selection was 757 
increased using a greater RNA to protein ratio (100:1) and shorter incubation periods.  758 
The final (16th) round of selection was performed using non his-tagged N and the bound 759 
and unbound species of RNA were separated by electrophoretic mobility shift.  The band 760 
on the gel corresponding to high molecular weight RNA/protein complexes was excised, 761 
and the RNA eluted from the gel slice and subjected to RT-PCR followed by T7 762 
transcription.  763 
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Figure 2 - 1:  Construction of random sequence nucleic acid pools and in vitro 765 
selection methodology.   766 
A.  Oligos used to construct pool 0 DNA.  The sense oligo (EcoT7SX5’) contained an EcoRI restriction 767 
site, a T7 promoter and a 3’ constant sequence that was complementary to the 3’ constant sequence on the 768 
antisense oligo (XBbsSx30).  The antisense oligo contained the 30 nucleotide long randomized region 769 
flanked by constant regions and a 5’ Xba1 restriction site.  Shaded boxes highlight constant regions present 770 
in both the oligo DNA and RNA.  B.  Randomized RNA sequence used for the in vitro selection.  C.  771 
Schematic diagram of the technique used to select and amplify RNAs that bound with high affinity to 772 
RVFV N.  Non-binding and binding RNAs were separated using N immobilized to Ni-charged resin as a 773 
target.  Therefore, the resin also immobilized RNAs that bound to the N, allowing unbound RNAs to be 774 
washed away and selected RNAs were purified and amplified.  RT-PCR was used to create more DNA 775 
template for transcription, generating more RNA for subsequent rounds of selection.  This cycle was 776 
repeated 15 times.  D.  Evolution of RNAs with high affinity to N after repeated rounds of selection. The 777 
pools RNA binding affinity for N was analyzed by EMSA.  The bands that migrate faster in the gel are 778 
unbound RNA species and the slower migrating bands represent N/RNA complexes.  RNAs were internally 779 
labeled with 32P-UTP and the gels visualized by phosphorimaging. 780 
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B. Binding affinity of pool RNAs to N increases with repeated rounds of selection 781 
Binding assays were performed at several intermediate rounds of the selection to 782 
assess the affinity of pool RNA sequences for N.  Pool RNAs were transcribed from RT- 783 
PCR products and internally labeled with 32P-UTP.  A constant amount of labeled RNAs 784 
(25,000 cpm) was incubated in binding buffer with either 1.2µM or 12µM RVFV N for 1 785 
hour at 30°C and then subjected to non-denaturing gel electrophoresis (Fig. 2-1D).  The 786 
range of N protein concentrations used in our study (0.6-35µM) was determined 787 
empirically.  The bands that migrate faster on the gel correspond to the free RNA species 788 
and the higher migrating bands represent high molecular weight RNA/protein complexes.  789 
Round 0 RNAs exhibited low overall binding affinity to N whereas the binding affinity of 790 
round 8 RNAs had increased dramatically.  When incubated with the highest 791 
concentration of N, most of round 8 and round 11 RNAs were present in the slowest 792 
migrating band, indicating that they were able to bind stably to N and that the affinity for 793 
N was increasing with subsequent rounds of selection.  Although the binding affinity of 794 
round 11 RNAs for N was high, several further rounds of selection were carried out to 795 
decrease the population complexity.  796 
C. Selected aptamer RNAs have a distinct primary sequence signature  797 
The RT-PCR products from rounds 1, 8, 15 and 16 of the selection were cloned into 798 
pUC18 plasmid.  Individual clones from rounds 1 and 8 and a total of 100 individual 799 
clones from rounds 15 and 16 were sequenced. Analysis of round 1 sequences showed a 800 
distribution of 27% A, 19% G, 32 % C, and 23 % T (Table 2-1).  Interestingly, when 801 
these percentages were compared to the nucleotide distribution of sequences isolated 802 
from rounds 8, 15 and 16 of the selection, a progressive enrichment for both guanosine 803 
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and thymidine residues was evident.  While the enrichment observed for guanosine 804 
residues stabilized by round 8, the percentage of thymidine residues continued to increase 805 
from 31% at round 8 to 40% in rounds 15 and 16.  Also, the percentage of adenosine and 806 
cytidine residues was reduced in sequences isolated from later rounds of selection 807 
compared to round 1 clones.  Analysis of individual sequences from rounds 15 and 16 of 808 
the selection showed that 49 out of the 100 sequences occurred with multiple frequencies 809 
or were at least 90% similar (Table 2-2).  These results suggest that, while identifiable 810 
sequence trends were evident throughout the population, several sequence families were 811 
beginning to dominate the pool. 812 
Table 2 - 1:  Distribution of nucleotides within the RVFV genome and the 813 
randomized region of clonal RNAsa.   814 
Sequence Analyzed % A % G % C % T 
Round 1 RNA 27 ± 9 19 ± 6 32 ± 11 23 ± 9 
Round 8 RNA 17 ± 8 29 ± 9 19 ± 5 31 ± 7 
Rounds 15&16 RNA 19 ± 6 28 ± 4 15 ± 5 40 ± 6 
RVFV S segment 23.6 23.1 25.9 27.4 
RVFV M segment 27.3 25.4 20.1 27.3 
RVFV L segment 29.2 23.8 20.3 26.7 
aSequences corresponding to the viral genome were obtained from the NCBI nucleotide database using the 815 
following accession numbers:  NC_014395.1, NC_014396.1, and NC_014397.1 that correspond to the S, 816 
M, and L segments respectively.  Eight sequences from round 1 and round 8 and a total of 100 sequences 817 
from rounds 15 and 16 were analyzed.  ± deviation from the mean. 818 
D. Characterization of binding affinity between selected aptamer RNAs and N 819 
protein  820 
Several clones from rounds 1, 8, and 15 of the selection were chosen to assess the 821 
evolution of aptamer affinity (Table 2-2).  The filter binding assay was used to compare 822 
the binding of individual clonal RNAs (Fig. 2-2A).  As expected, the binding affinity of 823 
the round 1 RNA (MBE1.3) was very low while the binding affinity of round 15 RNA 824 
(MBE15.3) to N was high.  Moreover, the persistence of RNAs with low binding affinity 825 
to N at round 8 underscored the need for further rounds of selection to cull lower-affinity 826 
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binders from the pool.  To confirm the high affinity of our aptamers cloned from the last 827 
selection rounds, we tested them in a competitive binding assay against a specific natural 828 
target, the terminal panhandle structure of RVFV genomic RNA. 829 
Table 2 - 2:  Alignment of the randomized region (5’-3’) of RNA aptamers isolated 830 
from the different rounds of selection. 831 
RNA a sequenceb 
Frequency  
(100 clones) 
MBE16.49 -------AGUAAUGCUAUGAUGAUAAUGUGUCCCGGGG--  1 
MBE16.41 -------AGUAACGCUAUGAUGAUAAUGUAUCCCGGGG-- 1 
MBE15.12 ----CUGUUUACUGAACUAUGAUACUUU---CUGGGG--- 5 
MBE16.64 -----AUGUUACUGACUUCUUCUGAUUU---CUAGUGG-- 2 
MBE15.2 ----UGUCGUACUGAU---UGAUGAUUUACUCUGGGG--- 5 
MBE15.8 ----UGUCGUACUGAU---UGAUGAUUUACUCGGGGG--- 1 
MBE16.87 AGCCAGUAUUACUGAU---UGAUGAUU----CUGUGG--- 2 
MBE16.59 -UGAUGCAGAACUGAU---UGAUUACUU---CUGGGG--- 2 
MBE15.21 --GCUACU--UCUGAU---UGAUUAUUU---CUCUGGUGG 2 
MBE16.50 ---AUGUCAUACUGAUUACUGAUGACUU----UGGGG--- 2 
MBE16.74 ---AUGUCAUACUGAUUACUGAUGAAUU----UAGGGG-- 1 
MBE8.1 --------CUUCUGAUUACUGAUUUCUUUCUCUAGUGG-- NDc 
MBE16.113 -------AAUGUCGAUUACUGGUUGCUGACUCUGGGG--- 1 
MBE16.114 -------AAUGUCGAUUACUGAUUGCUGAUUCUGGGG--- 2 
MBE15.7 -----UGCAUGCUGAUUACUG---AUUUUAUCCUGGGG-- 1 
MBE15.20 -----UGCAUGUUGAUUACUG---AUUU-AUCCUGGGG-- 1 
MBE15.14 -----UGCAGACUGAUUACUG---ACUUUCUCUAGUGG-- 3 
MBE16.40 ---AAUGCGGACUGAUUACUG---AUACUCUGGGG----- 5 
MBE8.6 --GUGGACGUCCUGCGUUGUG--GGCUUG---UGUGG--- ND 
MBE15.3 
MBE16.57 
MBE8.3 
MBE16.112 
MBE1.4 
MBE1.3 
-------CGUCCCGUAGUGUCGGUACUGAUUGAUGUG--- 
-------CGUCCCGUAGUGUCGGUACUGAUUAAUGUG--- 
-------CGCCCCGUAGUGCAUAGUCUGAUUGAUGUG--- 
----UGCGAUACUGAAU-AUGAAAGCUUUAGGUGG----- 
--ACGAGUGCCAUGCACUACAUUGUCUGUUGA-------- 
----CACCGUAACAAAGUUGUAAGACACCAACCA------ 
9 
1 
ND 
2 
ND 
ND 
Others Orphan sequence 51 
aAptamer RNAs are labeled using two numbers.  The first number corresponds to the round the aptamer 832 
was first isolated from and the second number is a unique identifier.  bThe constant regions are not shown.  833 
Sequences from rounds 15 and 16 that occurred with multiple frequencies or were <90% similar are shown.  834 
The GAUU motif is in bold font and the pyrimidine/guanine motif is underlined.  c Not determined 835 
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 836 
Figure 2 - 2:  Characterization of binding interactions between selected RNAs and 837 
N. 838 
A.  A nitrocellulose filter binding assay was used to compare N binding to clonal RNAs from round 839 
1(MBE1.3, open diamonds), round 8 (MBE8.1, filled triangles; MBE8.3, “X”; MBE8.6, open squares) and 840 
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round 15 (MBE15.3, open circles).  RNAs were internally labeled with 32P-UTP and radioactivity retained 841 
on filters was quantified by liquid scintillation counting.  B.  Top panel: mfold predicted secondary 842 
structure of viral genomic and antigenomic small RNA constructs.  Bottom panel: a filter binding assay was 843 
used to test the binding ability of genomic (“X”) and antigenomic (filled triangles) RNA constructs to the N 844 
protein.  C.  A competitive filter binding assay was used to test the ability of RNAs from the final (15th and 845 
16th) rounds of selection to inhibit binding of viral genomic RNA.  The amount of radiolabeled (32P-UTP) 846 
viral RNA retained on the nitrocellulose filters in either the absence (black fill) or presence of unlabeled 847 
competitor was measured by liquid scintillation counting.  The following aptamer RNAs were tested:  848 
MBE15.2, circle fill; MBE15.3, gray fill; MBE15.12, grid fill; MBE15.14; white fill. 849 
E. Aptamer RNAs compete with viral RNA sequences to bind N  850 
First, a binding experiment was performed to test the affinity of N for small RNA 851 
molecules that mimic the panhandle structures formed by the genomic or antigenomic 852 
RVFV RNAs (S segment).  The stem-loop structures are formed by the base-pairing 853 
interaction of the 5’ and 3’ ends of one RNA molecule. For practical reasons, the long 854 
intervening sequence of the S segment was replaced with a stretch of adenine residues 855 
(Fig. 2-2B).  The filter binding results showed that N binds well to both small RNA 856 
constructs (Fig. 2-2B). 857 
Next, we performed competitive binding experiments using the internally 858 
radiolabeled genomic panhandle RNA construct and unlabeled aptamer RNAs.  A 859 
constant amount of N (7µM) was incubated with varying amounts of unlabeled aptamer 860 
RNA (0.45 nM – 4.5 µM for 1 hour at 30°C.  Labeled genomic RNA (100,000 cpm/rxn) 861 
was added and the binding reaction incubated for 5 more hours at 30°C.  Binding of 862 
labeled RNA was then assessed by filter binding assay.  The results from the competition 863 
filter binding assay showed that when increasing amounts of unlabeled aptamer RNA 864 
were present during the binding reaction, less genomic panhandle RNA was retained on 865 
the filter (Fig. 2-2C).  Clearly, the presence of aptamer RNA inhibited the formation of 866 
genomic RNA-N complexes, suggesting the aptamer RNA binds to the same region on N 867 
as the viral panhandle. 868 
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F. Two conserved motifs are found in late-round aptamers 869 
We then checked for the presence of conserved motifs among the high-affinity 870 
aptamers of rounds 15 and 16 using primary sequence alignment and visual inspection.  871 
The results are summarized in Table 2-2.  A GAUU-containing motif was identified in 872 
82% of the 49 sequences isolated with high frequency.  This motif was variable in the 873 
number of GAUU repeats per RNA and the exact sequence observed.  For example, 874 
MBE16.74 had a GAUUACUGAUGAAUUU motif while sequencing of another isolate 875 
(MBE16.87) revealed a GAUUGAUGAUU motif (Table 2-2).  Despite these minor 876 
differences, the prevalence of variations of the GAUU motif in a high percentage of the 877 
RNAs isolated indicates that it may be an important recognition sequence for N.  Also, a 878 
pyrimidine/guanine motif we call the U/G-rich motif, located near the 3’ end of the 879 
random region, was present in many of the sequences isolated from rounds 15 and 16 880 
(Table 2-2).  Interestingly, alignment of aptamer sequences with the RVFV genome and 881 
antigenome using BLAST revealed that the U/G-rich motif UUUCUGGGGGCG isolated 882 
11 times in the selected RNAs was also present in the RVFV L antigenome (Table 2-3).  883 
The evolution of these two motifs could be responsible for the observed enrichment of 884 
guanosine and thymidine residues in sequences isolated from rounds 8, 15 and 16.  There 885 
was a strong correlation between the emergence of guanosine and thymidine rich primary 886 
sequences during the selection and the evolution of RNAs that bind with high affinity to 887 
N.  Together, these data suggest that N may preferentially bind to GAUU and/or U/G-rich 888 
sequences. 889 
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G. Directed mutagenesis of GAUU and U/G-rich motifs in aptamer RNAs 890 
Mutant aptamer RNA constructs were generated to test the hypothesis that N 891 
specifically recognizes and binds to GAUU and U/G-rich motifs on selected RNAs.  Two 892 
variants of the GAUUGAUGAUU motif, either obtained by scrambling the sequence or 893 
by introducing complementary nucleotides in place of the U/G-rich motif, were tested in 894 
the context of the MBE15.8 aptamer (Fig. 2-3A).  The binding affinity of MBE15.12 895 
RNA with similar disruptions to its U/G-rich motif (UUUCUGGGG) (Fig. 2-3B) was 896 
also tested. 897 
Filter binding assays were used to compare the affinity of mutant and wild type 898 
aptamer RNAs to N.  Scrambling one GAUU repeat in the MBE15.8 sequence caused a 899 
one-third decrease in the level of RNA bound at 12 µM N.  Complementary mutation of 900 
the first 7 nucleotides of the GAUU motif caused an even more dramatic decrease in 901 
binding.  The binding affinity of the complementary MBE15.8 mutant (15.8 COMP 902 
mutant) to N was even lower than the affinity observed for a round 1 RNA (Fig. 2-3A).  903 
Changing the U/G-rich motif from MBE15.12 RNA from UUUCUGGGG to 904 
UGUAAUCGU caused a slight decrease in the binding affinity to N compared to the 905 
affinity of the original sequence.  Unexpectedly, an RNA that contained a complementary 906 
mutation of the U/G-rich motif (15.12 COMP mutant) exhibited better binding than the 907 
original MBE15.12 aptamer (Fig. 2-3B).  Interestingly, closer examination of this mutant 908 
revealed that it contained an 11 nucleotide sequence identical to the 5’ end of the S 909 
segment of viral genomic RNA (Table 2-3). 910 
These data show that the GAUU motif and, to a lesser extent, the U/G motif, are 911 
important for N binding to aptamer RNA and they likely facilitate interactions between N 912 
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and other RNA molecules as well. The location of the motifs and the binding affinities of 913 
the RNA aptamers were then used to design truncated aptamers of diminished size. 914 
Table 2 - 3:  Regions of sequence similarity between RNA aptamers and the RVFV 915 
genome and antigenome identified using BLAST. 916 
Subject Sequence identified by BLAST Aptamer 
 
Frequency in 
aptamer pool 
(100 clones) 
S genome Aptamer    ACAAAGACCCC   
           ||||||||||| 
Sbjct    3 ACAAAGACCCC 13 
MBE12COMP 
mutant 
1 
S anti-
genome 
Aptamer    AUGAUUGUUCUGG  
           ||||||||||||| 
Sbjct  207 AUGAUUGUUCUGG 219 
MBE35 1 
M genome Aptamer    UCCAAAUGACUA 
           |||||||||||| 
Sbjct  770 UCCAAAUGACUA 781 
MBE101 1 
M genome Aptamer    CAGAACUGAUU  
           ||||||||||| 
Sbjct 2095 CAGAACUGAUU 2105 
2xMBE59 2 
L genome Aptamer    GUUACUGACUUU  
           |||||||||||| 
Sbjct 1789 GUUACUGACUUU 1800 
3xMBE14, 
2xMBE54, 
MBE81 
6 
L genome Aptamer    UUCUGAAUUUU  
           ||||||||||| 
Sbjct 3585 UUCUGAAUUUU 3595 
MBE1 1 
L genome Aptamer    CAGAACUGAUU  
           ||||||||||| 
Sbjct 3932 CAGAACUGAUU 3942 
2xMBE59 2 
L anti-
genome 
Aptamer    UUCUGGGGCGUCUUC   
           |||||| |||||||| 
Sbjct 1894 UUCUGGAGCGUCUUC 1908 
MBE35 1 
L anti-
genome 
Aptamer    UUUCUGGGGGCG  
           |||||||||||| 
Sbjct 4536 UUUCUGGGGGCG 4547 
5xMBE12, 
2xMBE29, 
2xMBE107, 
MBE10, MBE45  
11 
H. Identification of truncated RNA aptamers that bind with high affinity to RVFV 917 
N 918 
Starting with the sequences of several aptamers described above, a series of truncated 919 
RNA aptamers was generated in order to find one or more small RNAs that could 920 
eventually be chemically synthesized and fluorescently labeled.  We chose to truncate 921 
RNAs that were either highly represented in the final round of selection, that contained 922 
GAUU or U/G-rich sequence motifs, or contained sequences that were also present in 923 
viral RNA (Fig. 2-4).  During the truncation process we generally sought to preserve 924 
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important sequence motifs and predicted secondary structure.  A combination of RNase 925 
T1 and U2 structure probing and mfold were used to determine the conformation of 926 
several aptamer RNAs.  Overall, results obtained from the structure probing experiments 927 
provide support for the mfold predicted structures.  However, one common exception was 928 
that the mfold algorithm often predicted base pairing interactions at the apical stems of 929 
the aptamer RNAs.  The RNase T1 and U2 structure probing data showed that guanosine 930 
and adenosine nucleotides at the apical stems were reactive (single-stranded) (Fig. 2-4A, 931 
B and C).  All three RNAs presented here exhibit a strikingly similar stem loop structure 932 
that may serve as a binding site for N.  Our results indicate that preservation of this 933 
structure is necessary for truncated RNAs to retain their ability to bind N (Fig. 2-4D, E 934 
and F). 935 
MBE15.8 and MBE16.40 contained a GAUU motif that was shown above to be a 936 
requirement for N to bind MBE15.8 RNA.  When these aptamers were truncated and the 937 
stem loop structure containing the GAUU motif was preserved, both retained their ability 938 
to bind N (Fig. 2-4D and F).  Conversely, a truncation of MBE16.41 that disrupted the 939 
pyrimidine portion of U/G-rich motif caused the RNA to completely lose its affinity for 940 
N (Table 2-2; 7% input RNA bound at 12.5 µM).  These results further support our 941 
hypothesis that the GAUU and U/G-rich motifs are important components of N-RNA 942 
recognition.   943 
A truncated version of MBE15.14 that contained an 11 nucleotide-long sequence of 944 
RNA present in the L segment of viral genomic RNA bound N with high affinity (62% of 945 
input RNA bound at 12.5 µM).  This U-rich sequence was isolated a total of 6 times from 946 
the final pool of RNA and was also found in two aptamers unrelated to MBE15.14 (Table 947 
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2-3).  The 15.12 COMP mutant aptamer bound N better than the wild type aptamer 948 
MBE15.12 (Fig 2-3B).  MBE15.12 RNA was of interest because it contained a U/G-rich 949 
motif also found in the L segment of viral antigenomic RNA (Table 2-3).  Interestingly, 950 
the complement of the U/G-rich motif is a sequence found at the 5’ end of the S segment 951 
of viral genomic RNA.  The truncated version of 15.12 COMP mutant (15.12 TRNK 952 
COMP mutant) retained this viral sequence, bound N with high affinity and was 953 
predicted by RNA structure probing experiments and mfold to be a stem loop structure 954 
(Fig 2-4E).  Mutation of the large 15 nucleotide long loop in 15.12 TRNK COMP mutant 955 
to create RNAs with smaller loops (TRNK loop A and TRNK loop B) did not affect 956 
binding affinity to N (data not shown).  TRNK loop A and TRNK loop B RNAs retained 957 
all and most of the viral RNA sequence, respectively, which suggests that this sequence 958 
may be important for N recognizing and binding to both viral and aptamer RNA. 959 
 960 
Figure 2 - 3:  Characterization of binding affinity of mutant aptamer RNAs to N. 961 
A nitrocellulose filter binding assay was used to compare N binding to wild type and mutant aptamer RNAs 962 
where either the GAUU or U/G-rich primary sequence motifs were disrupted.  RNAs were internally 963 
labeled with 32P-UTP and radioactivity retained on filters was quantified by liquid scintillation counting.  964 
A.  Top panel: MBE15.8 aptamer RNA GAUU motif and mutant constructs.  Changes to sequence motif 965 
are in bold and lowercase font.  Bottom panel: Filter binding assay of wild type MBE15.8 aptamer, mutant 966 
constructs and round 1 MBE1.4 RNA.  MBE15.8 wild type RNA; open diamonds, MBE15.8 SC mutant; 967 
filled squares, MBE15.8 COMP mutant; filled triangles, and round 1 MBE1.4 RNA; “X”.  B.  Top panel: 968 
MBE15.12 aptamer RNA U/G rich motif and mutant constructs.  Changes to sequence motif are in bold 969 
and lowercase font.  Bottom panel: Filter binding assay of wild type MBE15.12 aptamer, mutant constructs 970 
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and round 1 MBE1.4 RNA.  MBE15.12 wild type RNA; open diamonds, MBE15.12 SC mutant; filled 971 
squares, MBE15.12 COMP mutant; filled triangles, round 1 MBE1.4 RNA; “X”. 972 
 973 
Figure 2 - 4:  Secondary structure model and binding affinity of full length and 974 
truncated RNA aptamers to RVFV N.   975 
A. to C.  Structure probing of full length RNA aptamers MBE15.8 (A), 15.12 COMP mutant (B) and 976 
MBE16.40 (C) was conducted to determine the reactivity of guanosine (lane T1) and adenosine (lane U2) 977 
residues to enzymes RNase T1 and RNase U2.  Lane Ø represents undigested RNA.  T1 and OH- ladders 978 
are used as RNA sequencing lanes.  D. to F.  Summary of nucleotide reactivity superimposed on secondary 979 
structure models of MBE 15.8 (D) 15.12COMP mutant (E) MBE16.40 (F).  Circles represent results 980 
obtained from experiments conducted with the single-strand guanosine specific T1 nuclease and stars are 981 
representative of the single-strand adenosine specific U2 nuclease.  The greater the number of symbols 982 
associated with a specific nucleotide, the stronger the reactivity.  Open symbols indicate a lack of 983 
reactivity.  Truncated aptamers are highlighted in gray.  Aptamers were rated based on percent of input 984 
RNA bound at 12.5 #M N:  40-49% = (+), 50-59% = (++), and 60-69% = (+++). 985 
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 986 
Figure 2 - 5:  Analysis of aptamer RNA-N binding interactions using fluorescence 987 
polarization (FP).  988 
A.  Binding profile for the association of N with fluorescently labeled aptamer RNA (open triangles).  B.  A 989 
competition assay where a fixed concentration of N was incubated with varying concentrations of 990 
unlabeled competitor RNAs (round 1 MBE1.4 RNA; filled squares, MBE15.3 aptamer RNA; open circles).  991 
Fluorescently labeled aptamer RNA was added and the FP signal is plotted versus competitor RNA 992 
concentration. 993 
I. Fluorescence polarization detection of N-aptamer binding 994 
A truncated RNA aptamer (15.12 TRNK COMP mutant, Fig. 2-4E) was chemically 995 
synthesized and 3’ end-labeled with fluorescein (TriLink BioTechnologies).  Fluorescent 996 
RNA was incubated in binding buffer with varying concentrations of RVFV N at 30°C 997 
for 1 hour and fluorescence polarization (FP) measured.  The results showed that the FP 998 
value was low (220 mP) when the label was attached to RNA alone and increased to 420 999 
mP when the RNA was incubated with increasing concentrations of N (Fig. 2-5A). 1000 
Titration of N with the 3’-FAM-labeled RNA aptamer gave an apparent Kd of 2.6 µM.  1001 
Next we performed competitive binding experiments by incubating a constant amount of 1002 
N (4.5 µM) with varying concentrations (450 pM-5.0 µM) unlabeled competitor RNA at 1003 
30°C for 40 minutes.  Labeled aptamer RNA was added (10 nM) and the reaction 1004 
incubated for 40 more minutes at 30°C.  Fluorescence polarization measurements were 1005 
taken and the results showed unlabeled aptamer RNA competed for N binding with 1006 
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labeled aptamer RNA.  Competition experiments were conducted with four different 1007 
aptamers and the apparent Ki values were all in the ~200 nM range.  A nonbinding RNA 1008 
(MBE1.4 RNA) was unable to effectively inhibit the labeled RNA from binding N (Fig 1009 
2-5B).  These data demonstrate that fluorescence polarization can be used to report 1010 
binding of fluorescently labeled aptamer RNA to N as a function of competitor binding 1011 
and that this approach could find utility as a biosensor or drug-screening tool. 1012 
J. Selected RNAs inhibit viral replication and production of viral protein in human 1013 
cell culture 1014 
To determine if RNAs selected to bind with high affinity to RVFV N protein could 1015 
inhibit viral replication and/or production of viral protein during an infection, we 1016 
cotransfected cells with a green fluorescent protein (GFP) reporter plasmid and either 1017 
non-binding RNAs (pool 0), RNAs that have undergone one round of the in vitro 1018 
selection process (pool 1 and Round 1-4) or an aptamer RNA that has undergone 16 1019 
rounds of selection and binds N with high affinity in vitro (MBE87).  The GFP reporter 1020 
plasmid was used to verify that equal and high levels of transfection efficiency were 1021 
achieved.  After transfection in 24-well plate format cells were harvested, counted and 1022 
reseeded in two 96-well plates.  To test the ability of selected RNAs to inhibit viral 1023 
replication over the course of several days, a 96 well plate of transfected cells was 1024 
infected with the MP-12 strain of RVFV using a low MOI (0.1) and the number of 1025 
infectious viral particles produced at three days post infection was measured using a 1026 
plaque assay.  The results show that RNAs that experienced either one or 15 rounds of 1027 
selection to bind N were able to significantly inhibit virus replication during a long term 1028 
(three day) infection (Fig. 2-6A). 1029 
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In parallel, to determine if selected RNAs could inhibit production of viral protein 1030 
during the early stages of an infection, the second 96-well plate of transfected cells was 1031 
infected with a RVF reporter virus that contains the gene for Renilla luciferase (RVF-luc) 1032 
using a MOI of 3.  Cells were harvested at 8 hours post infection and the amount of 1033 
protein produced by RVF-luc virus was quantified by adding a substrate to each sample 1034 
that when oxidized by Renilla luciferase produces light.  By measuring the luminescence 1035 
of each sample using a Biotek Synergy 2 plate reader the amount of protein produced by 1036 
RVF-luc virus in the presence or absence of a selected RNA can be measured.  The 1037 
results show that transfection of non-binding RNA into cells causes a slight 1038 
(approximately 2 fold) decrease in the production of viral protein when compared to cells 1039 
that were transfected with only plasmid DNA.  However, transfection of RNA that has 1040 
been selected once or multiple times to bind N causes an order of magnitude decrease in 1041 
viral protein production (Fig 2-6B). 1042 
To verify that selected RNAs specifically inhibit production of viral (and not cellular) 1043 
protein, cells were cotransfected with a plasmid containing the gene for Renilla luciferase 1044 
(phRL-CMV; Promega) and either GFP, non-binding or selected RNA.  After 1045 
transfection in 24-well plate format, cells were harvested, reseeded in 96-well plate 1046 
format and infected with the MP-12 strain of RVFV using a MOI of 3.  At 8 hours post 1047 
infection, the amount of protein translated by the host cell was quantified by adding 1048 
substrate to lysed cells and measuring luminescence (as described above).  The results 1049 
show that the presence of non-binding RNA and RNA that has experienced one round of 1050 
selection have little to no effect on host cell translation.  MBE 87 RNA that has 1051 
undergone 15 rounds of selection and binds N with high affinity causes an approximately 1052 
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2-fold decrease in host cell protein synthesis.  However, since the decrease in translation 1053 
of viral protein is significantly greater than the decrease host cell translation, these data 1054 
suggest that the selected RNAs are specifically targeted to and inhibiting RVFV (Fig. 2- 1055 
6C). 1056 
 1057 
Figure 2 - 6:  Analysis of the ability of selected RNA to inhibit RVFV protein 1058 
production and replication in cell culture. 1059 
A)  Plaque assay to determine the number of infectious viral particles produced from cells transfected with 1060 
either plasmid DNA alone (GFP plasmid), non-binding RNA (pool 0), RNA that has undergone one round 1061 
of selection (pool 1 and round 1-4) or aptamer RNA (MBE87).  B)  Luciferase assay showing the effects of 1062 
selected RNAs on the production of viral protein.  Cells were transfected with either plasmid DNA alone 1063 
(GFP plasmid), non-binding RNA (pool 0), RNA that has undergone one round of selection (pool 1 and 1064 
round 1-4) or aptamer RNA (MBE87).  Transfected cells were infected with a luciferase expressing RVFV 1065 
at a MOI of 3.  At 8 hours post infection cells were harvested, lysed and protein quantitated by measureing 1066 
luminescence using a microplate reader.  C)  Luciferase assay showing the effects of selected RNA on the 1067 
ability of the host cell to produce protein.  Cells were cotransfected with a plasmid containing the gene for 1068 
Renilla luciferase (phRL-CMV; Promega) and either plasmid DNA alone (GFP plasmid), non-binding 1069 
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RNA (pool 0), RNA that has undergone one round of selection (pool 1 and round 1-4) or aptamer RNA 1070 
(MBE87).  Transfected cells were infected with the MP-12 strain of RVFV at a MOI of 3.  At 8 hours post 1071 
infection cells were harvested, lysed and protein quantitated by measuring luminescence using a microplate 1072 
reader.  1073 
IV. Discussion 1074 
All known functions for N during viral replication involve binding RNA in either a 1075 
non-specific or specific manner.  On the one hand, N possesses sequence-independent 1076 
binding properties that allow it to form N-RNA complexes along the entire length of viral 1077 
RNA.  On the other hand, specific recognition of cognate RNA by N has been observed 1078 
in a number of viruses related to Rift Valley fever virus.  In the present study, we 1079 
characterize specific N-RNA interactions for Rift Valley fever virus.  1080 
RNA constructs that resemble the panhandle of RVFV viral RNA S segment bind 1081 
with medium to high affinity to N. These results corroborate studies in Sin Nombre virus 1082 
(SNV), a member of the Hantavirus genus, that show N specifically binds to a panhandle 1083 
structure formed by the self-complementary 5’ and 3’ ends of the viral genome (72, 76, 1084 
78).  The triplet repeat UAGUAGUAG is required for N to bind SNV mRNA and this 1085 
sequence is also present at the 5’ end of all three segments of the SNV genome and 1086 
antigenome (79).  Together these data show that the binding specificity of N is influenced 1087 
by both sequence and structural features of RNA.  N from several other species of 1088 
bunyavirus are known to preferentially bind to the 5’ end of the viral genome and 1089 
antigenome (85, 87, 109).  This binding event is thought to be an important signal that 1090 
causes N to switch from a specific to a nonspecific mode of binding and initiates 1091 
nucleocapsid assembly (98).  Binding outside this region was also observed in Jamestown 1092 
Canyon virus (Orthobunyavirus genus) but the sequences or secondary structures 1093 
involved in this N-RNA interaction were not specifically identified (85).  1094 
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To further characterize N-RNA binding motifs, we used an unbiased in vitro 1095 
evolution approach to search for RNA ligands of N without any a priori assumptions of 1096 
sequence or structural constraints.  A library of randomized RNA molecules was 1097 
incubated with N and the RNA species that bound N with high affinity were isolated, 1098 
amplified and used as substrates for the next round of selection.  Sequence analysis of 1099 
100 individual RNAs isolated from the final rounds of the in vitro selection showed 1100 
enrichment of guanosine and thymidine residues compared to sequences analyzed from 1101 
earlier rounds (Table 2-1).  Identification of regions of similarity between aptamer and 1102 
viral RNA sequences using BLAST revealed the presence of motifs located in different 1103 
regions of all three viral RNA segments.  The most frequent similarity is represented by 1104 
an U/G-rich motif in the RVFV L antigenome, found in 11 out of the 100 sequenced 1105 
aptamers (Table 2-3).  Surprisingly, an RNA that contained a complementary mutation of 1106 
the U/G-rich motif bound with even higher affinity to N than the wild type aptamer (Fig 1107 
2-3B).  These data suggest that N is able to recognize both a specific sequence and its 1108 
complement.  The same phenomenon has been observed in Jamestown Canyon virus, 1109 
where it was shown that N binds with high affinity a short segment of ssRNA that 1110 
corresponds to the 5’ end of the viral genome, as well as its complement (85).  1111 
Several GAUU rich aptamer sequences aligned with sequences present on the M 1112 
and L segments of the RVFV genome and the S antigenome (Table 2-3).  Mutation of the 1113 
GAUUGAUGAUU motif in the MBE15.8 aptamer showed that preservation of this 1114 
sequence is a requirement for N binding (Fig. 2-3A).  Although this sequence has not yet 1115 
been shown to be important for N-RNA recognition in other bunyaviruses, the bacterial 1116 
chaperone protein Hfq preferentially binds AU rich RNA (27, 108).  It is possible that 1117 
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like SNV, RVFV N has chaperone activity.  If so, binding and unwinding GAUU rich 1118 
stem loop structures in viral mRNA could increase the rate of production of viral 1119 
proteins.  Indeed, chaperone proteins have been shown to be essential for some RNA 1120 
viruses, such as phage Q! (33, 34, 80). 1121 
Interestingly, the novel N-RNA binding motifs that we identified in aptamer 1122 
sequences map to coding regions of the different viral RNA segments (Tables 2-2 and 2- 1123 
3).  Further analysis of these data could potentially shed light on N-RNA interactions that 1124 
are important for N to function during other phases of the viral replication cycle.  For 1125 
example, interaction with host translational machinery, specifically ribosomal protein 1126 
S19, suggests a role for N in translation of viral mRNA (19, 46).  Also, accumulation of 1127 
N is required to trigger the switch from transcription to full-length cRNA synthesis (106).  1128 
It is possible that during these processes N interacts with non-terminal viral RNA 1129 
sequences.  Future work will involve determining if the N binding motifs identified in 1130 
this study are important for regulation of viral replication.   1131 
Information obtained from sequence analysis of the RNA aptamers was also used to 1132 
make a biosensor that reports on N-RNA binding.  We chose the 15.12 TRNK COMP 1133 
aptamer as the RNA sensor for two reasons. First, it was one of the RNA constructs that 1134 
retained a high affinity for the N protein upon truncation (Fig 2-4E).  Second, analysis of 1135 
sequence similarities revealed that its 3’ end contained an 11-nucleotide motif present at 1136 
the 5’ terminus of the S segment of RVFV RNA (Table 2-3).  In fact, the first 6 1137 
nucleotides of this motif are highly conserved, as they are present at the 5’ end of all 1138 
segments of the viral RNA genome and antigenome.  Significant changes in fluorescence 1139 
polarization (FP) of a labeled 15.12 TRNK COMP RNA were detected as a result of N 1140 
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binding and this change in FP could be inhibited by addition of an unlabeled RNA that 1141 
also binds N with high affinity. Aptamer RNAs could thus be used as a sensitive 1142 
fluorescence-based sensor of RVFV N binding with potential applications for drug 1143 
screening and imaging methodologies.  1144 
Several lines of evidence suggest that targeting nucleocapsid protein is a viable 1145 
therapeutic strategy.  Experiments conducted in La Crosse virus (genus Orthobunyavirus) 1146 
show that interferon-induced cellular MxA protein inhibits viral genome production by 1147 
binding and depleting the infected cell of N.  This binding interaction causes N to be 1148 
sequestered in cytoplasmic inclusion bodies and inaccessible during viral replication (61).  1149 
Furthermore, RNA aptamers against HIV-1 Gag polyprotein have been shown to cause 1150 
inhibition of viral replication in cell culture.  Some of these aptamers function by 1151 
targeting the nucleocapsid (NC) component of the polyprotein and competing with viral 1152 
genomic RNA for binding (99).  Finally, the characterization of several novel antiviral 1153 
agents that target HIV-1 and respiratory syncytial virus nucleocapsid proteins (18, 102) 1154 
underscore the potential utility of understanding and exploiting N-RNA interactions for 1155 
antiviral strategies.   1156 
 1157 
  1158 
 58 
 1159 
CHAPTER 3:  IDENTIFICATION OF RIFT VALLEY 1160 
FEVER VIRUS NUCLEOCAPSID PROTEIN-RNA BINDING 1161 
INHIBITORS USING A HIGH-THROUGHPUT 1162 
SCREENING ASSAY 1163 
This chapter is a modified version of the manuscript published in the Journal of 1164 
Biomolecular Screening in September 2012; 10.1177/1087057112448100 1165 
 1166 
 1167 
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I. Introduction 1168 
Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes 1169 
disease ranging from a mild influenza-like illness to hemorrhagic fever in humans.  1170 
Domestic livestock such as sheep, goats and cattle are also susceptible to RVFV 1171 
infection.  The mortality rate for young and newborn animals is close to 100% and the 1172 
virus causes abortion in pregnant livestock (10).  Although historically confined to sub- 1173 
Saharan Africa, RVFV has spread north to Egypt and was discovered outside of Africa 1174 
for the first time in 2000.  Disease symptoms can be particularly severe when the virus 1175 
encounters a naïve host and outbreaks along the Nile River in Egypt and the Arabian 1176 
Peninsula resulted in several devastating epidemics (6, 15, 69, 119).  Global climate 1177 
change, international trade and the ability of RVFV to infect a broad range of mosquito 1178 
species demonstrate the possibility that RVFV will continue to disseminate 1179 
geographically.  Currently, treatment options for RVFV infected individuals and 1180 
livestock are extremely limited.  Ribavirin has been used to treat patients during past 1181 
outbreaks but its use is limited due to undesirable side effects and concern related to the 1182 
potential to cause birth defects (11, 111).  T-705 (favipiravir), a promising new broad- 1183 
spectrum inhibitor of viral hemorrhagic fever, is able to inhibit bunyavirus replication in 1184 
experimentally infected hamsters when administered 24 hours post infection (41).  1185 
Studies with influenza virus showed that T-705 metabolite inhibits the viral RNA- 1186 
dependent RNA polymerase (36).  However, the efficacy of the drug in RVFV infected 1187 
humans or livestock has not yet been determined.  The paucity of drugs currently licensed 1188 
and available to treat viral hemorrhagic fever infection coupled with the ability of RNA 1189 
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viruses to mutate and develop resistance to drugs emphasize the need for continued 1190 
identification of antiviral compounds.    1191 
RVFV has a tripartite single-stranded negative-sense RNA genome that encodes 1192 
seven proteins.  One of these gene products, the nucleocapsid (N) protein, is a 26kDa 1193 
RNA binding protein that plays an important role during several stages of the viral 1194 
replication cycle.  N helps to package the RNA genome into the budding virus particle 1195 
and regulates transcription and translation of viral mRNA and protein (79, 89, 115).  To 1196 
discriminate between different species of RNA in the host cell, N recognizes and binds to 1197 
specific sequences and secondary structures of viral RNA (76, 78).  After an initial 1198 
specific binding event, N switches to a non-specific mode of binding and forms polymers 1199 
along the entire length of the viral genome or antigenome.  This encapsidation process 1200 
protects the viral RNA and prevents the formation of double stranded RNA during 1201 
replication, which would activate the host anti-viral response.  Inhibition of RNA binding 1202 
to the essential viral nucleocapsid protein represents an attractive anti-viral therapeutic 1203 
strategy because all of the functions performed by N during an infection involve RNA 1204 
binding.  Furthermore, significant progress has been made toward exploiting 1205 
nucleocapsid protein as a drug target in HIV, respiratory syncytial virus and influenza 1206 
(18, 38, 99).   1207 
To target RNA binding activity of N, we developed a fluorescence polarization- 1208 
based high-throughput drug screening (HTS) assay to test chemical compounds for their 1209 
ability to disrupt an N-RNA complex in vitro.  From libraries of FDA approved drugs, 1210 
drug-like molecules, and natural product extracts, 26,424 compounds were screened and 1211 
we identified 79 compounds that are inhibitors of the N-RNA interaction.  We then 1212 
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retested the 79 hit compounds to eliminate false positives and used fluorescence 1213 
polarization and filter binding assays to determine the IC50 of lead compounds.    1214 
II. Materials and Methods 1215 
A. Compound libraries 1216 
The chemical libraries screened are a subset of either commercially available small 1217 
molecule or natural product extract libraries maintained at the NERCE National 1218 
Screening Laboratory (NSRB), located in the ICCB Longwood screening facility 1219 
(Harvard Medical School, Boston MA).  Compounds are stored desiccated at -20˚C in 1220 
384-well plates at comparable concentration of either 3.3 to 10 mM or 2 to 15 mg/ml in 1221 
DMSO.  Since the 23rd and 24th columns are empty for all compound plates we tested, 1222 
these columns were used for screening controls. 1223 
B. Fluorescent RNA aptamer to RVFV nucleocapsid N protein 1224 
The sequence of the fluorescent RNA aptamer used in the screening was obtained in 1225 
our laboratory by in vitro selection (30).  Briefly, a pool of randomized RNA molecules 1226 
was positively selected for efficient binding to RVFV N protein using a SELEX 1227 
procedure.  After 16 rounds of selection, sequencing of individual clones revealed several 1228 
families of RNA aptamers.  Representative clones of each family were then either 1229 
terminally truncated or mutated by substitution of internal motifs.  The best and smallest 1230 
N aptamer resulting from these studies was the 15.12 TRNK COMP clone (30).  For that 1231 
reason, this aptamer was chosen to be the one used during HTS.  A 35 nucleotide long 1232 
15.12 TRNK COMP RNA was chemically synthesized, 3’ end labeled with FAM and 1233 
HPLC purified (TriLink Biotechnologies, San Diego, CA).  The fluorescent label was 1234 
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attached to the RNA using a six-carbon linker.  The fluorescent RNA was stored at -80˚C 1235 
at a concentration of 86 #M in water. 1236 
C. Overexpression and purification of RVFV nucleocapsid N protein 1237 
The nucleocapsid N protein sequence used in this study is derived from the 1238 
experimental live attenuated RVF virus vaccine strain (MP-12; (16)), cloned into the N- 1239 
terminal (His-Asn)6-tag pEcoli plasmid (Clontech, Mountain View, CA). The N protein 1240 
expression plasmid was transformed into E. coli strain BL21 (DE3) pLysS.  Transformed 1241 
cells were grown at 37˚C in LB media containing 100 µg/ml ampicillin and 50 µg/ml 1242 
chloramphenicol until OD600=0.6-0.8.  Protein expression was induced by addition of 1243 
IPTG to a final concentration of 0.5 mM and cultures were grown overnight at room 1244 
temperature (24˚C).  Cells were harvested by centrifugation and stored at -80˚C until 1245 
processed.  Eight to twelve liters of culture were processed weekly for three months.  1246 
Because of the modest level of soluble protein expression, a total amount of purified N 1247 
protein from 130 liters of culture was required for the screening. 1248 
Cells were lysed by resuspension of thawed pellets in Solulyse (Genlantis, San 1249 
Diego, CA) lysis buffer containing a cocktail of protease inhibitors (Thermo Fisher 1250 
Scientific, Waltham MA).  Benzonase (EMD Chemicals, Rockland, MA) was added to 1251 
the lysis buffer at a concentration of 12 units/mL to degrade nucleic acids.  Insoluble cell 1252 
debris was removed from the lysate by centrifugation at 10,000 RPM for 30 minutes at 1253 
4˚C.  The (His-Asn)6-tagged N was batch purified from the cell lysate by using Co2+- 1254 
charged Talon resin (Clontech).  The resin was washed with 15 volumes of wash buffer 1255 
(35 mM imidazole, 500 mM NaCl, 1 M urea, 50 mM Tris-HCl pH 8.0), and the protein 1256 
eluted with 4 volumes of elution buffer (300 mM imidazole, 500 mM NaCl, 50 mM Tris- 1257 
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HCl pH 8.0).  The eluate was dialyzed overnight against the storage buffer (500 mM 1258 
NaCl, 10% v/v glycerol, 50 mM Tris-HCl pH 8.0, two buffer changes) and concentrated 1259 
using 10K MWCO centrifugal filters (Amicon Millipore, Billerica, MA).  After flash 1260 
freezing with liquid nitrogen, the aliquots were stored at -80˚C.  The purity of the protein 1261 
was checked by SDS-PAGE (90%; evaluated by Coomassie staining) and the protein 1262 
concentration was determined by the absorbance at 280 nm using extinction coefficient 1263 
obtained from the ExPASy website (33,920 M-1.cm-1) 1264 
 1265 
Figure 3 - 1:  High throughput screening methodology.   1266 
Schematic diagram of the technique used to identify compounds that inhibit RNA binding to N protein in 1267 
vitro.  N was loaded into 384 well microplates, drug compound was added and then fluorescently labeled 1268 
RNA.  After a one hour incubation, fluorescence polarization (FP) measurements were taken.  A high FP 1269 
signal indicates that the compound was unable to prevent the RNA from binding N protein and would not 1270 
be considered a potential antiviral drug.  A low FP signal is indicative of a compound that inhibits the N- 1271 
RNA interaction.  Experimental wells that exhibit a low FP signal are considered “hits” and the compounds 1272 
in those wells could be good drug candidates.  Hits identified during the initial screen are subjected to 1273 
further testing and verified in follow up assays. 1274 
D. High-throughput screening 1275 
The binding of the fluorescent RNA aptamer to the RVFV N protein was monitored 1276 
by fluorescence polarization.  The high-throughput assay tested the ability of compounds 1277 
to prevent the binding of the RNA aptamer to N (Fig. 3-1).  Screening was performed in 1278 
384-well low volume flat bottom black microplates (Corning #3820, Corning, NY).  A 1279 
pilot screening (June 2011) was used to test and streamline the standard operating 1280 
procedure.  The frozen stocks of 10-fold binding buffer, N protein, and fluorescent RNA 1281 
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were sent to the screening facility ahead of time (NSRB/ICCB Longwood, Harvard 1282 
Medical School, Boston MA).  The optimum N protein and RNA aptamer concentrations 1283 
were previously determined to be 12 #M and 10 nM, respectively because that resulted in 1284 
a greater than 90% fractional saturation of the N-RNA complex (30).  The assay was 1285 
further checked for HTS robustness during the pilot screening. 1286 
The main screening (August 2011) started by the thawing and pooling of all N 1287 
protein aliquots.  The concentration of the resulting stock was 130 #M (i.e. 11-fold 1288 
concentrated) and was kept at 4˚C.  Each morning the amount necessary to screen the 1289 
plates for the day was removed and diluted from 11- to 1.2-fold with binding buffer.  The 1290 
binding buffer (final concentration) is composed of 10 mM Hepes-NaOH pH 8, 150 mM 1291 
NaCl, 20 mM KCl, and 5 mM MgCl2.  The standard operating procedure consists of 1292 
several sequential steps.  First, ten to twenty six assay plates were consecutively loaded 1293 
with 10 #l of N protein (1.2-fold in binding buffer) with a Matrix WellMate dispenser 1294 
(Thermo Scientific) in all but the last (24th) column, which received 10#l of binding 1295 
buffer. Second, 100 nl of each compound from the compound plates were transferred into 1296 
the corresponding wells of the 384-well assay plates with the Epson Compound Transfer 1297 
Robot.  Third, two #l of fluorescent RNA was added to all wells of the assay plates with 1298 
a Multidrop Combi nL (Thermo Fisher Scientific).  After a quick centrifugation, the 1299 
plates were incubated in a closed drawer at room temperature (24˚C) for 30 min.  Finally, 1300 
the fluorescence polarization (FP) was measured with the EnVision plate reader (Perkin 1301 
Elmer, Waltham, MA) and the FITC FP 480 (excitation) and 535 (emission) filters.  1302 
Results were stored in Microsoft (Redmond, WA) Excel files. 1303 
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E. Data analysis and hit scoring 1304 
The results were transferred into a single Microsoft Excel 2011 file and analyzed 1305 
using the FP, parallel and perpendicular channels values.  The fluorescence polarization 1306 
is defined as (92): 1307 
   FP = (Is-Ip)/(Is+Ip)      Eq. (1) 1308 
 where FP is polarization, Is and Ip are parallel and perpendicular polarization emission 1309 
light, respectively.  Practically, the FP signal is calculated as follow: 1310 
   FP=1000*(S-G*P)/(S+G*P)     Eq. (2) 1311 
 where FP is polarization in milliP (mP) units, S and P are the values of the parallel and 1312 
perpendicular channels, respectively.  The G-factor used during our screening was preset 1313 
to 0.63.  1314 
To evaluate the robustness of the assay, we quantified the Z’ parameter (122) for 1315 
each plate using the FP values of columns 23 and 24. A Z’ value above 0.5 describes a 1316 
suitable HTS assay (122).  The FP values of column 24 (RNA alone) are called positive 1317 
controls, since they give the same signal than one would expect with an ideal compound, 1318 
i.e. inhibiting 100% of protein/RNA interactions.  Accordingly, FP values in column 23 1319 
(N protein and RNA) represent negative controls.   1320 
Several parameters were first calculated: the sum of the fluorescence of the 1321 
parallel and perpendicular channels, the average and standard deviation of positive and 1322 
negative controls, the plate Z’, and the amplitude of FP signal for the plate (called 1323 
amplitudeFP, i.e. average of negative controls minus average of positive controls).    1324 
Experimental wells were excluded from scoring if the sum of the parallel and 1325 
perpendicular channels was lower than 10 million or greater than 20 million fluorescence 1326 
units.  These data allowed us to eliminate compounds that interfere with the assay 1327 
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detection either through quenching or compound fluorescence.  The next calculation 1328 
expressed the percentile of FP for an experimental well (X) related to the plate FP 1329 
amplitude, provided that the well was not excluded: 1330 
%FPX = 100*(FPX-averagePOS)/amplitudeFP    Eq. (3) 1331 
 where FPX is the FP value for the well and the other parameters are described in previous 1332 
paragraphs.  The %FPX values were then filtered-in if they are below a certain percentile 1333 
or filtered-out if they are above.  Finally the %FPX for duplicates was averaged and the 1334 
resulting hits were visually inspected. 1335 
F. Cherry picking and final compound assessment 1336 
The protocol used during HTS was modified as followed.  The final volume of the 1337 
reaction in binding buffer 1x was increased from 12.1 to 24.6 #l that includes 20 #l of N 1338 
protein at a concentration of 14.8 #M, 4 #l of fluorescent aptamer RNA at 61.5 nM, and 1339 
0.6 #l of diluted compound in DMSO 50% v/v.  The cherry-picked compounds (1.2 #l 1340 
each in DMSO) were received in a 384-well plate format.  A volume of 2.4 #l DMSO 1341 
25% v/v was added to each 1.2 #l of compound, so that 0.6 #l of diluted compound (in 1342 
DMSO 50% v/v) could be pipetted per reaction.  Except for DMSO, all other molecules, 1343 
including N protein, fluorescent aptamer RNA, and compound, were tested at the same 1344 
concentrations than the ones used during HTS.  However, we checked that the slightly 1345 
higher DMSO concentration used (1.2% vs. 0.8%) did not affect fluorescence 1346 
polarization (data not shown).  The compounds were tested in triplicate and the results 1347 
were analyzed as described above for the main HTS experiment. 1348 
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G. Fluorescence polarization competition assay  1349 
Fluorescence polarization competition assays were performed in 30 #L volumes and 1350 
384-well microplate format.  Samples were prepared by incubating varying 1351 
concentrations of compound (8.9 nM–500 #M final) or natural product extract (2.37E-5- 1352 
0.266 #g/#L final) for 20 min. at room temperature (~24˚C) with 10 #M N in binding 1353 
buffer (10 mM Hepes-NaOH pH 8, 150 mM NaCl, 20 mM KCl, and 5 mM MgCl2).  1354 
Next FAM-labeled aptamer RNA (10 nM final) was added and the reaction incubated for 1355 
1 hour at room temperature.  Fluorescence polarization values were measured using a 1356 
Biotek Synergy 2 plate reader.  Excitation and emission wavelengths were 485 nm and 1357 
528 nm, respectively and the G-factor was 0.87.  Binding profiles were plotted and IC50 1358 
values were calculated using Graph-Pad Prism software. 1359 
H. Filter binding competition assay 1360 
Samples were prepared by incubating varying concentrations of compound (8.9 nM– 1361 
500 #M final) or natural product extract (2.37E-5-0.266 #g/#L final) for 20 min. at room 1362 
temperature with 10 #M N in binding buffer (10 mM Hepes-NaOH pH 8, 150 mM NaCl, 1363 
20 mM KCl, and 5 mM MgCl2).  Next, 1 µL of radiolabeled RNA (32P-UTP, 25,000 1364 
cpm/#L) was added to the reaction and the final volume was 12 #L.  After incubation at 1365 
room temperature for one hour, reactions were diluted to 100 µL with ice-cold binding 1366 
buffer and filtered through pre-soaked nitrocellulose filters (Millipore HAWP).  The 1367 
filters were washed twice with 500 µL ice-cold binding buffer, dried, and the 1368 
radioactivity retained on filters was measured by scintillation counting.  Binding profiles 1369 
were plotted and IC50 values were calculated using Graph-Pad Prism software. 1370 
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I. Plaque assays 1371 
Confluent monolayers of human 293 cells grown in 96-well plate format were treated 1372 
with one microliter of natural product extract, unique compound, or DMSO.  Next, cells 1373 
were infected with RVF MP-12 virus using a MOI of 0.1.  Supernatants of virus infected 1374 
and uninfected cells were harvested at 2 and 3 days post infection.  The supernatants were 1375 
serially diluted in MEM and subsequently used to infect confluent Vero cells grown in 6- 1376 
well plate format.  After a 2 hour incubation the cells were overlaid with MEM 1377 
containing 1% agarose and incubated for 7 days.  Cells were fixed with 9.25% 1378 
formaldehyde and plaques revealed using crystal violet stain.  After 2 or 3 days the 1379 
cytotoxicity of natural product extracts or compounds was measured using resazurin 1380 
fluorescence.  Resazurin (0.08 mM final) was added to wells containing cells treated with 1381 
natural product extract, unique compound, or DMSO and the fluorescence measured at 1382 
490 nM using a Biotek Synergy 2 plate reader.   1383 
III. Results and Discussion 1384 
A. HTS assay validation 1385 
To identify compounds that could be used to develop prophylactic molecules against 1386 
Rift Valley Fever Virus infection, we developed a screening assay to find inhibitors of 1387 
the RVFV nucleocapsid (N) protein RNA-binding activity.  Since viral RNA molecules 1388 
are too large to chemically synthesize and fluorescently label we used an in vitro 1389 
selection technique to isolate a small RNA aptamer that bound to N protein with high 1390 
affinity.  Competitive binding experiments using a RNA molecule that mimics the 1391 
panhandle structure formed by the S segment of RVFV genomic RNA showed that the 1392 
aptamer RNA binds to the same region on N as the viral panhandle (30).  We used 1393 
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fluorescence polarization (FP) to measure binding between N and a fluorescent RNA 1394 
aptamer.  Compounds that inhibit the protein-RNA binding decrease the FP value 1395 
because the anisotropy of the free fluorescent RNA is less than that of the N-RNA 1396 
complex.  For instance, an ideal compound inhibiting 100% would have the same FP 1397 
value than the positive control (RNA alone).  During the HTS screen, the average value 1398 
for the positive controls was 158.3±8.3 mP and the negative control average was 282.7± 1399 
10.8 mP, resulting in an amplitude of 124.4 mP (Fig. 1). 1400 
We validated our binding assay for HTS by testing in a low volume 384-well plate 1401 
format and calculating the HTS-related Z’ score (122).  Initial experiments conducted in 1402 
our own and Dr. Brian Geiss’ laboratory (Colorado State University, Fort Collins, CO) 1403 
showed that Z’ values at or above 0.5 could be obtained (data not shown).  When the 1404 
experiments were done in a complete HTS environment (NSRB/ICCB Longwood, 1405 
Harvard Medical School, Boston MA), the value of the pilot Z’ plate was 0.51, while the 1406 
plates Z’ of the main screen ranged from 0.437 to 0.801. The overall Z’ average of 1407 
0.73±0.052 and the 95% confidence interval for the mean of 0.73±0.01 underscored the 1408 
validity of the assay for HTS. 1409 
B. Compound screening results 1410 
The main screen was conducted over two days with 4708 and 21076 compounds 1411 
tested during the first and second day, respectively. The first three series of experiments 1412 
were done in duplicate. The stable and reproducible nature of the controls, as evidenced 1413 
by individual plate Z’ values, the reasonable number of positive hits and the rare 1414 
occurrence of positive/negative pairs among duplicates (99.4% of duplicate values were 1415 
15% or less apart), as well as the limited amount of N available to work with prompted us 1416 
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to screen the last 52 compound plates only once in the initial screen. Compounds 1417 
showing activity in this broad initial screen would be verified in follow-up assays. 1418 
Hit analysis was done for all compound well values using Microsoft Excel (see 1419 
Materials & Methods) and the results are reported in Fig. 3-2 and Table 3-1.  We chose a 1420 
cut-off of no less than 42% inhibition (= a FP amplitude decrease of more than 58%) that 1421 
led to a total of 79 hits (hit rate at 0.3%, 79/26424).  The average inhibition for the hits 1422 
was 52±13% with a 48% median.  Five of the 79 hits (6%) may be either false positive or 1423 
negative: one of the two duplicate values would not have registered the compound as a 1424 
hit on its own.  Fifty-four of the hits belong to natural products extracts libraries (Table 3- 1425 
1).  1426 
To validate the hits, we tested the 79 compounds and extracts in 384-well plates in 1427 
our laboratory.  We doubled the reaction volume and 3-fold diluted the stock of 1428 
compounds we received, so a small volume of compound could be pipetted effectively.  1429 
We checked that the small increase of DMSO in the final reaction had no effect on the 1430 
binding yield (data not shown).  The total confirmation rate was 63%, 40% for unique 1431 
compounds and 74% for natural products extracts (Table 3-1). 1432 
Structural analysis of the 79 hit compounds revealed that four were from Life 1433 
Chemicals F1860 series of aryl-benzofuran compounds. Two other molecules, Life 1434 
Chemicals F0862-0529 and Chembridge 5406174, contain a quinone with an attached 1435 
derivatized benzene ring (Table 3-2).  We have yet to pursue medicinal chemistry of 1436 
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these compounds to determine critical features of the inhibitory mechanism. 1437 
  1438 
Figure 3 - 2:  Scatter plot of HTS results.  1439 
The X-axis represents the fluorescence polarization in mP units for each well.  The Y-axis represents the 1440 
sum of the parallel and perpendicular fluorescence channels in relative fluorescence units.  The limits of the 1441 
Y-axis correspond to the values used to filter in experimental values during hit analysis (between 1-2 x 107 1442 
RFU).  Positive (RNA alone) and negative (RNA and protein, no compound or extract) controls are 1443 
indicated by dark triangles and dark squares, respectively.  The values for the 79 hits and 26345 non-hits 1444 
compounds wells are indicated by black crosses and open circles, respectively. 1445 
 1446 
Table 3 - 1:  Summary of statistical data from the HTS  1447 
 Total Unique compounds 
Natural product 
extracts 
Number of 
compounds 
screened 
26424 21144 5280 
Total hits 79 25 54 
Overall hit rate 0.3% 0.12% 1% 
Percent repeat 63% 40% 74% 
Number of 
compounds 
repeated 
50 10 40 
Number of 
compounds tested 8 6 2 
Average Z’ 0.727±0.052 0.734±0.047 0.707±0.063 
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Table 3 - 2:  Lead compounds and natural product extracts   1448 
Structure Company/Library & Compound ID 
Percent 
Inhibition 
HTS 
IC50 a 
Avg. 
Hill 
slope 
 
Sigma Lopac 
suramin sodium 
salt 
93.3 16.3±7.3 (µM) -2.76 
 
BIOMOL 
topotecan 85.9 ND
b NDb 
 
BIOMOL 4 
quinacrine 
dihydrochloride 
 
65.7 162±26 (µM) -2.99 
 
Sigma Lopac 
S 4063 50.3 
6.7±2.9 
(µM) -1.64 
 
Life Chemicals 
5406174 47.9 
5.1±0.6 
(µM) 
-0.97 
 
 
Maybridge 
BTB 11461 
 
44.1 17.2±3.9 (µM) -1.27 
Not applicable ICGB Extracts 18 600 6990 72.8 
0.015 
± 0.0006 
(ng/µL) 
 
-3.24 
Not applicable ICGB Extracts 18 600 7051 45.7 
0.030 ± 
0.0004 
(ng/µL) 
-0.99 
aCompetitive binding assays were conducted using fluorescence polarization with the exception of 1449 
quinacrine which was done using a filter binding assay technique previously described in Ellenbecker et al., 1450 
2012.  ND, not determined.  b Topotecan caused protein precipitation; none of the other compounds caused 1451 
obvious precipitation. 1452 
C. Dose-response studies 1453 
Cherry picked compounds that were confirmed as giving a positive result in our 1454 
laboratory were purchased and the IC50 values for five commercially available 1455 
compounds was determined using fluorescence polarization (FP).  Competitive filter 1456 
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binding assays were also conducted to ensure that the results obtained using FP were 1457 
accurate (Fig. 3-3).  Chemical structures, results from the HTS and results from the dose- 1458 
response assays for five unique compounds are summarized in Table 3-2.  Nearly all of 1459 
the compounds tested had an IC50 value in the low micromolar range (5-17.2 #M).  1460 
Suramin, the best inhibitor of N binding RNA in the HTS assay, is a drug that has been 1461 
used to treat trypanosomiasis.  Suramin also exhibits antiretroviral activity in vivo by 1462 
inhibiting reverse transcriptase enzymes and has been shown to have an affinity for 1463 
purinergic binding sites (26, 58, 116).  These data suggest that in our system suramin 1464 
prevents formation of the N-RNA complex by interacting with the RNA binding cleft of 1465 
N.  Suramin is amenable to medicinal chemistry, as evidenced by the several derivatives 1466 
that have been described.  1467 
The IC50 value of quinacrine dihydrochloride was higher (162 #M) than the other 1468 
compounds tested.  Since quinacrine is known to intercalate into double-stranded DNA 1469 
and structured RNA molecules, it is likely that this compound is targeting RNA itself, 1470 
rather than the interaction with N protein directly (84, 97, 113).  We hypothesize that 1471 
quinacrine binds to the aptamer RNA, altering its structure and thus decreasing its affinity 1472 
for N.  Studies conducted in picornaviruses showed that quinacrine inhibited translation 1473 
of viral proteins by binding to internal ribosome entry sites in 5’ untranslated region of 1474 
viral mRNA (37).   1475 
Two natural product extracts selected for further testing based on their performance 1476 
in the HTS and follow-up assays were provided by Jon Clardy (Harvard Medical School).  1477 
The IC50 values of extracts 6990 and 7051 were 0.015 ng/#L and 0.030 ng/#L 1478 
respectively.  It is difficult to directly compare the commercially available compounds to 1479 
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the natural products extracts because we do not know the size or number of compounds 1480 
present in an extract.  As a loose approximation for discussion purposes, if we assume 1481 
that the extracts contained ~20 compounds averaging ~300 Da then the IC50 for the 1482 
active component(s) would be in the low micromolar range (2-5 #M) and would be 1483 
performing as well, or even better than the unique compounds (Table 3-2). We are 1484 
currently seeking to identify and characterize the active component(s) in the natural 1485 
product extracts that show good activity in the molecular target assay.  1486 
 1487 
Figure 3 - 3:  Dose-response curves of suramin and natural product extract 6990. 1488 
Nitrocellulose filter binding assays (closed symbols) and fluorescence polarization (FP) (open symbols) 1489 
were used to measure the ability of either suramin (A; circles) or natural product extract 6990 (B; triangles) 1490 
to inhibit binding of aptamer RNA to N.  The competition assays involved incubating a fixed concentration 1491 
of N with varying concentrations of compound and either fluorescent or radiolabeled RNA.  For the filter 1492 
binding assay the amount of radiolabeled (32P-UTP) aptamer RNA retained on filters was measured by 1493 
liquid scintillation counting and the percent RNA bound is plotted versus compound or natural product 1494 
extract concentration.  The fluorescence polarization experiments used fluorescently labeled aptamer RNA 1495 
and the FP signal (mP) is plotted versus compound or natural product extract concentration.  The IC50 value 1496 
calculated for suramin using a filter binding assay (A; closed circles) was 11.3 #M and using FP (A; open 1497 
circles) was 16.3 #M.  The IC50 value calculated for natural product extract 6990 using a filter binding 1498 
assay (B; closed triangles) was .038 ng/µL and using FP (B; open triangles) was .015 ng/µL.  Similar 1499 
experiments were conducted to calculate IC50 values for the other unique compounds and natural product 1500 
extract (Table 2).  The results are the average of at least two independent experiments. 1501 
D. Suramin and 5406174 inhibit RVFV replication in cell culture 1502 
Plaque assays were conducted to measure the ability of the unique compounds 1503 
identified in the HTS assay to inhibit the production of viable virus over the course of 1504 
several days.  Human 293 cells were infected at a low multiplicity of infection (MOI 0.1) 1505 
in the presence or absence of compound and the number of infectious viral particles 1506 
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produced was quantitated using a plaque assay.  Of the eight unique compounds tested 1507 
thus far, two have exhibited antiviral activity in cell culture.  Treatment of cells with 1508 
either 5406174 or suramin decreased the number of plaque forming units per mL by 1509 
approximately one log at two and three days post infection.  Conversely, no decrease in 1510 
virus production was observed when cells were treated with compound 0250 (Fig. 3-4).  1511 
The cytotoxicity of the compounds was measured using resazurin fluorescence.  The 1512 
metabolic activity of living cells converts resazurin into a fluorescently active compound 1513 
that can be detected at 490 nm using a microplate reader.  The amount of compound used 1514 
to treat cells was previously determined to be non-cytotoxic (data not shown). 1515 
 1516 
Figure 3 - 4:  Analysis of the effect of unique compounds on virus yield in cell 1517 
culture.   1518 
Plaque assay to determine the number of infectious viral particles produced from cells treated with either 1519 
DMSO (no drug), 5406174, suramin or 0250 at two and three days post infection (dpi). 1520 
E. A subset of natural product extracts identified in the HTS assay inhibit RVFV 1521 
replication in cell culture 1522 
Plaque assays were conducted to measure the ability of the natural product extracts to 1523 
inhibit production of viable virus over the course of several days.  The cytotoxicity of the 1524 
extracts was also measured using resazurin fluorescence and only extract N5 exhibited 1525 
cytotoxicity in cell culture (Fig. 3-6B).  Unexpectedly, some natural products stimulated 1526 
virus production.  For example, at both two and three days post infection natural product 1527 
extract 6990 increased virus yield (Fig. 3-5).  Six of extracts tested inhibited RVFV 1528 
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replication by 50% or more and were not cytotoxicity to cells (Fig 3-6A and B). 1529 
 1530 
Figure 3 - 5:  Analysis of the effect of natural product extracts on virus yield in cell 1531 
culture. 1532 
A) Plaque assay to determine the number of infectious viral particles produced from cells treated with 1533 
either DMSO (no drug), extract 6990 or extract 7051 at two and three days post infection.  B) 1534 
Quantification of the plaque assay in Fig. 3-2A.  Cells were treated with either DMSO (purple fill), extract 1535 
6990 (blue fill), or 7051 (green fill). 1536 
 1537 
 1538 
Figure 3 - 6:  Analysis of the effects of natural product extracts on virus yield and 1539 
cell viability in human cell culture. 1540 
A) Quantification of plaque assays to determine the number of infectious viral particles produced from cells 1541 
treated with either DMSO (no drug) or natural product extract (F5-F9).  Asterisks indicate natural product 1542 
extracts that decrease virus production by 50% or more and are not cytotoxic to cells.  B) Cytotoxicity 1543 
assay to measure the effects of natural product extracts on cell viability.  Resazurin was added to wells 1544 
treated with either DMSO or natural product extract (F5-F9) and the fluorescence measured at 490 nm 1545 
In conclusion, we describe a high-throughput molecular target assay that was used 1546 
to identify FDA approved drugs, unique compounds and natural product extracts that 1547 
have the ability to disrupt the RVFV N-RNA complex in vitro.  Since N is indispensible 1548 
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for bunyavirus replication, we anticipate that a subset of the lead compounds or 1549 
derivatives designed using medicinal chemistry will be efficacious in cell culture (64). 1550 
The ability of the compounds and natural product extracts to inhibit viral replication over 1551 
the course of several days was determined using plaque assays to quantitate production of 1552 
viable virus.  These secondary assays allowed us identify the compounds and extracts that 1553 
have the potential to become antiviral drugs and provide us with promising candidates for 1554 
future in vivo studies.  The work presented here represents a promising start toward 1555 
identifying new inhibitors of RVFV infection. 1556 
 1557 
 1558 
. 1559 
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 1560 
CHAPTER 4:  CHARACTERIZATION OF RIFT VALLEY 1561 
FEVER VIRUS NUCLEOCAPSID PROTEIN-RNA 1562 
COMPLEX FORMATION AND DISSOCIATION BY THE 1563 
INHIBITOR SURAMIN 1564 
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I. Introduction 1565 
Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus (genus 1566 
Phlebovirus) that causes severe disease in humans and ruminant livestock.  In humans 1567 
disease symptoms can range from a mild flu-like illness to hemorrhagic fever, 1568 
encephalitis, neurological disorders and blindness (65).  Pregnant livestock are at risk for 1569 
miscarriage and high mortality rates among newborn animals have been reported (20-22).  1570 
RVFV can be transmitted by a diverse set of mosquito species and outbreaks have been 1571 
more severe outside of the historically defined endemic areas of Sub-Saharan Africa.  1572 
The potential for RVFV to cause devastating epidemics worldwide is evidenced by its 1573 
classification as a Category A high priority disease agent by the National Institute for 1574 
Allergy and Infectious Diseases (NIAID) (10, 112).  There are currently no proven safe, 1575 
effective treatment options for RVFV infected individuals or livestock.  Increasing our 1576 
understanding of the basic molecular virology of this important pathogen represents an 1577 
essential step toward identification of new drug targets and the development of more 1578 
efficacious antiviral therapeutic compounds.  1579 
The single-stranded RNA genome of RVFV is composed of three segments (L, M 1580 
and S) that appear circular by electron microscopy due to complementarity between the 1581 
5’ and 3’ terminal regions (49).  The L segment encodes the RNA dependent RNA 1582 
polymerase responsible for transcription and replication of the viral genome.  The M 1583 
segment encodes glycoproteins (Gn and Gc) involved in entry into the host cell and non- 1584 
structural proteins Nsm and 78-kDa (62).  The S segment utilizes an ambisense strategy 1585 
to encode the nucleocapsid (N) and NSs proteins while the genes of the M and L 1586 
segments are in the negative sense (39).  Among all viral gene products, the importance 1587 
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of N is underscored by its involvement during many stages of the RVFV replication 1588 
cycle.  N is an RNA binding protein that plays important roles during transcription, 1589 
translation, replication and packaging of the viral genome into virions (74, 79, 88, 89, 1590 
101, 114).  During replication N monomers cooperatively bind along the entire length of 1591 
the viral genome and antigenome.  This encapsidation event protects the viral RNA from 1592 
degradation and prevents the formation of double stranded RNA intermediates that could 1593 
activate the host innate immune response (105).  To discriminate between full-length 1594 
viral RNA and the plethora of other abundant species of RNAs present in the host cell, it 1595 
is thought that N must initially recognize some distinct sequence and/or secondary 1596 
structural element specific to viral RNA.  Subsequently, additional N molecules bind the 1597 
entire length of the viral RNA.  Studies conducted in other related viruses such as 1598 
Bunyamwera, Sin Nombre, Hantaan and La Crosse viruses identified single or double 1599 
stranded structures within the terminal non-coding regions of the RNA genome as 1600 
containing important sequence recognition elements for N (72, 76, 78, 87, 98, 109).  Our 1601 
laboratory used an in vitro selection technique (SELEX) to identify and amplify RNAs 1602 
called aptamers that bind to RVFV N with high affinity.  In the in vitro selection scheme 1603 
we observed a recurring GAUU motif that was found to be important for N recognition 1604 
and binding to many of these aptamer RNAs (30). 1605 
A high-resolution crystallographic structure of N bound to RNA was recently 1606 
published (100).  Analysis of this structure revealed an RNA binding groove containing 1607 
several highly conserved basic amino acid residues located within the C-terminal core 1608 
domain, but the structure did not lend insight into how N may recognize RNAs in a 1609 
sequence or structure-dependent fashion. The N monomer also contained a flexible N- 1610 
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terminal arm that interacts with the neighboring N monomer and this protein-protein 1611 
interaction likely facilitates cooperative N binding (32, 100).  However, the details of 1612 
how RVFV N and other viral nucleocapsid proteins interact with their cognate RNAs are 1613 
not well understood.  We hypothesize that N binds RNA in a biphasic manner.  After an 1614 
initial specific binding event, subsequent N monomers bind in a non-specific mode and 1615 
coat the entire length of the viral genome or antigenome.  Furthermore, we propose that 1616 
the inhibition of RNA binding to N represents an attractive antiviral therapeutic strategy 1617 
because several essential steps in the RVFV replication cycle involve N binding to viral 1618 
RNA. 1619 
In this study we characterize the cooperative assembly of N monomers onto an 1620 
RNA molecule using mutational analysis, biochemical binding assays and RNA structure 1621 
probing techniques.  We elucidate the mechanism utilized by suramin, a small molecule 1622 
identified by our laboratory in a high-throughput screen as an N-RNA binding inhibitor, 1623 
to disrupt both the initial specific binding event, as well as subsequent non-specific 1624 
binding events important for ribonucleoprotein (RNP) complex formation (29).  Finally, 1625 
we show that suramin inhibits RVFV replication in human cell culture.  Using time of 1626 
addition analysis, we determine that suramin exerts its inhibitory effect both by 1627 
interfering with N-RNA binding and by blocking virus uptake into cells and/or other 1628 
step(s) post entry that have not yet been described.   1629 
II. Materials and Methods 1630 
A. Overexpression and purification of RVFV wild type and mutant N proteins 1631 
The WT N protein sequence used in this study corresponds to the experimental live 1632 
attenuated RVFV MP-12 vaccine strain (17).  A mutated variant of N lacking the 33 1633 
 82 
amino acid residues that comprise the N-terminal oligomerization domain (%33 mutant) 1634 
and a mutant that is unable to bind RNA (RNA binding (-) mutant) were also used.  Three 1635 
conserved basic residues in the RNA binding cleft of N were changed to aspartic acid 1636 
(R64D, K67D and K74D) to abolish the RNA binding activity of N (32).  Sequences for 1637 
the WT N and mutant constructs were cloned into the N-terminal (His-Asn)6-tag pEcoli 1638 
plasmid (Clontech, Mountain View, CA).  Plasmids encoding WT, %33 or RNA binding 1639 
(-) mutant RVFV N protein were transformed into E. coli strain BL21-CodonPlus.  1640 
Transformed cells were grown at 37°C in LB media containing 100 µg/ml ampicillin and 1641 
50 µg/ml chloramphenicol until the optical density at 600 nm reached 0.6-0.8.  Protein 1642 
expression was induced by addition of IPTG to a final concentration of 0.5 mM and 1643 
cultures were grown overnight at room temperature (24°C).  Cells were harvested by 1644 
centrifugation and stored at -80°C.  1645 
The thawed cell pellets were lysed by resuspension in lysis buffer (50 mM sodium 1646 
phosphate pH 8.0, 50 mM NaCl, 10 mM imidazole, 1 M urea, 1% v/v Triton X-100) in 1647 
the presence of protease inhibitors.  Benzonase (Novagen) was added to the lysis buffer 1648 
at a concentration of 12 units/mL to degrade DNA and free RNA.  Insoluble cell debris 1649 
was removed from the lysate by centrifugation at 10,000 RPM for 30 minutes at 4°C.  1650 
The (His-Asn)6-tagged proteins were batch purified from the cell lysate using Co2+- 1651 
charged Talon resin (Clontech).  The resin was washed 4 times with 50 mM sodium 1652 
phosphate pH 8.0, 500 mM NaCl,10 mM imidazole, 1M urea and the protein eluted with 1653 
25 mM HEPES pH 8.0, 500 mM NaCl, 300 mM imidazole.  The eluate was dialyzed 1654 
overnight against the storage buffer (500 mM NaCl, 10% v/v glycerol, 50 mM Tris-HCl 1655 
pH 8.0, two buffer changes) and concentrated using Amicon centrifugal filters (10K 1656 
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MWCO).  After flash freezing with liquid nitrogen, the aliquots were stored at -80˚C.  1657 
The purity of the protein was checked by SDS-PAGE and the protein concentration was 1658 
determined by the absorbance at 280 nm using extinction coefficients obtained from the 1659 
ExPASy website (33,000 M-1cm-1 for WT and RNA binding (-) mutant and 24,750 M- 1660 
1cm-1 for the %33 mutant).  1661 
B. Synthesis of aptamer RNA constructs 1662 
Two PCR reaction and ligation steps were conducted to build an RNA construct that 1663 
contains an aptamer RNA sequence (previously shown to bind N with high affinity) 1664 
attached to the 3’ end of the human 5S rRNA sequence.  First, a sense primer containing 1665 
a SalI site (5’- CCA TAC GAG TCG ACG GCA TTA CGG CCG GG-3’) and an anti- 1666 
sense primer containing a XbaI site (5’-GCT CTA GAA GAC GC-3’) were used to 1667 
amplify a 55-nt-long sequence that corresponds to MBE59 aptamer RNA (30).  The PCR 1668 
fragment was agarose gel-purified, digested with SalI and XbaI and ligated into a pAV 1669 
plasmid using the Quick ligation kit (New England Biolabs).  The pAV plasmid 1670 
containing the 5S rRNA gene followed by SalI and XbaI restriction sites for insertion of 1671 
sequences encoding test RNAs was a kind gift from David Engelke (University of 1672 
Michigan, Ann Arbor, MI) (91).  Second, a sense primer containing an EcoRI site with a 1673 
T7 RNA polymerase promoter (5’-CGG AAT TCT AAT ACG ACT CAC TAT AGG 1674 
GTC TAC GGC CAT ACC ACC-3’) and an anti-sense primer containing a BamHI site 1675 
(5’-ACA GGA TCC GCT CTT CCA AAA GCG GAC CGA AG-3’) were used to 1676 
amplify the 200-nt-long segment corresponding to the human 5S rRNA gene plus the 1677 
MBE59 aptamer RNA sequence.  The PCR product was agarose gel-purified, digested 1678 
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with EcoRI and BamHI and ligated into the pUC18 plasmid.  The MBE59/5S plasmid 1679 
DNA construct was verified by DNA sequencing.     1680 
RNA was synthesized in vitro using the MBE59/5S construct digested with XbaI as a 1681 
template for T7 RNA polymerase.  MEGAshortscript kits (Ambion) were used to 1682 
synthesize non-radioactive RNA and MAXIscript kits (Ambion) were used to synthesize 1683 
RNA in the presence of radioactive "-32P-UTP (800Ci/mmol; PerkinElmer).  The 1684 
transcription reaction was DNase treated and purified by phenol/chloroform extraction 1685 
and ethanol precipitation.  The RNA was further purified by denaturing gel 1686 
electrophoresis.  The band corresponding to the RNA was visualized by UV shadowing, 1687 
excised, eluted into 0.5M ammonium acetate, 1.0mM EDTA pH 8.0 and 0.2% SDS, and 1688 
ethanol precipitated. 1689 
C. Electrophoretic mobility shift assays 1690 
For electrophoretic mobility shift assays, a 35nt long fluorescently labeled aptamer- 1691 
based RNA was used (sequence: 5’- CGG GCU GUU UAC UGA ACU AUG AUA CAA 1692 
AGA CCC CG-fluorescein-3’; previously described in reference 9).  N protein (50 µM 1693 
final) was incubated with FAM-RNA (1.0 µM final) in a binding buffer (10 mM HEPES 1694 
pH 7.3, 150 mM NaCl, 20 mM KCl, and 5 mM MgCl2 final concentration) at 10°C for 1695 
varying amounts of time.  Samples for competitive binding experiments were incubated 1696 
at room temperature (~24°C) for varying amounts of time before competitor RNA (25 1697 
µM final) was added and the reaction incubated for 1 more hour.  After incubation the 1698 
reactions were placed on ice and glycerol loading dye was added to each tube.  Samples 1699 
were loaded onto pre-chilled 6% acrylamide/1X TB gels that were run in the cold room at 1700 
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120 volts for 75 minutes.  Gels were visualized and quantified on a Fuji FLA3000G 1701 
Image Analyzer.    1702 
D. Fluorescence polarization measurements 1703 
Aliquots of WT and %33 N were serially diluted to varying concentrations in a 1704 
binding buffer (10mM HEPES pH 8, 150mM NaCl, 20mM KCl, 5mM MgCl2 and 10% 1705 
v/v glycerol).  To determine the equilibrium dissociation constant of N/FAM-RNA 1706 
complex, various dilutions of N were added to 10 nM FAM-labeled aptamer RNA that 1707 
had been subjected to denaturation at 90°C for two minutes followed by snap cooling on 1708 
ice.  Reactions were incubated at room temperature (24°C) for 1 hour.  Samples for 1709 
competitive binding experiments were prepared by incubating either WT (15 µM) or %33 1710 
mutant (50 µM) with 10 nM FAM-labeled RNA in binding buffer at room temperature 1711 
for 1 hour.  Next, varying concentrations of suramin were added (524 pM to 588 µM 1712 
final concentration) and the reaction incubated for 1 hour at room temperature.  1713 
Fluorescence polarization values were measured using a Synergy 2 plate reader (BioTek).  1714 
Binding profiles were plotted and apparent Kd and EC50 values were calculated using 1715 
GraphPad Prism software. 1716 
E. Gel filtration chromatography 1717 
Purification of recombinant WT N from bacteria results in a heterogeneous 1718 
population of monomers and multimers in a complex with E. coli RNA.  For some 1719 
experiments isolation of the lowest molecular weight species (monomeric population) 1720 
was required and gel filtration chromatography was used to fractionate N.  A Superose 12 1721 
10/300 GL column (GE Healthcare Life Sciences) was equilibrated in FPLC running 1722 
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buffer (10 mM HEPES pH 8.0, 500 mM NaCl, 20 mM KCl and 5 mM MgCl2) using an 1723 
ÄKTA FPLC system (Amersham Biosciences).  After elution from the cobalt resin, N 1724 
was concentrated to approximately 10 mg/ml and 200 µL was loaded onto the column.  1725 
Protein was eluted at a flow rate of 0.2 ml/min and monitored by absorbance at 280 nm.  1726 
The following standard proteins were used to calibrate the column: carbonic anhydrase 1727 
(29 kDa), alcohol dehydrogenase (ADH) monomer (44 kDa), albumin (66 kDa), ADH 1728 
dimer (74 kDa) and tetramer (150 kDa).  Blue dextran (2000 kDa) was used to determine 1729 
the void volume. 1730 
The Superose 12 column was also used analytically to compare the multimeric state 1731 
of N in the presence and absence of suramin.  First, the column was equilibrated in FPLC 1732 
running buffer.  Purified WT or RNA binding (-) N was adjusted to a concentration of 5 1733 
mg/mL in 10 mM HEPES pH 8.0/500 mM NaCl/20 mM KCl/5 mM MgCl2 and 1734 
incubated at room temperature for 1 hour in either the presence or absence of varying 1735 
concentrations of suramin.  N was loaded onto the column (600 µg; 120 µL), eluted at a 1736 
flow rate of 0.2 ml/min and absorbance at 280 nm measured.  Fractions (0.5 ml) were 1737 
collected and analyzed for RNA content by phenol/chloroform extraction, ethanol 1738 
precipitation and denaturing gel electrophoresis.  Gels were stained with ethidium 1739 
bromide, scanned using a Fuji FLA-3000G phosphorimager and RNA content quantified 1740 
by measuring band intensities using Image Gauge software.  1741 
F. Time-dependent RNA structure probing 1742 
First, MBE59/5S was subjected to denaturation at 90°C for two minutes followed by 1743 
snap cooling on ice.  Next, WT monomeric N (30 µM) and RNA (0.5 µM) were 1744 
incubated in a binding buffer (10mM HEPES pH 8, 150mM NaCl, 20mM KCl and 5mM 1745 
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MgCl2) for 5 minutes or 5 hours at 10°C to allow ribonucleoprotein (RNP) complexes to 1746 
form.  The MBE59/5S alone and RNP complexes were probed using either RNase T1 or 1747 
RNase A.  T1 RNase reactions were each incubated with 0.18 units of enzyme per tube 1748 
for 4 minutes at 10°C and RNase A reactions were each incubated with 6.25 ng of 1749 
enzyme per tube for 2 minutes at 10°C.  Reactions were stopped by phenol/chloroform 1750 
extraction followed by ethanol precipitation.  Samples were resuspended in Nanopure 1751 
water and stored at -20°C. 1752 
G. Analysis of probing experiments 1753 
The probed RNA samples were reverse transcribed using three different $-32P-labeled 1754 
DNA oligonucleotides located 10-40 nucleotides upstream of the region of interest on the 1755 
RNA and AMV-RT (Promega).  The sequences of the primers used are:  5’-TCT AGA 1756 
AGA CGC CCC-3’, 5’-ACG CCT ACA GCA CCC-3’ and 5’-AGG CCC GAC CCT 1757 
GC-3’.  After a 30 minute primer extension at 42°C NaOH was added at a 0.1N final 1758 
concentration to each sample and incubated at 65°C for 10 minutes.  Samples were 1759 
ethanol precipitated, dried, resuspended in formamide loading dye and subjected to 1760 
denaturing gel electrophoresis.  Gels were exposed using a Fuji FLA- 3000G 1761 
phosphorimager and quantification of band intensity (which corresponds to the reactivity 1762 
of RNA bases) was performed using Image Gauge software.  Band intensities were 1763 
adjusted to eliminate small variation in lane loading by dividing all bases affected by N 1764 
by an internal control value.  In other words, the intensity of each experimental band was 1765 
divided by the intensity of a control band present in each lane.  For control bands, we 1766 
used naturally occurring RT pause/stop sites referred to as K-bands. These bands were 1767 
identified by their appearance in the MBE59/5S control lanes (K-lanes) where samples 1768 
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were not treated with RNases. Since the intensities of the K-bands are consistent for each 1769 
sample, these bands were used to normalize experimental bands and compensate for any 1770 
differences in band intensity that could be attributed to experimental error.  After 1771 
normalizing all of the experimental bands, the intensity of bands in samples incubated 1772 
with N for 5 minutes or 5 hours were compared to the band intensities of the RNA alone 1773 
control. 1774 
H. Cell culture studies 1775 
Human 293 cells were maintained in Dulbecco’s modified eagle medium (DMEM) 1776 
supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin.  Vero 1777 
cells were maintained in minimum essential medium (MEM) alpha medium 1778 
supplemented with 10% FBS, penicillin and streptomycin.  The Rift Valley fever virus 1779 
(RVFV) vaccine strain, MP-12, was kindly provided by Brian Gowen (Utah State 1780 
University, Logan, UT).  During infection, human 293 cells and virus were maintained in 1781 
DMEM supplemented with 2% FBS, penicillin and streptomycin.  Incubations were 1782 
carried out at 37°C and 5% CO2 unless otherwise stated. 1783 
I. Virus yield reduction assays 1784 
Growth media from confluent monolayers of human 293 cells in 96-well plate format 1785 
was removed and replaced with DMEM supplemented with 2% FBS.  Cells were treated 1786 
with one microliter of suramin (20 mM stock; 100 µM final concentration) or DMSO.  1787 
Next, cells were infected with RVFV using a MOI of 0.1 and incubated for 2 hours.  1788 
After incubation media was removed, cells were washed with PBS and fresh media as 1789 
well as one microliter of suramin or DMSO were added.  Supernatants of virus infected 1790 
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and uninfected cells were harvested at two and three days post infection.  The amount of 1791 
virus present in the supernatant was quantitated using plaque assays.  1792 
J. Time of addition virus yield reduction assays 1793 
To determine if suramin blocks an early or late step in the virus lifecycle we 1794 
modified the protocol described in the previous paragraph.  Growth media from confluent 1795 
monolayers of human 293 cells grown in 96-well plate format was removed and cells 1796 
were washed with cold DMEM.  Next, 100 µL of cold DMEM supplemented with 2% 1797 
FBS was added to each well.  Either ammonium chloride (an inhibitor of viral entry; 12 1798 
mM final concentration) or suramin (50 or 100 µM final concentration) was added to 1799 
cells that received drug before infection.  Cells were infected with RVFV using a MOI of 1800 
1.0 and incubated for 1 hour at 4°C to allow virus to attach but not enter cells.  After 1801 
incubation media was removed, cells were washed with cold PBS to remove unbound 1802 
virus and 200 µL of prewarmed media was added to each well.  Ammonium chloride and 1803 
suramin were added back to wells that received drug before infection and the plate was 1804 
incubated for one hour to allow the virus to enter the cells.  After 1 hour either 1805 
ammonium chloride or suramin was added to experimental wells that received drug after 1806 
the virus entered cells.  Supernatants of virus infected cells were harvested the next 1807 
morning.     1808 
K. Plaque assays 1809 
Supernatants from virus infected and uninfected cells were serially diluted in MEM 1810 
and subsequently used to infect confluent monolayers of Vero cells grown in 6-well plate 1811 
format.  After a 2 hour incubation the cells were overlaid with minimum essential 1812 
medium (MEM) containing 1% agarose and incubated for 7 days.  Cells were fixed with 1813 
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9.25% formaldehyde and plaques revealed using crystal violet stain.  After 2 and 3 days 1814 
the cytotoxicity of suramin was measured using resazurin fluorescence.  Resazurin (0.08 1815 
mM final) was added to wells containing cells treated with either suramin or DMSO and 1816 
the fluorescence measured at 490 nM using a Biotek Synergy 2 plate reader. 1817 
III. Results 1818 
A. Competitor RNA is unable to displace prebound RNA in mature Rift Valley 1819 
fever virus ribonucloprotein complexes 1820 
An electrophoretic mobility shift assay was conducted to test the ability of a 1821 
fluorescently (3’-FAM) labeled RNA to bind Rift Valley fever virus (RVFV) 1822 
nucleocapsid (N) protein and visualize the ribonucleoprotein (RNP) complexes of 1823 
varying size that form during an N-RNA binding event.  A constant amount of FAM- 1824 
RNA and N were incubated at 10°C for varying amounts of time (1 minute – 5 hours).  1825 
The binding reaction was incubated at 10°C to decrease the speed of RNP formation 1826 
because previous experiments conducted in our laboratory indicated that N binds RNA 1827 
rapidly at room temperature (data not shown).  After incubation, the samples were 1828 
subjected to non-denaturing gel electrophoresis at 4°C.  The bands that migrate faster on 1829 
the gel correspond to free RNA species and the higher migrating bands represent higher 1830 
molecular weight RNA/protein complexes.  The results showed that when the binding 1831 
reaction was incubated for 1 minute – 2 hours two distinct N-RNA complexes were 1832 
formed.  However, after a 5-hour incubation period the bands that corresponded to the 1833 
lower molecular weight N-RNA complex and free RNA species disappeared suggesting 1834 
that over time the RNP complex becomes larger (Fig. 4-1A), suggesting that additional 1835 
molecules of N bind along the length of the RNA molecule and eventually incorporate all 1836 
of the FAM-RNA into the highest molecular weight N-RNA complexes.    1837 
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 1838 
Figure 4 - 1:  Characterization of N-RNA binding interactions.   1839 
A.  EMSA analysis of fluorescently (3’-FAM) labeled RNA binding affinity for N after incubation for 1840 
varying amounts of time.  The bands that migrate faster on the gel are unbound RNA species and the 1841 
slower migrating bands represent N/RNA complexes.  B.  A competitive EMSA to test the ability of an 1842 
unlabeled competitor RNA to displace FAM-RNA that was preincubated with N for varying amounts of 1843 
time. 1844 
Since N bound RNA efficiently, we next chose to study the stability of N-RNA 1845 
complexes.  A competitive binding experiment was performed to test the ability of an 1846 
unlabeled RNA to bind N and displace a fluorescently (FAM) labeled RNA.  A constant 1847 
amount of FAM-RNA was incubated at room temperature with N for varying amounts of 1848 
time (5-60 minutes) and then competitor RNA was added.  The reactions were incubated 1849 
at room temperature for an additional hour and subjected to non-denaturing gel 1850 
electrophoresis.  The results showed that competitor RNA was able to bind N and 1851 
displace some FAM-RNA when added 5 or 10 minutes into the incubation period.  1852 
However, when FAM-RNA and N were incubated for 30 to 60 minutes prior to addition 1853 
of competitor, significantly less FAM-RNA was displaced (Fig. 4-1B).  These data 1854 
suggest that after an initial N/RNA binding event the RNP complex undergoes a 1855 
conformational change and a more robust and impenetrable complex is formed.  It is also 1856 
possible that competitor RNA is unable to displace prebound RNA after prolonged 1857 
incubation because the dissociation rate (koff) of the mature complex is very slow.  To 1858 
further study the formation of high molecular weight N-RNA complexes we used RNA 1859 
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structure probing to visualize changes in the reactivity of RNA bases that occur over time 1860 
as a result of N binding. 1861 
B. A specific RNA binding event triggers cooperative binding between N monomers 1862 
Previously, we used an in vitro selection technique (SELEX) to generate high affinity 1863 
55 nt-long RNA ligands, or aptamers, to RVFV N.  Mutational analysis of aptamer RNAs 1864 
identified a GAUU motif found in many of the aptamers as an important recognition 1865 
sequence for N (30).  To create a longer (~200 nt) RNA molecule with additional non- 1866 
specific N-binding sites and additional primer binding sites for structure probing studies, 1867 
we added the human 5S rRNA sequence to the 5’ end of an aptamer RNA with a GAUU 1868 
motif (MBE59/5S).  The 5S rRNA molecule was chosen because the structure is well 1869 
characterized, robust, and folds readily and stably into its native structure. Therefore, 1870 
addition of new sequence to its terminus does not alter the structure of the attached 1871 
aptamer RNA.   1872 
The MBE59/5S RNA was incubated with N in a binding buffer for 5 minutes or 5 1873 
hours at 10°C to allow RNP complexes to form.  The complexes were then probed using 1874 
either RNase T1 (cleaves after single-stranded guanosine residues) or RNase A (cleaves 1875 
after single-stranded uridine and cytidine residues).  The probed RNA samples were 1876 
extended using a $-32P-labeled DNA primer and AMV reverse transcriptase and the 1877 
reactivity of the individual bases to the RNase enzymes in the presence and absence of N 1878 
was analyzed.  By comparing cDNA band patterns produced by primer extension of 1879 
probed RNA alone and probed RNA complexed with N, nucleotides exhibiting either 1880 
reduced or enhanced reactivates in the N-RNA complex were identified.  This 1881 
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information was then used to deduce the RNA sequences specifically contacted by N, as 1882 
well as secondary structural rearrangements that occurred when N bound RNA.  1883 
When N was incubated with MBE59/5S and then probed with RNase T1 there was a 1884 
strong and very rapid protection of two G residues located within the GAUU motif (G156 1885 
and G152), suggesting that this sequence is immediately recognized and bound by N 1886 
(Fig. 4-2C; Fig. 4-3).  However, G residues located away from the GAUU motif (G75, 1887 
G48 and G47) exhibited little to no protection at the 5 minutes time point but after an 1888 
extended incubation showed moderate (G75) and significant decreases in reactivity (G48 1889 
and G47) (Fig. 4-2A and B; Fig. 4-3). These data are consistent with the idea that an 1890 
initial specific binding event triggers subsequent binding of N monomers and/or that the 1891 
highest affinity binding sites are occupied first followed by binding to lower affinity sites.     1892 
A pattern similar to the one described above was observed when RNP complexes 1893 
were probed with RNase A.  For example, a U residue present in the GAUU motif 1894 
(U159) was strongly protected at both the 5 minute and 5 hour time points whereas 1895 
several C and U residues located closer to the 5’ end of the RNA construct and farther 1896 
away from the GAUU motif exhibit weak protections at 5 minute time point but became 1897 
more protected over time (Fig. 4-2D-F; Fig. 4-3).  Interestingly, residues U130 and U76 1898 
located approximately in the middle of the RNA construct initially exhibited enhanced 1899 
reactivity and then became protected after 5 hours (Fig. 4-2E and F; Fig. 4-3).  It is 1900 
possible that binding of the first molecule of N stabilizes or alters an adjacent binding site 1901 
for additional N molecules.  These enhancements could be caused by a structural 1902 
rearrangement in the RNA that occurs when N initially recognizes and binds the GAUU 1903 
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motif.  Then later, as N oligomers coat the entire RNA molecule protection of all reactive 1904 
G, C and U residues was observed (Fig. 4-2D-F; Fig. 4-3). 1905 
 1906 
Figure 4 - 2:  RNase T1 and RNase A structure probing analysis of an N-RNA 1907 
binding interaction.   1908 
Lanes designated A, C, G and U are sequencing lanes.  K lanes are primer extensions of MBE59/5S 1909 
untreated with RNases.  Lanes 5’ and 5h indicate the length of time that N and RNA were incubated 1910 
together before probing.  Arrows indicate reactive nucleotides and asterisks (*) indicate bands used to 1911 
normalize band intensities for quantification purposes as described in materials and methods.  A-C.  Primer 1912 
extension analysis of MBE59/5S probed with RNase T1 in duplicate.  D-F.  Primer extension analysis of 1913 
MBE59/5S probed with RNase A in duplicate.  1914 
After gaining insight into the molecular details of an N-RNA binding event, we 1915 
were interested in studying how the small molecule, suramin, identified in a high- 1916 
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FIGURE 2.  RNase T1 and RNase A structure probing analysis of an N-RNA binding interaction.  
Lanes designated A, C, G and U are sequencing lanes.  K lanes are primer extensions of MBE59/5S 
untreated with RNases.  Lanes 5’ and 5h indicate the length of time that N and RNA were incubated 
together before probing.  Arrows indicate reactive nucleotides and asterisks (*) indicate bands used to 
normalize band intensities for quantification purposes as described in materials and methods.  A-C.  
Primer extension analysis of MBE59/5S probed with RNase T1 in duplicate.  D-F.  Primer extension 
analysis of MBE59/5S probed with RNase A in duplicate. 
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throughput drug-screening assay conducted by our laboratory, disrupts an N-RNA 1917 
binding interaction (29).  1918 
 1919 
Figure 4 - 3:  Summary of the nucleotide reactivities superimposed on an Mfold 1920 
predicted secondary structure model of MBE59/5S.   1921 
MBE59/5S is an RNA construct containing an aptamer RNA sequence with a GAUU motif attached to the 1922 
3’ end of the human 5S rRNA sequence.  The GAUU motif located within the 55-nucleotide long aptamer 1923 
RNA sequence is underlined.  Circles represent RNase A probing of cytidine and uridine residues and stars 1924 
represent RNase T1 probing of guanosine residues.  Open symbols represent enhanced reactivity and closed 1925 
symbols represent a decrease in reactivity.  The number of symbols next to a residue indicate the relative 1926 
level of reactivity of the residue after incubation with N for either 5 minutes (symbols before bar) or 5 1927 
hours (symbols after bar) when compared to the RNA alone control.  Band intensities were quantitated 1928 
using GraphPad Prism software and the number of symbols used is based on the percent change in band 1929 
intensity compared to the RNA alone control:  0-25% = 1 symbol, 26-50% = 2 symbols, 50-75% = 3 1930 
symbols, 76-100% = 4 symbols. 1931 
C. Suramin inhibits RNA binding to wild-type and mutant N protein 1932 
A fluorescence polarization experiment was performed to compare the ability of wild 1933 
type (WT) and a mutated version of RVFV N that lacks the amino-terminal 33 amino 1934 
acid residues important for N oligomerization (%33) to bind RNA.  A fluorescently 1935 
labeled (3’-FAM) RNA previously shown to bind wild type RVFV N was incubated in 1936 
binding buffer with varying concentrations of WT and % 33 N at 30°C for 1 hour and 1937 
fluorescence polarization (FP) measured.  Titration of WT N with FAM-RNA gave an 1938 
apparent Kd of 1.2 µM and a Hill coefficient of 2.2.  Titration of the %33 mutant version 1939 
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FIGURE 3. Summary of the nucleotide reactivities superimposed on an Mfold predicted secondary 
structure model of MBE59/5S. MBE59/5S is an RNA construct containing an aptamer RNA sequence 
with a GAUU motif attached to the 3’ end of the human 5S rRNA sequence. The GAUU motif located 
within the 55-nucleotide long aptamer RNA sequence is underlined. Circles represent RNase A probing 
of cytidine and urid ne residues and sta s present RNAse T1 probing of guanosine residues. Open 
symbols represent enhanced reactivity and closed symbols represent a decrease in reactivity. The 
number of symbols next to a residue indicate the relative level of reactivity of the residue after 
incubation with N for either 5 minutes (symbols before bar) or 5 hours (symbols after bar) when 
compared to the RNA alone control. Band int nsities were quantitated using GraphP d Prism software 
and the number of symbols used is based on the percent change in band intensity compared to the RNA 
alone control: 0-25% = 1 symbol, 26-50% = 2 symbols, 50-75% = 3 symbols, 76-100% = 4 symbols.
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of N gave an apparent Kd of 9.0 µM and a Hill coefficient of 1.4 (Fig. 4-4A).  The 7.5 1940 
fold decrease in the apparent Kd of WT N when compared to the %33 mutant shows that 1941 
removing the N-terminal arm decreases the ability of N to bind RNA.  The Hill 1942 
coefficients for both WT and mutant N proteins were greater than 1 indicating that N 1943 
binds RNA in a positively cooperative manner.  The N-terminal arm may play an 1944 
important role in the ability of N to oligomerize because the WT N protein exhibited a 1945 
steeper binding curve and larger Hill coefficient than the %33 mutant.  Next we 1946 
performed competitive binding experiments by incubating a constant amount of N (15 1947 
µM of WT; 50 µM of %33) with 10 nM RNA at room temperature (RT) for 1 hour.  1948 
Increasing concentrations of suramin (524 pM-588 µM) were added and the reaction 1949 
incubated for one more hour at RT.  FP measurements were taken and the results showed 1950 
suramin competed with aptamer RNA for N binding.  The EC50 value of suramin for WT 1951 
N was approximately 3 fold higher than for the %33 mutant protein (22.3 µM for WT vs. 1952 
7.1 µM for %32) (Fig. 4-4B).  These data show that the absence of the N-terminal arm 1953 
increases the ability of suramin to disrupt an N-RNA binding interaction and suggest that 1954 
the N-terminal arm may play an important role in stabilizing the RNP complex. 1955 
 1956 
Figure 4 - 4:  Analysis of the effects of suramin on WT and !33 N-RNA binding 1957 
interactions using fluorescence polarization.   1958 
A.  Binding profile for the association of WT (filled squares) and %33 mutant (open circles) N with 1959 
fluorescently (FAM) labeled RNA.  B.  A competition assay where a fixed concentration of WT (filled 1960 
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squares) and %33 mutant (open circles) N was incubated with FAM-RNA.  Varying concentrations of 1961 
suramin was added and the FP signal was plotted versus suramin concentration.  The results are the average 1962 
of two independent experiments. 1963 
D. Suramin inhibits a specific N-RNA binding interaction 1964 
Our previous results have shown that N specifically recognizes and binds to GAUU 1965 
motifs on selected aptamer RNAs.  RNA structure probing experiments were conducted 1966 
(as described above) in the presence of varying concentrations of suramin (0.8 – 800 #M) 1967 
to determine if suramin is able to inhibit this specific binding interaction.  Consistent with 1968 
the results obtained previously, G156 and G152 in the GAUU motif were reactive in the 1969 
absence of N and became strongly protected when N bound the MBE59/5S.  When 1970 
suramin was added to the binding reaction the protective effect of N was abolished and 1971 
G156 and G152 regained their susceptibility to cleavage by RNase T1 (Fig. 4-5).  These 1972 
data suggest that suramin disrupts the ability of N to specifically recognize and bind its 1973 
cognate RNA.  Next we sought to determine if suramin was able to disrupt non-specific 1974 
N-RNA interactions that are important for the formation of high molecular weight RNP 1975 
complexes.         1976 
 1977 
Figure 4 - 5:  RNase T1 probing analysis of the effects of suramin on an N-RNA 1978 
binding interaction.   1979 
RNase T1 structure probing followed by primer extension was used to visualize the effects of increasing 1980 
concentrations of suramin (0.8 – 800 µM) on the ability of N to bind the GAUU motif of MBE59/5S.  1981 
Lanes A, C and G are sequencing lanes, the K lane is a primer extension of untreated MBE59/5S and 1982 
arrows indicate reactive guanosine nucleotides. 1983 
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E. Suramin disrupts formation of high molecular weight N-RNA complexes 1984 
Purification of recombinant WT N protein (31 kDa) from bacteria results in a 1985 
heterogeneous population of N dimers and multimers in a complex with E. coli RNA.  1986 
Gel filtration chromatography yielded two protein/RNA fractions of  ~153 and 90 kDa 1987 
apparent molecular weight based on elution volumes from a Superose 12 (S-12) column 1988 
that was calibrated with protein standards (Fig. 4-6A).  The calibrated S-12 column was 1989 
used to compare the multimeric state of wild type N in the presence and absence of 1990 
suramin.  Our results showed that when N was incubated with increasing concentrations 1991 
of suramin higher molecular weight ribonucleoprotein complexes were disrupted, 1992 
resulting in the formation of lower molecular weight complexes (Fig. 4-6A).  The peak at 1993 
10.7 mL in the absence of suramin corresponded to a molecular weight of approximately 1994 
90 kDa and is likely two molecules of N bound to E.coli RNA.  When 10 mM suramin 1995 
was added this peak decreased in size significantly and a peak at 14.8 mL appeared that 1996 
corresponded to a molecular weight of ~37 kDa (Fig. 4-6A).  To compare the amount of 1997 
RNA in higher molecular weight N-RNA complexes vs. lower molecular weight 1998 
complexes formed by incubation with 10 mM suramin, fractions of N were collected, 1999 
phenol/chloroform extracted and the amount of RNA in each fraction determined by 2000 
denaturing gel electrophoresis followed by densitometry.  Next, the protein concentration 2001 
was plotted against the elution volume of the gel filtration column, and the relative 2002 
amounts of co-purifying RNA was observed at each point.  Large amounts of RNA were 2003 
present in the fractions that corresponded to the 90 kDa peak, however, the 37 kDa peak 2004 
formed during incubation with 10 mM suramin was devoid of RNA (Fig. 4-6B and C).  2005 
These data show that suramin is able to displace the RNA from the higher molecular 2006 
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weight N-RNA complexes resulting in the formation of a lower molecular weight species 2007 
that could be an N monomer bound to suramin.   2008 
 2009 
 2010 
Figure 4 - 6:  Characterization of the effects of suramin on the multimeric state of N 2011 
using gel filtration chromatography.   2012 
A.  Gel filtration profile of wild type (WT) N under the following conditions:  no suramin, solid line; 1 mM 2013 
suramin, dashed line; 10 mM suramin, dotted line.  B.  Analysis of the RNA content of fractionated WT N 2014 
in the absence of suramin.  RNA level (dashed line) and protein concentration (solid line) are plotted 2015 
against the elution volume of the gel filtration column.  C.  Analysis of the RNA content of fractionated 2016 
WT N after incubation with 10 mM suramin.  To compare the amount of RNA in high molecular weight N- 2017 
RNA complexes versus lower molecular weight N-RNA complexes formed by incubation with 10 mM 2018 
suramin, RNA level (dashed line) and protein concentration (solid line) are plotted against the elution 2019 
volume of the gel filtration column.  D.  Gel filtration profile of RNA binding (-) mutant N under the 2020 
following conditions:  no suramin, solid line; 1 mM suramin, dashed line; 10 mM suramin, dotted line. 2021 
To determine whether the observed shift to a lower molecular weight species is 2022 
caused by suramin blocking the RNA binding site of RVFV N protein or inhibiting N-N 2023 
interactions required for multimerization, we tested the ability of suramin to disrupt a 2024 
dimer structure formed by a mutated N that is unable to bind RNA.  The predominant 2025 
peak for the RNA binding (-) mutant corresponded to a molecular weight of 54 kDa and 2026 
likely represents an N dimer without RNA (Fig. 4-6D).  The gel filtration profile of the 2027 
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mutated N was identical in both the presence and absence of suramin, suggesting that 2028 
suramin was unable to disrupt the protein–protein interactions important for the 2029 
formation and stabilization of the N dimer structure (Fig. 4-6D).  Together, these data 2030 
suggest that suramin disrupts formation of high molecular weight N-RNA complexes by 2031 
binding directly to and obstructing the RNA binding cleft.  These results illustrate the 2032 
ability of suramin to block N-RNA binding interactions in vitro and prompted us to next 2033 
test the efficacy of suramin as an antiviral agent in cell culture. 2034 
F. Suramin inhibits RVFV replication in cell culture 2035 
Plaque assays were conducted to measure the ability of suramin to inhibit the 2036 
production of viable virus over the course of several days.  Human 293 cells were 2037 
infected at a low multiplicity of infection (MOI 0.1) in the presence or absence of 2038 
suramin and the number of infectious viral particles produced was quantitated using a 2039 
plaque assay.  The cytotoxicity of suramin was measured using resazurin fluorescence.  2040 
The metabolic activity of living cells converts resazurin into a fluorescently active 2041 
compound that can be detected at 490 nm using a microplate reader.  Suramin (100 µM) 2042 
decreased the number of plaque forming units per mL by approximately 1 log at 2 and 3 2043 
days post infection (dpi) and was not cytotoxic to human 293 cells (Fig. 4-7A-C).   2044 
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 2045 
Figure 4 - 7:  Analysis of the effects of suramin on virus yield and cell viability in 2046 
human cell culture.   2047 
A.  Plaque assay to determine the number of infectious vial particles produced from cells treated with either 2048 
DMSO (no drug) or 100 µM suramin at two and three days post infection.  B.  Quantification of the plaque 2049 
assay in Fig. 4-7A.  Cells were treated with either DMSO (dark grey fill) or 100 µM suramin (light grey 2050 
fill).  C.  Cytotoxicity assay to measure the effects of suramin on cell viability.  Resazurain was added to 2051 
wells treated with either DMSO (dark grey fill) or 100 µM suramin (light grey fill) and the fluorescence 2052 
measured at 490 nm. 2053 
G. Suramin blocks both entry and post-entry steps in the RVFV lifecycle 2054 
Time of addition experiments were performed to determine if suramin blocks an early 2055 
and/or late step in the virus lifecycle.  First, human 293 cells were treated with 2056 
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ammonium chloride (12 mM), a known potent blocker of viral entry, either before or at 2057 
varying time points after infection to determine the amount of time required for RVFV 2058 
MP-12 to enter cells.  We found that at one-hour post infection ammonium chloride was 2059 
no longer able to block infection, suggesting that entry is complete within one hour (data 2060 
not shown).  Next, cells were treated with ammonium chloride or suramin either before or 2061 
after the virus (MOI 1.0) entered cells.  Supernatants of infected cells were harvested the 2062 
next morning (15 hours post infection) and the number of infectious viral particles 2063 
produced was quantitated using a plaque assay.  The results showed that 50 #M suramin 2064 
added before infection effectively blocked viral replication, but when added one-hour 2065 
post infection, the inhibitory effect was significantly diminished (Fig. 4-8A and B).  2066 
However, if a higher concentration of suramin was used (100 µM), the drug was able to 2067 
effectively inhibit replication when added either before or after virus entry into cells (Fig. 2068 
4-8A and B).  The concentrations of ammonium chloride and suramin used in these 2069 
experiments had no effect on cell viability (Fig. 4-8C).  These data suggest that suramin 2070 
is able to prevent RVFV replication at multiple stages of the virus life cycle.  The ability 2071 
of the virus to enter cells is clearly inhibited by suramin, as well as one or more steps 2072 
post-entry that have yet to be determined. 2073 
 103 
 2074 
Figure 4 - 8:  Time-of-addition assays to determine the stage(s) of the virus life cycle 2075 
inhibited by suramin.   2076 
A.  Plaque assay showing the effects of drug concentration and time of addition on the ability of suramin to 2077 
inhibit viral replication.  Cells were either pretreated (before entry) with suramin or ammonium chloride or 2078 
treated one hour post infection (after entry) with suramin or ammonium chloride.  B.  Quantification of the 2079 
plaque assay in Fig. 4-8A.  Cells were treated with either DMSO (“untreated”; dark grey fill), pretreated 2080 
with suramin or ammonium chloride (light grey fill) or treated one hour post infection with suramin or 2081 
ammonium chloride (diagonal fill).  C.  Cytotoxicity assay to measure the effects of suramin and 2082 
ammonium chloride on cell viability.  Resazurain was added to wells treated with either DMSO 2083 
(“untreated”; dark grey fill), pretreated with suramin or ammonium chloride (light grey fill) or treated one 2084 
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hour post infection with suramin or ammonium chloride (diagonal fill) and the fluorescence measured at 2085 
490 nm.    2086 
IV. Discussion 2087 
In order for N to preferentially encapsidate full-length viral RNA during replication, 2088 
N must interact with RNA in both a specific and non-specific manner. Interfering with 2089 
either of these N-RNA binding modes could significantly abrogate viral replication. In 2090 
the present study, we explore the nature of the RVFV N-RNA binding interaction, 2091 
beginning with the initial recognition event followed by subsequent binding of N 2092 
monomers in a sequence independent manner, resulting in the formation large, stable 2093 
ribonucleoprotein (RNP) complexes.  We demonstrate that suramin inhibits the initial 2094 
specific N-RNA binding event and is capable of dissociating the high molecular weight 2095 
N-RNA complexes. Furthermore, we demonstrate the therapeutic potential of suramin by 2096 
showing that it functions well as an inhibitor of RVFV in vitro and inhibits viral 2097 
replication in human cell culture.   2098 
In support of a biphasic RNA binding model, our experiments showed that N 2099 
exhibited positive cooperativity when binding to an RNA molecule, resulting in the 2100 
formation of high molecular weight N-RNA complexes (Figs. 4-1A and 4-4A).  Over 2101 
time, these complexes matured and prebound RNA became increasingly resistant to 2102 
displacement by competitor RNA (Fig. 4-1B).  RNP complexes are also known to be 2103 
resistant to degradation by ribonucleases and high salt treatment (94).  A high resolution 2104 
structure of N multimers bound non-specifically to RNA shows that the RNA bases are 2105 
sequestered in a deep binding groove that is contiguous along adjacent N monomers; this 2106 
arrangement could explain the inability of competitor RNA to displace prebound RNA 2107 
(100).  Removal of 33 residues from the amino-terminal domain of N (%33 mutant) 2108 
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decreased the cooperativity of N binding as well as the affinity of N for RNA by 2109 
approximately 7.5 fold compared to WT N (Fig. 4-4A).  These results are consistent with 2110 
high-resolution structures that suggest that the N-terminus plays an important role in N 2111 
oligomerization.  N forms ring shaped multimers in which the flexible N-terminal arm 2112 
wraps around the solvent side of an adjacent subunit, where it binds to a hydrophobic 2113 
groove (32, 100).  2114 
We propose that RNA encapsidation by N is triggered by an initial specific binding 2115 
event and previously reported that N specifically recognizes and binds appropriately- 2116 
positioned GAUU sequences on aptamer RNA molecules (30).  Time-resolved RNA 2117 
structure probing experiments allowed us to observe sequential N binding to RNA and 2118 
showed that N first bound and protected G and U residues located within a GAUU motif 2119 
from cleavage by RNases.  At the same time point, bases adjacent to the initial binding 2120 
site exhibited a slight increase in reactivity (Fig. 4-3).  These enhancements could be a 2121 
result of the binding of the first N monomer causing a secondary structural rearrangement 2122 
that prepares the adjacent binding site for another molecule of N to bind.  Sequential 2123 
binding of N monomers onto our RNA construct was also observed.  RNA bases at the 2124 
N-RNA recognition site near the 3’ end of the RNA molecule were protected first and 2125 
bases toward the 5’ end were protected later (Fig. 4-3).  As the complex matured over 2126 
time, global protection of all reactive RNA bases was observed (Fig. 4-3).  These results 2127 
support a model of RNP formation that involves a specific RNA binding event initiating 2128 
cooperative binding between N monomers, which then switch to a non-specific mode of 2129 
RNA binding that allows N to coat the viral genome.   2130 
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Interestingly, during replication encapsidation of viral RNA by N has been 2131 
proposed to occur in the 5’ to 3’ direction (87, 109). We observed sequential binding in 2132 
the opposite (3’ to 5’) direction, suggesting either that N is able to oligomerize in both 2133 
directions or that binding occurred first at a high affinity site and subsequently at sites 2134 
further upstream.  That N exhibits disparate binding behaviors on different RNAs has 2135 
been demonstrated in La Crosse virus infected cells (44).  During the later stages of a La 2136 
Crosse viral infection (24-48 h.p.i.) as the concentration of N in the host cell increases, 2137 
viral mRNAs become encapsidated (44).  Viral mRNAs are considered secondary targets 2138 
because at low concentrations of N, only genomes and antigenomes are complexed with 2139 
N.  At higher concentrations, viral but not cellular mRNAs are associated with N protein 2140 
(44).  This suggests that the viral mRNA has a lower-affinity N recognition motif(s), but 2141 
at a critical concentration of N, the mRNA can be bound first specifically and then 2142 
cooperatively by N.  It is thought that encapsidation of viral mRNA is a mechanism to 2143 
regulate viral protein synthesis because encapsidated mRNAs cannot be translated by the 2144 
ribosome.   2145 
Suramin was identified in a high-throughput screening assay for compounds that 2146 
inhibit a specific RVFV N-RNA binding interaction (29).  Suramin is a symmetric, 2147 
polyanionic compound that contains two naphthalene-1,3,5-trisulfonic acid head moieties 2148 
and has been used successfully in the past to treat parasitic infections, specifically 2149 
trypanosomiasis and human onchocerciasis (4, 47).  Here we observed that although 2150 
competitor RNA was unable to disrupt mature N-RNA complexes, suramin was able to 2151 
penetrate and disrupt both WT and %33 mutant N-RNA complexes (Figs. 4-1B; 4-4B; 4- 2152 
5; 4-6A).  Interestingly, a significantly lower concentration of suramin was required to 2153 
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disrupt the %33 mutant complex (Fig. 4-4B).  This could be because the N-terminal arm 2154 
not only facilitates the formation of multimers onto an RNA molecule, but helps stabilize 2155 
and strengthen the RNP complex as well.  We reasoned that suramin could exert this 2156 
inhibitory effect by either occluding the RNA binding site directly or inhibiting protein- 2157 
protein interactions that are required for assembly of the viral nucleocapsid.  Because we 2158 
found that N purified by gel filtration chromatography in the presence of suramin was 2159 
diminished in RNA content, and because suramin was unable to disrupt a dimer structure 2160 
formed by a mutated N that is unable to bind RNA, we conclude that suramin binds 2161 
directly to and obscures the RNA binding cleft.   2162 
Suramin, or derivatives thereof, may be useful in the development of broad 2163 
spectrum antiviral agents. A recent crystal structure of N from a related phlebovirus 2164 
(severe fever with thrombocytopenia syndrome virus, SFTSV) with a bound suramin 2165 
showed that the head of the suramin molecule penetrated deeper into the RNA binding 2166 
slot than an RNA molecule (56).  The ability of suramin to penetrate further into the 2167 
RNA binding groove could explain why we found that suramin is able to eject prebound 2168 
RNA.  Suramin inhibits Norovirus RNA dependent RNA polymerase by its negatively 2169 
charged naphthalenetrisulfonic acid groups binding to a positively charged cleft near the 2170 
active site and likely preventing incoming NTPs to access to the active site (66).  It is also 2171 
thought that suramin binds retroviral reverse transcriptase at or near the polymerase 2172 
active site through interactions between its negatively charged head groups and basic 2173 
amino acid residues (86).  2174 
Suramin was not only effective at disrupting RVFV N-RNA binding interactions in 2175 
vitro, it also successfully inhibited viral replication in human cell culture (Fig. 4-7).  2176 
 108 
Suramin blocked virus entry into cells (or another early step) as well as a subsequent 2177 
step(s) in the viral replication cycle (Fig. 4-8).  Polyanionic compounds are known to 2178 
interfere with the virus adsorption process.  It is also possible that suramin in the media 2179 
could penetrate the viral particle and begin to disrupt the RNP complex and/or the RNA 2180 
dependent RNA polymerase before it enters the cell.  Similar to the results obtained here, 2181 
previous studies show that in addition to the anti-RT activity mentioned above, suramin 2182 
prevents HIV-1 from binding to cells possibly by interacting with the viral glycoprotein 2183 
gp120 (26, 107).  2184 
This study demonstrates that suramin is not only a useful tool to study RVFV N- 2185 
RNA binding interactions, it may form the basis for future broad spectrum antiviral 2186 
therapeutic strategies, due to its ability to inhibit RVFV replication at multiple steps in 2187 
cell culture, and its ability to inhibit replication of several diverse viruses.  Furthermore, 2188 
continuing to increase our understanding of the molecular details of viral RNA 2189 
encapsidation could ultimately aid in the design of more effective drugs targeted to viral 2190 
nucleocapsid proteins. 2191 
 2192 
 2193 
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 2194 
CHAPTER 5:  GENERAL DISCUSSION AND FUTURE 2195 
DIRECTIONS 2196 
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The overall goals of our research were to better understand how Rift Valley fever 2197 
virus (RVFV) nucleocapsid (N) protein interacts with RNA, to develop a high-throughput 2198 
screening (HTS) assay for identification of compounds that inhibit a N-RNA binding 2199 
interaction and to test the efficacy of potential anti-viral drug compounds during RVFV 2200 
infection.  We have identified interesting new sequences and secondary structural 2201 
elements of RNA that are specifically recognized and bound by N.  The biological 2202 
relevance and function of these binding determinants during RVFV infection are 2203 
currently unknown but warrant further discussion and study.  Implementation of a HTS 2204 
assay developed in our laboratory allowed us to identify small molecules and natural 2205 
product extracts that inhibit N-RNA binding interactions in vitro and RVFV replication in 2206 
cell culture.  The compounds and extracts identified in this study represent potential 2207 
antiviral therapeutic strategies as well as useful as tools to study RVFV N-RNA binding 2208 
interactions.  Increasing our understanding of how RVFV N recognizes and binds to its 2209 
cognate RNA will aid in the design of more potent and less cytotoxic compounds targeted 2210 
to viral nucleocapsid proteins. 2211 
I. Rift Valley fever virus nucleocapsid protein-RNA binding interactions  2212 
The majority of previous research aimed at elucidating requisite RNA features for a 2213 
specific N-binding event has focused on the 5’ and 3’ non-coding ends of the viral RNA.  2214 
The terminal nucleotide sequences are highly conserved among bunyaviruses of the same 2215 
genus and base-pairing of the terminal nucleotides results in the formation of stable 2216 
panhandle structures and allows the genome and antigenome to circularize.  It is thought 2217 
that the sequences and/or panhandle structures at the ends of the genome allow viral 2218 
nucleocapsid protein to recognize and preferentially bind to its own RNA (72, 76, 78).  2219 
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This specific binding may be important for initiation of viral transcription, replication and 2220 
packaging.  However, N is involved in other steps during an infection that require it to 2221 
interact with non-terminal sequences and/or secondary structural elements of the viral 2222 
genome and antigenome, as well as viral mRNA.  For example, hantavirus N 2223 
preferentially binds RNA containing a 5’ m7G cap when compared with uncapped RNA 2224 
or the cap analog, 2’-O-methyl G (73).  This cap-binding activity plays an important role 2225 
in allowing N to augment production of viral protein in trans by acting as a translation 2226 
initiation factor.  In fact, N is able to replace the eIF4F initiation complex by mimicking 2227 
the cap binding activity of eIF4E, directly recruiting the 43S pre-initiation complex to the 2228 
mRNA (a function normally performed by eIF4G) and the RNA chaperone activity of N 2229 
obviates the need for the RNA helicase eIF4A (77, 89).  Also, during an RNA virus 2230 
infection a correlation between an increased concentration of N in the host cell and the 2231 
switch from transcription of viral mRNA to replication of the viral genome has been 2232 
observed.  The mechanism underlying this switch is poorly understood but it has been 2233 
proposed that N acts as an anti-terminator during mRNA synthesis and promotes full- 2234 
length complementary RNA synthesis (118).  The events described above likely involve 2235 
binding interactions between N and viral RNA that have not yet been characterized.  2236 
To gain a better understanding of the RNA sequence and secondary structural 2237 
elements specifically recognized by RVFV N during an RNA-binding event, we used an 2238 
in vitro selection technique (SELEX) to evolve RNAs that bound with high affinity 2239 
(aptamer RNAs) to N.  Analysis of these aptamer RNAs allowed us to identify RNA 2240 
features required for N binding without any biased assumptions about what sequences or 2241 
structures constitute favorable binding targets.  Analysis of the nucleotide distribution of 2242 
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RNA sequences from the last two rounds of the selection showed enrichment for both 2243 
guanosine and uridine residues when compared to sequences from round one.  Consistent 2244 
with this observation, GAUU and pyrimidine/guanine motifs were found in many of our 2245 
aptamer RNAs. Mutational analysis verified that the GAUU motif and, to a lesser extent 2246 
the pyrimidine/guanine motif, are important for N binding to aptamer RNA.  We 2247 
conducted RNA structure probing experiments that allowed us to observe N binding to a 2248 
GAUU motif in real time.  When N first bound the RNA it protected G and U residues 2249 
located within the motif from cleavage by RNases.  At the same time point, bases 2250 
adjacent to the initial binding site and located within stem loop structures exhibited an 2251 
increase in reactivity.  These enhancements in reactivity could be a result of N disrupting 2252 
adjacent stem loop structures as it binds to the GAUU motif.  This type of activity could 2253 
be important for relieving secondary structural elements on viral RNA that could 2254 
decrease the processivity of a polymerase and/or impede the progress of the ribosome.  2255 
For example, N binding to and unwinding mRNA secondary structure during translation 2256 
could increase the speed and efficiency of viral protein synthesis.  BLAST analysis 2257 
revealed multiple regions of sequence similarity between RNA aptamers and the coding 2258 
region of the viral genome and antigenome, which supports the idea that N interacts with 2259 
non-terminal viral RNA sequences during a replication cycle. 2260 
As previously mentioned, a pyrimidine/guanine motif was present in many of our 2261 
aptamer RNAs.  The pyrimidine portion of this motif exhibited some sequence variability 2262 
but it always ended with a stretch of five G residues.  For example, MBE15.12 had a 2263 
UUUCUGGGGG motif while sequencing of MBE16.40 revealed a CUCUGGGGG 2264 
motif.  Interestingly, a UG-rich RNA element is known to be involved in regulating 2265 
 113 
transcription termination in RVFV (53).  This UG-rich motif (UGGGGUGGUGGGGU) 2266 
is located directly upstream of a conserved pentanucleotide (CGUCG) sequence and is 2267 
present on the S and M segments of viral mRNA (53).  Although the mechanism of 2268 
transcription termination is not well understood, it likely involves a viral or host cellular 2269 
factor interacting with these RNA elements.  It has also been proposed that annealing 2270 
between the nascent mRNA and template during transcription is involved in causing the 2271 
RNA-dependent RNA polymerase to terminate.  In bunyaviruses, drugs that inhibit 2272 
translation (such as cycloheximide) also inhibit mRNA synthesis.  Specifically, in La 2273 
Crosse viruses addition of cycloheximide did not affect the rate of mRNA initiation, but 2274 
caused all S segment mRNA transcripts to terminate prematurely at nucleotide 175.  2275 
However, the polymerase could be made to read through nucleotide 175 to the end of the 2276 
RNA molecule in the absence of protein synthesis by replacing guanosines residues with 2277 
inosine (7, 8).  These data provide support for the idea that premature termination is due 2278 
to base-pairing of the nascent mRNA chain with the template and that concurrent 2279 
translation of viral mRNA in the cytoplasm of the host cell prevents the formation of ds- 2280 
RNA and premature termination.  Experiments conducted in Sendai virus (a non- 2281 
segmented negative-sense RNA virus) show that as the concentration of N increases in 2282 
the host cell during an infection, a switch from transcription to full-length cRNA 2283 
synthesis occurs because at a certain critical concentration, N begins to encapsidate viral 2284 
RNA as it is being synthesized by the RNA-dependent RNA polymerase (118).  We 2285 
hypothesize that in our system, RVFV N could function as an anti-terminator during 2286 
transcription and facilitate the switch to full-length genome replication by specifically 2287 
recognizing and binding to the UG-rich motif on the M and S segments of viral mRNA.  2288 
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This would prevent base-pairing between the nascent mRNA chain and the template and 2289 
promote full length complementary RNA synthesis.  If this were true, one would expect 2290 
to see a full-length antigenomic RNA with a 5’ 7mG cap present in RVFV infected cells.  2291 
Interestingly, small amounts of an S RNA transcript that starts like an mRNA but ends 2292 
like the antigenome have been detected in La Crosse virus infected cells (98) and could 2293 
represent an intermediate RNA molecule formed during the switch from transcription to 2294 
genome replication. 2295 
When RVFV N binds RNA it is unclear whether RNA sequence, secondary 2296 
structure, or both are important for determining the specificity of binding.  Experiments 2297 
conducted using Sin Nombre hantavirus N suggest that formation of a panhandle 2298 
structure allows selective encapsidation of cognate RNA molecules during an infection 2299 
(76).  However hantavirus N also binds the 5’ end of single-stranded RNA with higher 2300 
affinity than the 3’ end suggesting that sequence as well as secondary structure play a 2301 
role in the ability of nucleocapsid protein to specifically recognize viral RNA (75).  We 2302 
propose that the GAUU sequence is recognized and bound by N and therefore it is 2303 
important that the motif be located in a single-stranded region of an RNA molecule.  2304 
However, this hypothesis has not been rigorously tested and it is likely that secondary 2305 
structural elements are important binding determinants for other aptamer RNAs identified 2306 
during our in vitro selection.  Recently, a collaborator (Doug Raiford) developed an 2307 
algorithm to mutate the sequence but not the mfold-predicted secondary structure of 2308 
aptamer RNAs.  We are currently in the process of synthesizing RNAs that will be used 2309 
to compare the binding affinity of N for WT and mutant aptamer RNA molecules.  These 2310 
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studies will ultimately allow us to measure the individual contribution of a sequence or 2311 
secondary structure to a RVFV N-RNA-binding event. 2312 
A recent crystal structure of single-stranded RNA encapsidated by RVFV N shows 2313 
the ribonucleoprotein complex existing as a hexamer, pentamer or tetramer.  Analysis of 2314 
this structure revealed an RNA-binding groove that contains several highly conserved 2315 
basic amino acid side chains and the N-terminal domain of an N monomer facilitates 2316 
oligomerization by binding to a hydrophobic pocket on an adjacent subunit.  The sugar 2317 
phosphate backbone of the RNA is oriented toward the solvent exposed side of the RNA 2318 
binding groove and the RNA bases, which are inserted into the slot, are involved in 2319 
hydrophobic and base-stacking interactions with N (100).  The mode of binding 2320 
represented by this crystal structure is considered non-specific because N is only involved 2321 
in H-bond interactions with the sugar phosphate backbone of RNA and is not recognizing 2322 
a specific H-bond pattern formed by the nitrogenous bases.  Structures of N from other 2323 
negative-sense RNA viruses, including influenza and vesicular stomatitis virus (VSV) 2324 
have been solved.  Similar to the RVFV structure, the RNP oligomers form high-order 2325 
ring structures and oligomerize by N and/or C terminal arm-like extensions interacting 2326 
with neighboring monomers.  However, the orientation of the RNA bases within the 2327 
RNA-binding cleft of influenza and VSV RNP complexes is different.  Influenza virus N 2328 
coats the RNA sugar phosphate backbone and the bases are oriented toward the solvent 2329 
(123).  The crystal structure of VSV N shows that the RNA bases adopt a unique 2330 
conformation where some of the bases are facing toward and others away from the 2331 
solvent (42).  The nitrogenous bases of VSV N encapsidated RNA exhibit varying 2332 
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degrees of reactivity when chemically probed and these data are consistent with the high- 2333 
resolution structure model that shows some of the bases are solvent exposed (54). 2334 
RNA structure probing experiments conducted in our laboratory yielded some 2335 
thought provoking results.  As discussed previously, when RVFV N was incubated with 2336 
aptamer RNA and then probed with RNases, initially N protected G and U residues 2337 
present in a GAUU motif from cleavage.  After the RNA was incubated with N for an 2338 
extended period of time, all reactive nucleotides were protected.  We observed sequential 2339 
binding in the 3’ to 5’ direction, suggesting either that N is either able to oligomerize in 2340 
both (5’ to 3’ and 3’ to 5’) directions or that binding occurred first at a high affinity site 2341 
and subsequently at lower affinity sites further upstream.  Unexpectedly, when RNA was 2342 
incubated with N and then probed with DMS, enhancements in the reactivity of RNA 2343 
bases were observed.  Since the crystal structure of RVFV N shows the nitrogenous bases 2344 
buried deep within the RNA-binding groove we expected to see a decrease in reactivity 2345 
of the bases when N binds.  However, our results suggest that when N binds RNA it 2346 
positions the Watson-Crick face of some A and C residues in such a way that they 2347 
become more available for DMS modification.  When N encapsidates RNA it removes 2348 
secondary structures and the RNA becomes single-stranded.  Perhaps disruption of H- 2349 
bond interactions that stabilize stem loop structures could increase the availability of 2350 
some RNA bases for chemical modification.  Also, not all RVFV N-encapsidated RNA 2351 
bases are sequestered within the RNA binding groove.  Each N subunit binds four RNA 2352 
nucleotides in the RNA binding slot and 2 to 3 additional nucleotides at the subunit 2353 
interface.  It is possible that DMS is able to modify the bases in between the N 2354 
monomers.  If this were true we would expect to see a pattern emerge where every 5th, 6th 2355 
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and 7th A or C residue is reactive; however, our probing results did not show this type of 2356 
periodicity.    2357 
During replication as the viral RNA exits the RNA-dependent RNA polymerase it 2358 
is sequentially bound by N in the 5’ to 3’ direction.  However, in our experimental system 2359 
we were only able to observe binding in the 3’ to 5’ direction.  To evaluate whether 2360 
sequential binding can occur in both directions, it would be useful to create an RNA 2361 
molecule that contains a high affinity RVFV N-binding site flanked by 100 or so 2362 
nucleotides of low affinity non-aptamer-like RNA sequence.  To determine the 2363 
directionality of N binding, a quench flow apparatus that incubates a binding reaction for 2364 
a specified amount of time ranging from milliseconds to hours could be used to perform 2365 
time-resolved RNA structure probing experiments.  First, we would expect to see changes 2366 
in reactivity in RNA bases that correspond to the central portion of the RNA molecule 2367 
that contains the high affinity aptamer RNA sequence because this is where N should 2368 
bind first.  Then later we would expect RNA sequences upstream and/or downstream of 2369 
the aptamer RNA sequence to exhibit changes in reactivity as N subsequently binds the 2370 
lower affinity sites.  Our previous results suggest that the initial N-RNA binding events 2371 
occur rapidly and then over the course of several minutes to hours the ribonucleoprotein 2372 
complex matures.  Since the quench flow apparatus can take multiple snapshots of an N- 2373 
RNA binding event that has been incubating for milliseconds or seconds, we could 2374 
potentially observe N monomers binding one at a time to an RNA molecule.  These data 2375 
would allow us to observe RNA encapsidation in real time and deduce the directionality 2376 
of N oligomerization.  2377 
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DMS probing results suggest that as N binds, RNA bases become more available 2378 
for chemical modification.  Perhaps an increase in the reactivity of RNA bases is 2379 
observed when small, hydrophobic chemical probes are used because they can penetrate 2380 
into the RNA-binding groove and modify bases involved in hydrophobic interactions 2381 
with N.  It would be interesting to try RNA structure probing using kethoxal, a small 2382 
molecule that modifies N1 and N2 of guanosine to see if the results are similar to those 2383 
obtained using DMS.  We could also directly compare the reactivity of G residues to a 2384 
chemical probe vs. RNase T1 using kethoxal.  Hydroxyl radical structure probing 2385 
experiments could be conducted to see how well protected by N the RNA sugar 2386 
phosphate backbone becomes over time.  Hydroxyl radicals react with and degrade the 2387 
ribose ring of the RNA and protein bound to the RNA backbone lowers the reactivity of 2388 
the ribose rings.  Completion of the proposed RNA structure probing experiments would 2389 
allow us to further elucidate the solvent accessibility of various components of an RNA 2390 
molecule during an N-RNA binding event.  This information could be used to create a 2391 
detailed model of a RVFV N-RNA encapsidation event. 2392 
II. High-throughput drug screening assay  2393 
We developed a fluorescence-based high-throughput drug screening (HTS) assay to 2394 
test 26,424 chemical compounds for their ability to disrupt an N-RNA complex, and 2395 
potentially inhibit viral replication.  We found 10 unique compounds and 40 natural 2396 
product extracts that were capable of disrupting the N-RNA complex in vitro and a subset 2397 
displayed efficacy in cell culture.  Transfection of RNA aptamers directed against N 2398 
inhibited viral translation and replication in cell culture providing support for our 2399 
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hypothesis that inhibition of N binding to RNA represents a viable antiviral therapeutic 2400 
strategy.  2401 
Two unique compounds (Life Chemicals, 5406174 and suramin) were able to 2402 
decrease RVFV replication in cell culture by approximately 1 log.  Compound 5406174 2403 
contains a quinone, which is a reactive moiety and can modify cysteine residues.  Some 2404 
scientists label compounds that contain quinones as “PAINS” (Pan Assay Interference 2405 
compounds) because they appear as hits in many high-throughput screens and question 2406 
the specificity of compounds that are promiscuous hitters.  However, quinone-containing 2407 
compounds have been successfully developed into drugs and are common in anti-cancer 2408 
therapy (5).  Also, only one of the two quinones that were confirmed hits from our HTS 2409 
screen decreased viral replication in cell culture, suggesting that compound 5406174 2410 
exhibits specificity for its target.  Therefore, we believe that compound 5406174 should 2411 
not be dismissed as a hit and intend to continue to study its mechanism of inhibition both 2412 
in vitro and in human cell culture.   2413 
Suramin is a negatively charged compound that contains two naphthalene-1,3,5- 2414 
trisulfonic acid head groups.  It effectively inhibited RVFV replication in cell culture and 2415 
was an easy to use tool to study N-RNA binding interactions biochemically because it is 2416 
colorless, stable and water soluble.  Analysis of the in vitro inhibitory mechanism of 2417 
suramin showed that it was able to disrupt N-RNA interactions by binding directly to and 2418 
obscuring the RNA binding cleft.  We also discovered that suramin inhibits RVFV 2419 
replication in cell culture by preventing the virus from entering cells and by blocking 2420 
other subsequent steps of the virus life cycle.  Suramin could be useful in the 2421 
development of broad-spectrum antiviral therapies due to its ability to inhibit replication 2422 
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of RVFV and several other viruses such as retroviruses.  Although it is difficult to put an 2423 
exact figure on the cost of creating a new drug, it is extremely expensive and estimates 2424 
range from hundreds of millions to billions of dollars.  However, since suramin has been 2425 
used successfully to treat parasitic diseases, its relative safety in humans has already been 2426 
proven and this could significantly decrease length of time and cost required to bring the 2427 
drug to market. 2428 
We used a variety of biochemical assays to determine how suramin disrupts an N- 2429 
RNA binding event and a similar strategy could be utilized to study the inhibitory 2430 
mechanism(s) of the other nine unique compounds.  We anticipate that compounds 2431 
identified in our HTS assay inhibit N-RNA binding by either occluding the RNA binding 2432 
site or inhibiting protein-protein interactions that are required for assembly of the viral 2433 
nucleocapsid.  To distinguish between these potential mechanisms, we could use 2434 
fluorescence polarization to report on N-RNA binding in the presence or absence of drug 2435 
compound, and compare WT vs. a mutated version of N that is unable to multimerize.  2436 
We could also perform gel filtration on purified N protein in the presence and absence of 2437 
compound to determine how addition of compound affects formation of N multimers.  2438 
RNA structure probing could be used to determine whether a compound is capable of 2439 
inhibiting a specific and/or non-specific N-RNA binding interaction.  It would be 2440 
extremely fortuitous to discover a compound that inhibits one mode of binding but not 2441 
the other.   2442 
Lead natural product extracts were tested for cytotoxicity and their ability to inhibit 2443 
viral replication in cell culture.  The results were promising and showed that six extracts 2444 
inhibited RVFV replication by 50% or more and were not cytotoxic to cells.  Since 2445 
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natural product extracts are a complex mixture of compounds, the active component(s) of 2446 
the extract may be dilute.  Therefore, once the functional component is isolated, the 2447 
natural product could be an even more potent inhibitor of viral replication.  2448 
Characterization of the active components(s) in the natural product extracts could 2449 
potentially result in the discovery of novel anti-viral compounds invented by Mother 2450 
Nature.  Interestingly, at two and three days post infection natural product extract 6990 2451 
stimulated or increased virus yield.  Although it would not be useful to pursue this extract 2452 
as a potential anti-viral drug, it could be useful as a tool to study the mechanism of RVFV 2453 
replication.  Identification of the molecular target(s) of extract 6990 could help us 2454 
determine specific virus and/or host factors that play an important role during the viral 2455 
replication cycle.  Microarray-based experiments could be conducted to compare the gene 2456 
expression profiles of cells infected with RFVF in the presence and absence of extract 2457 
6990.  Identification of genes that are up-regulated in the presence of extract 6990 could 2458 
help determine specific genes or cellular pathways utilized by RVFV during an infection.  2459 
This research has increased our understanding of how viral nucleocapsid proteins 2460 
recognize and bind their cognate RNA and rearrange RNA structure.  We have also 2461 
developed a high throughput drug-screening tool and established RVFV N as a promising 2462 
drug target.  Natural product extracts that could contain novel anti-viral compounds have 2463 
been identified and we show that suramin and Life Chemicals 5406174 possess drug 2464 
development potential. 2465 
 122 
 2466 
CHAPTER 6:  REFERENCES 2467 
 123 
 2468 
1. Al-Hazmi, M., E. A. Ayoola, M. Abdurahman, S. Banzal, J. Ashraf, A. El- 2469 
Bushra, A. Hazmi, M. Abdullah, H. Abbo, A. Elamin, T. Al-Sammani el, M. 2470 
Gadour, C. Menon, M. Hamza, I. Rahim, M. Hafez, M. Jambavalikar, H. 2471 
Arishi, and A. Aqeel. 2003. Epidemic Rift Valley fever in Saudi Arabia: a 2472 
clinical study of severe illness in humans. Clin Infect Dis 36:245-252. 2473 
2. Alrajhi, A. A., A. Al-Semari, and J. Al-Watban. 2004. Rift Valley fever 2474 
encephalitis. Emerg Infect Dis 10:554-555. 2475 
3. Anderson, G. W., Jr., and J. F. Smith. 1987. Immunoelectron microscopy of 2476 
Rift Valley fever viral morphogenesis in primary rat hepatocytes. Virology 2477 
161:91-100. 2478 
4. Anderson, J., and H. Fuglsang. 1978. Further studies on the treatment of ocular 2479 
onchocerciasis with diethylcarbamazine and suramin. Br J Ophthalmol 62:450- 2480 
457. 2481 
5. Baell, J. B., and G. A. Holloway. 2010. New substructure filters for removal of 2482 
pan assay interference compounds (PAINS) from screening libraries and for their 2483 
exclusion in bioassays. J Med Chem 53:2719-2740. 2484 
6. Balkhy, H. H., and Z. A. Memish. 2003. Rift Valley fever: an uninvited 2485 
zoonosis in the Arabian peninsula. Int J Antimicrob Agents 21:153-157. 2486 
7. Bellocq, C., and D. Kolakofsky. 1987. Translational requirement for La Crosse 2487 
virus S-mRNA synthesis: a possible mechanism. J Virol 61:3960-3967. 2488 
8. Bellocq, C., R. Raju, J. Patterson, and D. Kolakofsky. 1987. Translational 2489 
requirement of La Crosse virus S-mRNA synthesis: in vitro studies. J Virol 2490 
61:87-95. 2491 
9. Billecocq, A., M. Spiegel, P. Vialat, A. Kohl, F. Weber, M. Bouloy, and O. 2492 
Haller. 2004. NSs protein of Rift Valley fever virus blocks interferon production 2493 
by inhibiting host gene transcription. J Virol 78:9798-9806. 2494 
10. Bird, B. H., T. G. Ksiazek, S. T. Nichol, and N. J. Maclachlan. 2009. Rift 2495 
Valley fever virus. J Am Vet Med Assoc 234:883-893. 2496 
11. Borio, L., T. Inglesby, C. J. Peters, A. L. Schmaljohn, J. M. Hughes, P. B. 2497 
Jahrling, T. Ksiazek, K. M. Johnson, A. Meyerhoff, T. O'Toole, M. S. 2498 
Ascher, J. Bartlett, J. G. Breman, E. M. Eitzen, Jr., M. Hamburg, J. Hauer, 2499 
D. A. Henderson, R. T. Johnson, G. Kwik, M. Layton, S. Lillibridge, G. J. 2500 
Nabel, M. T. Osterholm, T. M. Perl, P. Russell, and K. Tonat. 2002. 2501 
Hemorrhagic fever viruses as biological weapons: medical and public health 2502 
management. Jama 287:2391-2405. 2503 
12. Botros, B., A. Omar, K. Elian, G. Mohamed, A. Soliman, A. Salib, D. 2504 
Salman, M. Saad, and K. Earhart. 2006. Adverse response of non-indigenous 2505 
cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. 2506 
J Med Virol 78:787-791. 2507 
13. Bouloy, M., and R. Flick. 2009. Reverse genetics technology for Rift Valley 2508 
fever virus: current and future applications for the development of therapeutics 2509 
and vaccines. Antiviral Res 84:101-118. 2510 
 124 
14. Bouloy, M., C. Janzen, P. Vialat, H. Khun, J. Pavlovic, M. Huerre, and O. 2511 
Haller. 2001. Genetic evidence for an interferon-antagonistic function of rift 2512 
valley fever virus nonstructural protein NSs. J Virol 75:1371-1377. 2513 
15. C.D.C. 2000. Outbreak of Rift Valley fever-Saudia Arabia, August-October, 2514 
2000. MMWR Morb Mortal Wkly Rep 49:905-908. 2515 
16. Caplen, H., C. J. Peters, and D. H. Bishop. 1985. Mutagen-directed attenuation 2516 
of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 ( 2517 
Pt 10):2271-2277. 2518 
17. Caplen, H., C. J. Peters, and D. H. Bishop. 1985. Mutagen-directed attenuation 2519 
of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 ( 2520 
Pt 10):2271-2277. 2521 
18. Chapman, J., E. Abbott, D. G. Alber, R. C. Baxter, S. K. Bithell, E. A. 2522 
Henderson, M. C. Carter, P. Chambers, A. Chubb, G. S. Cockerill, P. L. 2523 
Collins, V. C. Dowdell, S. J. Keegan, R. D. Kelsey, M. J. Lockyer, C. Luongo, 2524 
P. Najarro, R. J. Pickles, M. Simmonds, D. Taylor, S. Tyms, L. J. Wilson, 2525 
and K. L. Powell. 2007. RSV604, a novel inhibitor of respiratory syncytial virus 2526 
replication. Antimicrob Agents Chemother 51:3346-3353. 2527 
19. Cheng, E., A. Haque, M. A. Rimmer, I. T. Hussein, S. Sheema, A. Little, and 2528 
M. A. Mir. 2011. Characterization of the Interaction between hantavirus 2529 
nucleocapsid protein (N) and ribosomal protein S19 (RPS19). J Biol Chem 2530 
286:11814-11824. 2531 
20. Coetzer, J. A. 1977. The pathology of Rift Valley fever. I. Lesions occurring in 2532 
natural cases in new-born lambs. Onderstepoort J Vet Res 44:205-211. 2533 
21. Coetzer, J. A. 1982. The pathology of Rift Valley fever. II. Lesions occurring in 2534 
field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res 2535 
49:11-17. 2536 
22. Coetzer, J. A., and K. G. Ishak. 1982. Sequential development of the liver 2537 
lesions in new-born lambs infected with Rift Valley fever virus. I. Macroscopic 2538 
and microscopic pathology. Onderstepoort J Vet Res 49:103-108. 2539 
23. Collett, M. S., A. F. Purchio, K. Keegan, S. Frazier, W. Hays, D. K. 2540 
Anderson, M. D. Parker, C. Schmaljohn, J. Schmidt, and J. M. Dalrymple. 2541 
1985. Complete nucleotide sequence of the M RNA segment of Rift Valley fever 2542 
virus. Virology 144:228-245. 2543 
24. Daubney, R. J., Hudson, J.R. and Garnham, P.C. 1931. Journal of Pathology 2544 
and Bacteriology 34:545-579. 2545 
25. Davies, F. G., K. J. Linthicum, and A. D. James. 1985. Rainfall and epizootic 2546 
Rift Valley fever. Bull World Health Organ 63:941-943. 2547 
26. De Clercq, E. 1979. Suramin: a potent inhibitor of the reverse transcriptase of 2548 
RNA tumor viruses. Cancer Lett 8:9-22. 2549 
27. de Haseth, P. L., and O. C. Uhlenbeck. 1980. Interaction of Escherichia coli 2550 
host factor protein with Q beta ribonucleic acid. Biochemistry 19:6146-6151. 2551 
28. de Rocquigny, H., V. Shvadchak, S. Avilov, C. Z. Dong, U. Dietrich, J. L. 2552 
Darlix, and Y. Mely. 2008. Targeting the viral nucleocapsid protein in anti-HIV- 2553 
1 therapy. Mini Rev Med Chem 8:24-35. 2554 
 125 
29. Ellenbecker, M., J. M. Lanchy, and J. S. Lodmell. 2012. Identification of Rift 2555 
Valley fever virus nucleocapsid protein-RNA binding inhibitors using a high- 2556 
throughput screening assay. J Biomol Screen 17:1062-1070. 2557 
30. Ellenbecker, M., L. Sears, P. Li, J. M. Lanchy, and J. Stephen Lodmell. 2012. 2558 
Characterization of RNA aptamers directed against the nucleocapsid protein of 2559 
Rift Valley fever virus. Antiviral Res 93:330-339. 2560 
31. Ellis, D. S., P. V. Shirodaria, E. Fleming, and D. I. Simpson. 1988. 2561 
Morphology and development of Rift Valley fever virus in Vero cell cultures. J 2562 
Med Virol 24:161-174. 2563 
32. Ferron, F., Z. Li, E. I. Danek, D. Luo, Y. Wong, B. Coutard, V. Lantez, R. 2564 
Charrel, B. Canard, T. Walz, and J. Lescar. 2011. The hexamer structure of 2565 
the rift valley Fever virus nucleoprotein suggests a mechanism for its assembly 2566 
into ribonucleoprotein complexes. PLoS Pathog 7:e1002030. 2567 
33. Franze de Fernandez, M. T., L. Eoyang, and J. T. August. 1968. Factor 2568 
fraction required for the synthesis of bacteriophage Qbeta-RNA. Nature 219:588- 2569 
590. 2570 
34. Franze de Fernandez, M. T., W. S. Hayward, and J. T. August. 1972. 2571 
Bacterial proteins required for replication of phage Q ribonucleic acid. 2572 
Pruification and properties of host factor I, a ribonucleic acid-binding protein. J 2573 
Biol Chem 247:824-831. 2574 
35. Furuta, Y., B. B. Gowen, K. Takahashi, K. Shiraki, D. F. Smee, and D. L. 2575 
Barnard. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. 2576 
Antiviral Res 100:446-454. 2577 
36. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. 2578 
Kozaki, N. Nomura, H. Egawa, and K. Shiraki. 2005. Mechanism of action of 2579 
T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986. 2580 
37. Gasparian, A. V., N. Neznanov, S. Jha, O. Galkin, J. J. Moran, A. V. 2581 
Gudkov, K. V. Gurova, and A. A. Komar. 2010. Inhibition of 2582 
encephalomyocarditis virus and poliovirus replication by quinacrine: implications 2583 
for the design and discovery of novel antiviral drugs. J Virol 84:9390-9397. 2584 
38. Gerritz, S. W., C. Cianci, S. Kim, B. C. Pearce, C. Deminie, L. Discotto, B. 2585 
McAuliffe, B. F. Minassian, S. Shi, S. Zhu, W. Zhai, A. Pendri, G. Li, M. A. 2586 
Poss, S. Edavettal, P. A. McDonnell, H. A. Lewis, K. Maskos, M. Mortl, R. 2587 
Kiefersauer, S. Steinbacher, E. T. Baldwin, W. Metzler, J. Bryson, M. D. 2588 
Healy, T. Philip, M. Zoeckler, R. Schartman, M. Sinz, V. H. Leyva-Grado, H. 2589 
H. Hoffmann, D. R. Langley, N. A. Meanwell, and M. Krystal. 2011. 2590 
Inhibition of influenza virus replication via small molecules that induce the 2591 
formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A 2592 
108:15366-15371. 2593 
39. Giorgi, C., L. Accardi, L. Nicoletti, M. C. Gro, K. Takehara, C. Hilditch, S. 2594 
Morikawa, and D. H. Bishop. 1991. Sequences and coding strategies of the S 2595 
RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, 2596 
Sicilian Sandfly fever, and Uukuniemi viruses. Virology 180:738-753. 2597 
40. Gowen, B. B., D. F. Smee, M. H. Wong, J. O. Hall, K. H. Jung, K. W. Bailey, 2598 
J. R. Stevens, Y. Furuta, and J. D. Morrey. 2008. Treatment of late stage 2599 
 126 
disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced 2600 
toxicity suggests an alternative to ribavirin. PLoS One 3:e3725. 2601 
41. Gowen, B. B., M. H. Wong, K. H. Jung, A. B. Sanders, M. Mendenhall, K. W. 2602 
Bailey, Y. Furuta, and R. W. Sidwell. 2007. In vitro and in vivo activities of T- 2603 
705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2604 
51:3168-3176. 2605 
42. Green, T. J., X. Zhang, G. W. Wertz, and M. Luo. 2006. Structure of the 2606 
vesicular stomatitis virus nucleoprotein-RNA complex. Science 313:357-360. 2607 
43. Habjan, M., A. Pichlmair, R. M. Elliott, A. K. Overby, T. Glatter, M. 2608 
Gstaiger, G. Superti-Furga, H. Unger, and F. Weber. 2009. NSs protein of rift 2609 
valley fever virus induces the specific degradation of the double-stranded RNA- 2610 
dependent protein kinase. J Virol 83:4365-4375. 2611 
44. Hacker, D., R. Raju, and D. Kolakofsky. 1989. La Crosse virus nucleocapsid 2612 
protein controls its own synthesis in mosquito cells by encapsidating its mRNA. J 2613 
Virol 63:5166-5174. 2614 
45. Hacker, D., S. Rochat, and D. Kolakofsky. 1990. Anti-mRNAs in La Crosse 2615 
bunyavirus-infected cells. J Virol 64:5051-5057. 2616 
46. Haque, A., and M. A. Mir. 2010. Interaction of hantavirus nucleocapsid protein 2617 
with ribosomal protein S19. J Virol 84:12450-12453. 2618 
47. Hawking, F. 1940. Concentration of Bayer 205 (Germanin) in human blood and 2619 
cerebrospinal fluid after treatment. Trans R Soc Trop Med Hyg:37-52. 2620 
48. Hewlett, M. J., and W. Chiu. 1991. Virion structure. Curr Top Microbiol 2621 
Immunol 169:79-90. 2622 
49. Hewlett, M. J., R. F. Pettersson, and D. Baltimore. 1977. Circular forms of 2623 
Uukuniemi virion RNA: an electron microscopic study. J Virol 21:1085-1093. 2624 
50. Hunter, P., B. J. Erasmus, and J. H. Vorster. 2002. Teratogenicity of a 2625 
mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 2626 
69:95-98. 2627 
51. Ihara, T., H. Akashi, and D. H. Bishop. 1984. Novel coding strategy (ambisense 2628 
genomic RNA) revealed by sequence analyses of Punta Toro Phlebovirus S RNA. 2629 
Virology 136:293-306. 2630 
52. Ikegami, T., K. Narayanan, S. Won, W. Kamitani, C. J. Peters, and S. 2631 
Makino. 2009. Rift Valley fever virus NSs protein promotes post-transcriptional 2632 
downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. 2633 
PLoS Pathog 5:e1000287. 2634 
53. Ikegami, T., S. Won, C. J. Peters, and S. Makino. 2007. Characterization of 2635 
Rift Valley fever virus transcriptional terminations. J Virol 81:8421-8438. 2636 
54. Iseni, F., F. Baudin, D. Blondel, and R. W. Ruigrok. 2000. Structure of the 2637 
RNA inside the vesicular stomatitis virus nucleocapsid. Rna 6:270-281. 2638 
55. Jenkins, L. M., J. C. Byrd, T. Hara, P. Srivastava, S. J. Mazur, S. J. Stahl, J. 2639 
K. Inman, E. Appella, J. G. Omichinski, and P. Legault. 2005. Studies on the 2640 
mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2- 2641 
mercaptobenzamide thioesters. J Med Chem 48:2847-2858. 2642 
56. Jiao, L., S. Ouyang, M. Liang, F. Niu, N. Shaw, W. Wu, W. Ding, C. Jin, Y. 2643 
Peng, Y. Zhu, F. Zhang, T. Wang, C. Li, X. Zuo, C. H. Luan, D. Li, and Z. J. 2644 
Liu. 2013. Structure of severe fever with thrombocytopenia syndrome virus 2645 
 127 
nucleocapsid protein in complex with suramin reveals therapeutic potential. J 2646 
Virol 87:6829-6839. 2647 
57. Kakach, L. T., J. A. Suzich, and M. S. Collett. 1989. Rift Valley fever virus M 2648 
segment: phlebovirus expression strategy and protein glycosylation. Virology 2649 
170:505-510. 2650 
58. Kassack, M. U., K. Braun, M. Ganso, H. Ullmann, P. Nickel, B. Boing, G. 2651 
Muller, and G. Lambrecht. 2004. Structure-activity relationships of analogues 2652 
of NF449 confirm NF449 as the most potent and selective known P2X1 receptor 2653 
antagonist. Eur J Med Chem 39:345-357. 2654 
59. Keegan, K., and M. S. Collett. 1986. Use of bacterial expression cloning to 2655 
define the amino acid sequences of antigenic determinants on the G2 glycoprotein 2656 
of Rift Valley fever virus. J Virol 58:263-270. 2657 
60. Kilgore, P. E., T. G. Ksiazek, P. E. Rollin, J. N. Mills, M. R. Villagra, M. J. 2658 
Montenegro, M. A. Costales, L. C. Paredes, and C. J. Peters. 1997. Treatment 2659 
of Bolivian hemorrhagic fever with intravenous ribavirin. Clinical Infectious 2660 
Diseases 24:718-722. 2661 
61. Kochs, G., C. Janzen, H. Hohenberg, and O. Haller. 2002. Antivirally active 2662 
MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear 2663 
complexes. Proc Natl Acad Sci U S A 99:3153-3158. 2664 
62. Kolakofsky, D., and D. Hacker. 1991. Bunyavirus RNA synthesis: genome 2665 
transcription and replication. Curr Top Microbiol Immunol 169:143-159. 2666 
63. Le May, N., S. Dubaele, L. Proietti De Santis, A. Billecocq, M. Bouloy, and J. 2667 
M. Egly. 2004. TFIIH transcription factor, a target for the Rift Valley 2668 
hemorrhagic fever virus. Cell 116:541-550. 2669 
64. Lopez, N., R. Muller, C. Prehaud, and M. Bouloy. 1995. The L protein of Rift 2670 
Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic 2671 
genome-like RNA molecules. J Virol 69:3972-3979. 2672 
65. Madani, T. A., Y. Y. Al-Mazrou, M. H. Al-Jeffri, A. A. Mishkhas, A. M. Al- 2673 
Rabeah, A. M. Turkistani, M. O. Al-Sayed, A. A. Abodahish, A. S. Khan, T. 2674 
G. Ksiazek, and O. Shobokshi. 2003. Rift Valley fever epidemic in Saudi 2675 
Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2676 
37:1084-1092. 2677 
66. Mastrangelo, E., M. Pezzullo, D. Tarantino, R. Petazzi, F. Germani, D. 2678 
Kramer, I. Robel, J. Rohayem, M. Bolognesi, and M. Milani. 2012. Structure- 2679 
based inhibition of Norovirus RNA-dependent RNA polymerases. J Mol Biol 2680 
419:198-210. 2681 
67. McCormick, J. B., I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. 2682 
M. Johnson, L. H. Elliott, and R. Belmont-Williams. 1986. Lassa fever. 2683 
Effective therapy with ribavirin. N Engl J Med 314:20-26. 2684 
68. McIntosh, B. M., D. Russell, I. dos Santos, and J. H. Gear. 1980. Rift Valley 2685 
fever in humans in South Africa. S Afr Med J 58:803-806. 2686 
69. Meegan, J. M. 1979. The Rift Valley fever epizootic in Egypt 1977-78. 1. 2687 
Description of the epizzotic and virological studies. Trans R Soc Trop Med Hyg 2688 
73:618-623. 2689 
 128 
70. Meegan JM, B. C., Monath TP. 1989. Rift Valley fever., p. 51-76. In M. D. 2690 
Thomas P. Monath (ed.), The arboviruses:  epidemiology and ecology, vol. 4. 2691 
CRC Press Inc, Boca Raton, Florida. 2692 
71. Miller Jenkins, L. M., D. E. Ott, R. Hayashi, L. V. Coren, D. Wang, Q. Xu, 2693 
M. L. Schito, J. K. Inman, D. H. Appella, and E. Appella. 2010. Small- 2694 
molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer. Nat 2695 
Chem Biol 6:887-889. 2696 
72. Mir, M. A., B. Brown, B. Hjelle, W. A. Duran, and A. T. Panganiban. 2006. 2697 
Hantavirus N protein exhibits genus-specific recognition of the viral RNA 2698 
panhandle. J Virol 80:11283-11292. 2699 
73. Mir, M. A., W. A. Duran, B. L. Hjelle, C. Ye, and A. T. Panganiban. 2008. 2700 
Storage of cellular 5' mRNA caps in P bodies for viral cap-snatching. Proc Natl 2701 
Acad Sci U S A 105:19294-19299. 2702 
74. Mir, M. A., and A. T. Panganiban. 2006. The bunyavirus nucleocapsid protein 2703 
is an RNA chaperone: possible roles in viral RNA panhandle formation and 2704 
genome replication. Rna 12:272-282. 2705 
75. Mir, M. A., and A. T. Panganiban. 2006. Characterization of the RNA 2706 
chaperone activity of hantavirus nucleocapsid protein. J Virol 80:6276-6285. 2707 
76. Mir, M. A., and A. T. Panganiban. 2005. The hantavirus nucleocapsid protein 2708 
recognizes specific features of the viral RNA panhandle and is altered in 2709 
conformation upon RNA binding. J Virol 79:1824-1835. 2710 
77. Mir, M. A., and A. T. Panganiban. 2008. A protein that replaces the entire 2711 
cellular eIF4F complex. Embo J 27:3129-3139. 2712 
78. Mir, M. A., and A. T. Panganiban. 2004. Trimeric hantavirus nucleocapsid 2713 
protein binds specifically to the viral RNA panhandle. J Virol 78:8281-8288. 2714 
79. Mir, M. A., and A. T. Panganiban. 2010. The triplet repeats of the Sin Nombre 2715 
hantavirus 5' untranslated region are sufficient in cis for nucleocapsid-mediated 2716 
translation initiation. J Virol 84:8937-8944. 2717 
80. Miranda, G., D. Schuppli, I. Barrera, C. Hausherr, J. M. Sogo, and H. 2718 
Weber. 1997. Recognition of bacteriophage Qbeta plus strand RNA as a template 2719 
by Qbeta replicase: role of RNA interactions mediated by ribosomal proteins S1 2720 
and host factor. J Mol Biol 267:1089-1103. 2721 
81. Monath, T. P. 2008. Treatment of yellow fever. Antiviral Res 78:116-124. 2722 
82. Muller, R., C. Argentini, M. Bouloy, C. Prehaud, and D. H. Bishop. 1991. 2723 
Completion of the genome sequence of Rift Valley fever phlebovirus indicates 2724 
that the L RNA is negative sense and codes for a putative transcriptase-replicase 2725 
[corrected]. Nucleic Acids Res 19:5433. 2726 
83. Muller, R., O. Poch, M. Delarue, D. H. Bishop, and M. Bouloy. 1994. Rift 2727 
Valley fever virus L segment: correction of the sequence and possible functional 2728 
role of newly identified regions conserved in RNA-dependent polymerases. J Gen 2729 
Virol 75 ( Pt 6):1345-1352. 2730 
84. O'Brien, R. L., J. G. Olenick, and F. E. Hahn. 1966. Reactions of quinine, 2731 
chloroquine, and quinacrine with DNA and their effects on the DNA and RNA 2732 
polymerase reactions. Proc Natl Acad Sci U S A 55:1511-1517. 2733 
85. Ogg, M. M., and J. L. Patterson. 2007. RNA binding domain of Jamestown 2734 
Canyon virus S segment RNAs. J Virol 81:13754-13760. 2735 
 129 
86. Ono, K., H. Nakane, and M. Fukushima. 1985. Inhibition of the activities of 2736 
DNA primase-polymerase alpha complex from KB cells by hexasodium sym- 2737 
bis(m-aminobenzoyl-m-amino-p-methylbenzoyl-1-naphthylamino-4 ,6,8- 2738 
trisulfonate)carbamide. Nucleic Acids Symp Ser:249-252. 2739 
87. Osborne, J. C., and R. M. Elliott. 2000. RNA binding properties of bunyamwera 2740 
virus nucleocapsid protein and selective binding to an element in the 5' terminus 2741 
of the negative-sense S segment. J Virol 74:9946-9952. 2742 
88. Overby, A. K., R. F. Pettersson, and E. P. Neve. 2007. The glycoprotein 2743 
cytoplasmic tail of Uukuniemi virus (Bunyaviridae) interacts with 2744 
ribonucleoproteins and is critical for genome packaging. J Virol 81:3198-3205. 2745 
89. Panganiban, A. T., and M. A. Mir. 2009. Bunyavirus N: eIF4F surrogate and 2746 
cap-guardian. Cell Cycle 8:1332-1337. 2747 
90. Patterson, J. L., B. Holloway, and D. Kolakofsky. 1984. La Crosse virions 2748 
contain a primer-stimulated RNA polymerase and a methylated cap-dependent 2749 
endonuclease. J Virol 52:215-222. 2750 
91. Paul, C. P., P. D. Good, S. X. Li, A. Kleihauer, J. J. Rossi, and D. R. Engelke. 2751 
2003. Localized expression of small RNA inhibitors in human cells. Mol Ther 2752 
7:237-247. 2753 
92. Perrin, F. 1926. Polarisation de la lumière de fluorescence. Vie moyenne des 2754 
molécules dans l’état excité. J. Phys. Radium. 7:390-401. 2755 
93. Peters, C. J. a. A., G.W. Jr. 1981. Pathogenesis of Rift Valley fever. 2756 
Contributions to Epidemiology and Biostatistics 3:21-41. 2757 
94. Pettersson, R., L. Kaariainen, C. H. von Bonsdorff, and N. Oker-Blom. 1971. 2758 
Structural components of Uukuniemi virus, a noncubical tick-borne arbovirus. 2759 
Virology 46:721-729. 2760 
95. Pittman, P. R., C. T. Liu, T. L. Cannon, R. S. Makuch, J. A. Mangiafico, P. 2761 
H. Gibbs, and C. J. Peters. 1999. Immunogenicity of an inactivated Rift Valley 2762 
fever vaccine in humans: a 12-year experience. Vaccine 18:181-189. 2763 
96. Prehaud, C., N. Lopez, M. J. Blok, V. Obry, and M. Bouloy. 1997. Analysis of 2764 
the 3' terminal sequence recognized by the Rift Valley fever virus transcription 2765 
complex in its ambisense S segment. Virology 227:189-197. 2766 
97. Pritchard, N. J., A. Blake, and A. R. Peacocke. 1966. Modified intercalation 2767 
model for the interaction of amino acridines and DNA. Nature 212:1360-1361. 2768 
98. Raju, R., and D. Kolakofsky. 1987. Unusual transcripts in La Crosse virus- 2769 
infected cells and the site for nucleocapsid assembly. J Virol 61:667-672. 2770 
99. Ramalingam, D., S. Duclair, S. A. Datta, A. Ellington, A. Rein, and V. R. 2771 
Prasad. 2011. RNA aptamers directed to human immunodeficiency virus type 1 2772 
Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus 2773 
production. J Virol 85:305-314. 2774 
100. Raymond, D. D., M. E. Piper, S. R. Gerrard, G. Skiniotis, and J. L. Smith. 2775 
2012. Phleboviruses encapsidate their genomes by sequestering RNA bases. Proc 2776 
Natl Acad Sci U S A 109:19208-19213. 2777 
101. Ribeiro, D., J. W. Borst, R. Goldbach, and R. Kormelink. 2009. Tomato 2778 
spotted wilt virus nucleocapsid protein interacts with both viral glycoproteins Gn 2779 
and Gc in planta. Virology 383:121-130. 2780 
 130 
102. Rice, W. G., C. A. Schaeffer, B. Harten, F. Villinger, T. L. South, M. F. 2781 
Summers, L. E. Henderson, J. W. Bess, Jr., L. O. Arthur, J. S. McDougal, 2782 
and et al. 1993. Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C- 2783 
nitroso compounds. Nature 361:473-475. 2784 
103. Rice, W. G., J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. Clanton, M. 2785 
Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. 2786 
Bader, S. M. Halliday, L. Coren, R. C. Sowder, 2nd, L. O. Arthur, and L. E. 2787 
Henderson. 1995. Inhibitors of HIV nucleocapsid protein zinc fingers as 2788 
candidates for the treatment of AIDS. Science 270:1194-1197. 2789 
104. Ronka, H., P. Hilden, C. H. Von Bonsdorff, and E. Kuismanen. 1995. 2790 
Homodimeric association of the spike glycoproteins G1 and G2 of Uukuniemi 2791 
virus. Virology 211:241-250. 2792 
105. Ruigrok, R. W., T. Crepin, and D. Kolakofsky. 2011. Nucleoproteins and 2793 
nucleocapsids of negative-strand RNA viruses. Curr Opin Microbiol 14:504-510. 2794 
106. Schmaljohn, C. S. 1996. p. 1447-1471. In B. N. Fields (ed.), Virology, Raven, 2795 
New York. 2796 
107. Schols, D., R. Pauwels, J. Desmyter, and E. De Clercq. 1990. Dextran sulfate 2797 
and other polyanionic anti-HIV compounds specifically interact with the viral 2798 
gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. 2799 
Virology 175:556-561. 2800 
108. Senear, A. W., and J. A. Steitz. 1976. Site-specific interaction of Qbeta host 2801 
factor and ribosomal protein S1 with Qbeta and R17 bacteriophage RNAs. J Biol 2802 
Chem 251:1902-1912. 2803 
109. Severson, W. E., X. Xu, and C. B. Jonsson. 2001. cis-Acting signals in 2804 
encapsidation of Hantaan virus S-segment viral genomic RNA by its N protein. J 2805 
Virol 75:2646-2652. 2806 
110. Shvadchak, V., S. Sanglier, S. Rocle, P. Villa, J. Haiech, M. Hibert, A. Van 2807 
Dorsselaer, Y. Mely, and H. de Rocquigny. 2009. Identification by high 2808 
throughput screening of small compounds inhibiting the nucleic acid 2809 
destabilization activity of the HIV-1 nucleocapsid protein. Biochimie 91:916-923. 2810 
111. Sidwell, R. W., J. H. Huffman, B. B. Barnett, and D. Y. Pifat. 1988. In vitro 2811 
and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 2812 
32:331-336. 2813 
112. Sidwell, R. W., and D. F. Smee. 2003. Viruses of the Bunya- and Togaviridae 2814 
families: potential as bioterrorism agents and means of control. Antiviral Res 2815 
57:101-111. 2816 
113. Sinha, R., M. Hossain, and G. S. Kumar. 2007. RNA targeting by DNA binding 2817 
drugs: structural, conformational and energetic aspects of the binding of 2818 
quinacrine and DAPI to A-form and H(L)-form of poly(rC).poly(rG). Biochim 2819 
Biophys Acta 1770:1636-1650. 2820 
114. Snippe, M., J. Willem Borst, R. Goldbach, and R. Kormelink. 2007. Tomato 2821 
spotted wilt virus Gc and N proteins interact in vivo. Virology 357:115-123. 2822 
115. Strandin, T., J. Hepojoki, H. Wang, A. Vaheri, and H. Lankinen. 2011. The 2823 
cytoplasmic tail of hantavirus Gn glycoprotein interacts with RNA. Virology 2824 
418:12-20. 2825 
 131 
116. Ullmann, H., S. Meis, D. Hongwiset, C. Marzian, M. Wiese, P. Nickel, D. 2826 
Communi, J. M. Boeynaems, C. Wolf, R. Hausmann, G. Schmalzing, and M. 2827 
U. Kassack. 2005. Synthesis and structure-activity relationships of suramin- 2828 
derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem 2829 
48:7040-7048. 2830 
117. Ulmanen, I., P. Seppala, and R. F. Pettersson. 1981. In vitro translation of 2831 
Uukuniemi virus-specific RNAs: identification of a nonstructural protein and a 2832 
precursor to the membrane glycoproteins. J Virol 37:72-79. 2833 
118. Vidal, S., and D. Kolakofsky. 1989. Modified model for the switch from Sendai 2834 
virus transcription to replication. J Virol 63:1951-1958. 2835 
119. W.H.O. 2000. Rift Valley fever, Saudi Arabia (update). Wkly Epidemiol Rec 2836 
75:321. 2837 
120. WHO. 2007. Outbreaks of Rift Valley fever in Kenya, Somalia and United 2838 
Republic of Tanzania. Weekly Epidemiological Record 82:169-178. 2839 
121. Won, S., T. Ikegami, C. J. Peters, and S. Makino. 2007. NSm protein of Rift 2840 
Valley fever virus suppresses virus-induced apoptosis. J Virol 81:13335-13345. 2841 
122. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A Simple Statistical 2842 
Parameter for Use in Evaluation and Validation of High Throughput Screening 2843 
Assays. J Biomol Screen 4:67-73. 2844 
123. Zheng, W., and Y. J. Tao. 2013. Structure and assembly of the influenza A virus 2845 
ribonucleoprotein complex. FEBS Lett 587:1206-1214. 2846 
 2847 
 2848 
 2849 
